Patisiran, an RNAi Therapeutic, for Hereditary Transthy

New England Journal of Medicine
379, 11-21
DOI: 10.1056/nejmoa1716153

Citation Report

#	Article	IF	Citations
2	Alnylam launches era of RNAi drugs. Nature Biotechnology, 2018, 36, 777-778.	9.4	127
3	Small Activating RNAs as Promising Agents for Biotechnological Use. Current Pharmaceutical Biotechnology, 2018, 19, 602-603.	0.9	1
4	Oral Tecovirimat for the Treatment of Smallpox. New England Journal of Medicine, 2018, 379, 2084-2085.	13.9	12
5	Oligonucleotide Drugs for Transthyretin Amyloidosis. New England Journal of Medicine, 2018, 379, 2085-2086.	13.9	11
7	Emerging Therapeutic Approaches for Diamond Blackfan Anemia. Current Gene Therapy, 2018, 18, 327-335.	0.9	14
8	Recent Advances in Oligonucleotide-Based Therapy for Transthyretin Amyloidosis: Clinical Impact and Future Prospects. Biological and Pharmaceutical Bulletin, 2018, 41, 1737-1744.	0.6	12
9	Translating nanomedicines: Thinking beyond materials? A young investigator's reply to â€˜The Novelty Bubbleâ€™. Journal of Controlled Release, 2018, 290, 138-140.	4.8	12
10	Synthetic materials at the forefront of gene delivery. Nature Reviews Chemistry, 2018, 2, 258-277.	13.8	215
11	High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9944-E9952.	3.3	196
12	Patisiran: First Global Approval. Drugs, 2018, 78, 1625-1631.	4.9	387
13	PERIPHERAL NERVOUS SYSTEM INVOLVEMENT IN LYMPHOPROLIFERATIVE DISORDERS. Mediterranean Journal of Hematology and Infectious Diseases, 2018, 10, e2018057.	0.5	1
14	Nanoparticles That Deliver RNA to Bone Marrow Identified by in Vivo Directed Evolution. Journal of the American Chemical Society, 2018, 140, 17095-17105.	6.6	80
15	Case series: clinical outcomes of the transthyretin valine-to-isoleucine mutation in a brotherâ€“sister pair. European Heart Journal - Case Reports, 2018, 2, yty108.	0.3	0
16	Gene Silencing in the Right Place at the Right Time. Molecular Therapy, 2018, 26, 2539-2541.	3.7	0
18	Early Diagnosis of Cardiac Amyloidosis by Carpal Tunnel Surgery. Journal of the American College of Cardiology, 2018, 72, 2051-2053.	1.2	7
19	RNA Fibers as Optimized Nanoscaffolds for siRNA Coordination and Reduced Immunological Recognition. Advanced Functional Materials, 2018, 28, 1805959.	7.8	57
20	Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology, 2018, 91, e1999-e2009.	1.5	70
21	Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy. Arquivos De Neuro-Psiquiatria, 2018, 76, 609-621.	0.3	16

#	Article	IF	Citations
22	Amyloidosis cardiomyopathy. Current Opinion in Cardiology, 2018, 33, 571-579.	0.8	53
23	Clinical translation of immunoliposomes for cancer therapy: recent perspectives. Expert Opinion on Drug Delivery, 2018, 15, 893-903.	2.4	44
24	Modifying a Commonly Expressed Endocytic Receptor Retargets Nanoparticles in Vivo. Nano Letters, 2018, 18, 7590-7600.	4.5	37
25	Oligonucleotide Drugs for Transthyretin Amyloidosis. New England Journal of Medicine, 2018, 379, 82-85.	13.9	45
26	Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 2018, 379, 22-31.	13.9	1,000
27	Treatment success in hereditary transthyretin amyloidosis. Nature Reviews Neurology, 2018, 14, 509-509.	4.9	6
28	Stabilizing Transthyretin to Treat ATTR Cardiomyopathy. New England Journal of Medicine, 2018, 379, 1083-1084.	13.9	9
29	Gï»¿ene-silencing technology gets first drug approval after 20-year wait. Nature, 2018, 560, 291-292.	13.7	104
30	Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study. Transplant International, 2018, 31, 1207-1215.	0.8	32
31	Using Large Datasets to Understand Nanotechnology. Advanced Materials, 2019, 31, e1902798.	11.1	45
32	Carpal Tunnel Syndrome: A Potential Early, Red-Flag Sign of Amyloidosis. Journal of Hand Surgery, 2019, 44, 868-876.	0.7	65
33	Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics. Accounts of Chemical Research, 2019, 52, 2435-2444.	7.6	270
34	Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system. Clinical Autonomic Research, 2019, 29, 11-17.	1.4	13
35	Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNISâ€¯+â€¯7. Journal of the Neurological Sciences, 2019, 405, 116424.	0.3	54
36	Ligand Conjugated Multimeric siRNAs Enable Enhanced Uptake and Multiplexed Gene Silencing. Nucleic Acid Therapeutics, 2019, 29, 231-244.	2.0	11
37	Bisâ€Thioetherâ€Containing Lipid Chains in Cationic Amphiphiles: Physicochemical Properties and Applications in Gene Delivery. ChemPhysChem, 2019, 20, 2187-2194.	1.0	4
38	Which Nanobasics Should Be Taught in Medical Schools?. AMA Journal of Ethics, 2019, 21, E337-346.	0.4	3
39	Hyaluronan-modified nanoparticles for tumor-targeting. Expert Opinion on Drug Delivery, 2019, 16, 915-936.	2.4	27

#	Article	IF	Citations
41	Advances in the treatment of hereditary transthyretin amyloidosis: A review. Brain and Behavior, 2019, 9, e01371.	1.0	71
42	Cardiac Amyloidosis: Updates in Imaging. Current Cardiology Reports, 2019, 21, 108.	1.3	41
43	Myocardial Amyloidosis. JACC: Cardiovascular Imaging, 2019, 12, 2345-2356.	2.3	74
44	High-Throughput Analysis Reveals Rules for Target RNA Binding and Cleavage by AGO2. Molecular Cell, 2019, 75, 741-755.e11.	4.5	107
45	Gene Therapy Tools for Brain Diseases. Frontiers in Pharmacology, 2019, 10, 724.	1.6	131
46	Transthyretin Stabilization by AG10 in Symptomatic Transthyretin AmyloidÂCardiomyopathy. Journal of the American College of Cardiology, 2019, 74, 285-295.	1.2	170
47	Emerging Therapies for Transthyretin Cardiac Amyloidosis. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 40.	0.4	8
48	Letter by GonzÃ¡lez-Costello et al Regarding Article, â€œEffects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-mediated Amyloidosis: Analysis of the APOLLO Studyâ€. Circulation, 2019, 140, e90-e91.	1.6	2
49	The Truth Is Unfolding About Transthyretin Cardiac Amyloidosis. Circulation, 2019, 140, 27-30.	1.6	9
51	Emerging Therapeutics for the TreatmentÂof Light Chain and Transthyretin Amyloidosis. JACC Basic To Translational Science, 2019, 4, 438-448.	1.9	38
52	Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC: Heart Failure, 2019, 7, 709-716.	1.9	188
53	miR-125a-5p Functions as Tumor Suppressor microRNA And Is a Marker of Locoregional Recurrence And Poor prognosis in Head And Neck Cancer. Neoplasia, 2019, 21, 849-862.	2.3	39
54	A new era of amyloidosis: the trends at a major US referral centre. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 192-196.	1.4	14
55	Mechanical circulatory support for cardiac amyloidosis. Clinical Transplantation, 2019, 33, e13663.	0.8	22
56	Assessment of patients with hereditary transthyretin amyloidosis â€“ understanding the impact of management and disease progression. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 103-111.	1.4	40
57	Susceptibility of Enterovirus-D68 to RNAi-mediated antiviral knockdown. Antiviral Research, 2019, 170, 104565.	1.9	1
58	Cardiac amyloidosis: An underdiagnosed/underappreciated disease. European Journal of Internal Medicine, 2019, 67, 1-13.	1.0	29
59	Mucopenetrating lipoplexes modified with PEG and hyaluronic acid for CD44-targeted local siRNA delivery to the lungs. Journal of Biomaterials Applications, 2019, 34, 617-630.	1.2	24

#	Article	IF	Citations
60	Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. Expert Review of Clinical Pharmacology, 2019, 12, 701-711.	1.3	25
61	Long Non-Coding RNAs in Kidney Disease. International Journal of Molecular Sciences, 2019, 20, 3276.	1.8	71
62	Neuropathy Associated with Systemic Amyloidosis. Seminars in Neurology, 2019, 39, 578-588.	0.5	50
63	Cytosolic delivery of inhibitory antibodies with cationic lipids. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22132-22139.	3.3	39
64	Transcriptome analysis identified a novel 3-LncRNA regulatory network of transthyretin attenuating glucose induced hRECs dysfunction in diabetic retinopathy. BMC Medical Genomics, 2019, 12, 134.	0.7	15
65	Landscape of Noncoding RNA in Prostate Cancer. Trends in Genetics, 2019, 35, 840-851.	2.9	114
66	Beyond the Valve and into the Muscle: A Review of Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis. Structural Heart, 2019, 3, 462-468.	0.2	2
67	Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Failure, 2019, 6, 1128-1139.	1.4	113
68	A Therapeutic Silencing RNA Targeting Hepatocyte TAZ Prevents and Reverses Fibrosis in Nonalcoholic Steatohepatitis in Mice. Hepatology Communications, 2019, 3, 1221-1234.	2.0	36
69	Smart cancer nanomedicine. Nature Nanotechnology, 2019, 14, 1007-1017.	15.6	776
70	Method and its Composition for encapsulation, stabilization, and delivery of siRNA in Anionic polymeric nanoplex: An In vitro- In vivo Assessment. Scientific Reports, 2019, 9, 16047.	1.6	33
71	Neurological Manifestations of Transthyretin-Related Amyloidosis. , 2019, , .		2
72	Aptamers as Modular Components of Therapeutic Nucleic Acid Nanotechnology. ACS Nano, 2019, 13, 12301-12321.	7.3	102
73	Dominant collagen XII mutations cause a distal myopathy. Annals of Clinical and Translational Neurology, 2019, 6, 1980-1988.	1.7	24
75	Amyloidosis: diagnosis and new therapies for a misunderstood and misdiagnosed disease. Neurodegenerative Disease Management, 2019, 9, 289-299.	1.2	7
76	Biophysical characterization and modulation of Transthyretin Ala97Ser. Annals of Clinical and Translational Neurology, 2019, 6, 1961-1970.	1.7	14
78	Nanoparticles in the clinic: An update. Bioengineering and Translational Medicine, 2019, 4, e10143.	3.9	1,073
79	A novel intraperitoneal therapy for gastric cancer with DFPâ€10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model. Cancer Medicine, 2019, 8, 7313-7321.	1.3	7

#	Article	IF	Citations
80	A journey from microenvironment to macroenvironment: the role of metaflammation and epigenetic changes in cardiorenal disease. CKJ: Clinical Kidney Journal, 2019, 12, 861-870.	1.4	14
81	MicroRNA-421 confers paclitaxel resistance by binding to the KEAP1 3â€²UTR and predicts poor survival in non-small cell lung cancer. Cell Death and Disease, 2019, 10, 821.	2.7	56
82	Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. Journal of the Peripheral Nervous System, 2019, 24, 314-319.	1.4	46
83	Prevalence of hereditary transthyretin amyloid polyneuropathy in idiopathic progressive neuropathy in conurban areas. Neurological Research and Practice, 2019, 1, 30.	1.0	3
84	Characteristics of acquired transthyretin amyloidosis. Neurology, 2019, 93, e1587-e1596.	1.5	10
85	Diagnosis and treatment of heart failure in hereditary transthyretin amyloidosis. Clinical Autonomic Research, 2019, 29, 45-53.	1.4	8
86	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€”evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123.	1.4	230
87	Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management. Clinical Autonomic Research, 2019, 29, 33-44.	1.4	26
88	Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis. Clinical Autonomic Research, 2019, 29, 55-63.	1.4	21
90	Response by Solomon to Letter Regarding Article, â€œEffects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Studyâ€. Circulation, 2019, 140, e92-e93.	1.6	2
91	siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion. Translational Research, 2019, 214, 105-120.	2.2	48
92	Amyloid transthyretin cardiac amyloidosis: diagnosis and management. Expert Review of Cardiovascular Therapy, 2019, 17, 673-681.	0.6	10
93	Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: a systematic review. Clinical Autonomic Research, 2019, 29, 1-9.	1.4	22
94	Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment. International Journal of Molecular Sciences, 2019, 20, 4224.	1.8	35
95	The Clinical Spectrum of Amyloidosis. , 0, , .		0
96	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€”Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39.	0.7	107
97	Familial Amyloid Polyneuropathy. Noropsikiyatri Arsivi, 2019, 56, 150-156.	0.2	10
98	Polymeric Carriers for Nucleic Acid Delivery: Current Designs and Future Directions. Biomacromolecules, 2019, 20, 3613-3626.	2.6	67

#	Article	IF	Citations
99	Lipid-based nanoparticle formulations for small molecules and RNA drugs. Expert Opinion on Drug Delivery, 2019, 16, 1205-1226.	2.4	120
100	Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy. Clinical Autonomic Research, 2019, 29, 25-31.	1.4	9
101	Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis. Current Heart Failure Reports, 2019, 16, 180-188.	1.3	6
102	Nucleic acid-based theranostics in type 1 diabetes. Translational Research, 2019, 214, 50-61.	2.2	3
103	Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders. Frontiers in Genetics, 2019, 10, 868.	1.1	168
104	Design of Peptidomimetic Functionalized Cholesterol Based Lipid Nanoparticles for Efficient Delivery of Therapeutic Nucleic Acids. Molecules, 2019, 24, 3413.	1.7	5
105	Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis. Current Treatment Options in Neurology, 2019, 21, 50.	0.7	24
106	An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis. Expert Opinion on Pharmacotherapy, 2019, 20, 2223-2228.	0.9	9
107	Where Neurosurgery Meets Heart Failure: A Case Report of a Patient with Amyloid Transthyretin Wild Type in the Ligamentum Flavum and Cardiac Tissue with Bilateral Carpal Tunnel Syndrome. World Neurosurgery, 2019, 131, 104-107.	0.7	10
108	Multimodal retinal imaging of familial amyloid polyneuropathy. Ophthalmic Genetics, 2019, 40, 407-420.	0.5	13
109	Natural history and long-term effects of variant protein reduction in non-V30M ATTR amyloidosis. Neurology, 2019, 93, 714-716.	1.5	3
110	Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis. Journal of Cardiac Failure, 2019, 25, 147-153.	0.7	44
111	Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?. European Heart Journal, 2019, 40, 1009-1012.	1.0	18
112	Electrophysiological demyelinating features in hereditary ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 15-23.	1.4	12
113	Cationic Niosomes as Non-Viral Vehicles for Nucleic Acids: Challenges and Opportunities in Gene Delivery. Pharmaceutics, 2019, 11, 50.	2.0	59
114	Trojan horses for immunotherapy. Nature Nanotechnology, 2019, 14, 196-197.	15.6	8
115	Therapeutic Antisense Oligonucleotides Are Coming of Age. Annual Review of Medicine, 2019, 70, 307-321.	5.0	347
116	Targeted Therapeutics for Transthyretin Cardiac Amyloidosis. Circulation, 2019, 139, 444-447.	1.6	7

#	Article	IF	Citations
117	Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 10-14.	1.4	26
118	Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy. British Journal of Pharmacology, 2019, 176, 3447-3463.	2.7	115
119	Vectors for Glioblastoma Gene Therapy: Viral & Non-Viral Delivery Strategies. Nanomaterials, 2019, 9, 105.	1.9	88
120	Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis . Drug Design, Development and Therapy, 2019, Volume 13, 1515-1525.	2.0	60
121	Novel Therapies for Prevention and Early Treatment of Cardiomyopathies. Circulation Research, 2019, 124, 1536-1550.	2.0	47
122	Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis. Pharmaceuticals, 2019, 12, 78.	1.7	36
123	Method of levels not limits for assessment of cooling detection thresholds. Muscle and Nerve, 2019, 60, 109-110.	1.0	0
124	Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nature Reviews Neurology, 2019, 15, 387-404.	4.9	267
125	Messenger RNA delivery by hydrazone-activated polymers. MedChemComm, 2019, 10, 1138-1144.	3.5	11
126	Development of an imaged capillary isoelectric focusing method for characterizing the surface charge of mRNA lipid nanoparticle vaccines. Electrophoresis, 2019, 40, 2602-2609.	1.3	18
127	Gene therapy for hearing loss. Human Molecular Genetics, 2019, 28, R65-R79.	1.4	78
129	Emerging modes-of-action in drug discovery. MedChemComm, 2019, 10, 1550-1568.	3.5	22
130	A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH. Journal of Biological Chemistry, 2019, 294, 11259-11275.	1.6	16
131	Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc₃-Conjugated Antisense Oligonucleotides. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 475-485.	1.5	58
132	Clinical and genetic profiles of hereditary transthyretin amyloidosis in Taiwan. Annals of Clinical and Translational Neurology, 2019, 6, 913-922.	1.7	29
133	Theranostic Nanoparticles for RNA-Based Cancer Treatment. Accounts of Chemical Research, 2019, 52, 1496-1506.	7.6	111
134	Letter to the editor concerning the article: â€œAn indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathyâ€• Expert Opinion on Pharmacotherapy, 2019, 20, 1527-1528.	0.9	2
135	Response to the letter to the editor on â€œan indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathyâ€• Expert Opinion on Pharmacotherapy, 2019, 20, 1529-1530.	0.9	1

#	Article	IF	Citations
136	Emerging Techniques for Cardiovascular PET. Cardiovascular Innovations and Applications, 2019, 4, 13-24.	0.1	2
137	Formulation of Biocompatible Targeted ECO/siRNA Nanoparticles with Long-Term Stability for Clinical Translation of RNAi. Nucleic Acid Therapeutics, 2019, 29, 195-207.	2.0	22
138	Stereocontrolled Synthesis of Boranophosphate DNA by an Oxazaphospholidine Approach and Evaluation of Its Properties. Journal of Organic Chemistry, 2019, 84, 7971-7983.	1.7	17
139	MicroRNAs in Alzheimerâ€™s Disease: Diagnostic Markers or Therapeutic Agents?. Frontiers in Pharmacology, 2019, 10, 665.	1.6	105
140	Transthyretin Amyloid Cardiomyopathy. Journal of the American College of Cardiology, 2019, 73, 2872-2891.	1.2	573
141	Epidemiology of Cardiac Amyloidosisâ€“Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. Circulation: Heart Failure, 2019, 12, e005407.	1.6	126
142	Substrate reduction therapy for inborn errors of metabolism. Emerging Topics in Life Sciences, 2019, 3, 63-73.	1.1	15
143	Hereditary ATTR Amyloidosis with Cardiomyopathy Caused by the Novel Variant Transthyretin Y114S (p.Y134S). Internal Medicine, 2019, 58, 2695-2698.	0.3	3
144	Diabetic neuropathy. Nature Reviews Disease Primers, 2019, 5, 41.	18.1	692
145	Diabetic neuropathy. Nature Reviews Disease Primers, 2019, 5, 42.	18.1	82
146	Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation, 2019, 140, 16-26.	1.6	288
147	Next Viable Routes to Targeting Pancreatic Cancer Stemness: Learning from Clinical Setbacks. Journal of Clinical Medicine, 2019, 8, 702.	1.0	13
148	New molecular therapies for the treatment of hearing loss. , 2019, 200, 190-209.		49
149	Lipid Nanoparticles for Delivery of Therapeutic RNA Oligonucleotides. Molecular Pharmaceutics, 2019, 16, 2265-2277.	2.3	69
150	Diagnosis and management of sensory polyneuropathy. BMJ: British Medical Journal, 2019, 365, l1108.	2.4	34
151	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm, 2019, 16, e301-e372.	0.3	494
152	Broad-Spectrum Proteome Editing with an Engineered Bacterial Ubiquitin Ligase Mimic. ACS Central Science, 2019, 5, 852-866.	5.3	34
153	Dry powder inhalation of siRNA. Therapeutic Delivery, 2019, 10, 265-267.	1.2	11

#	Article	IF	Citations
154	Treatment of cardiac transthyretin amyloidosis: an update. European Heart Journal, 2019, 40, 3699-3706.	1.0	121
155	Clinicopathological spectrum and recent advances in the treatment of hereditary transthyretin amyloidosis. Neurology and Clinical Neuroscience, 2019, 7, 166-173.	0.2	6
156	Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis. American Journal of Cardiology, 2019, 124, 122-130.	0.7	14
157	Inflammatory and Molecular Pathways in Heart Failureâ€"Ischemia, HFpEF and Transthyretin Cardiac Amyloidosis. International Journal of Molecular Sciences, 2019, 20, 2322.	1.8	61
158	Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery. Journal of Visualized Experiments, 2019, , .	0.2	2
159	Clinical advances of siRNA therapeutics. Journal of Gene Medicine, 2019, 21, e3097.	1.4	120
160	Cell Subtypes Within the Liver Microenvironment Differentially Interact with Lipid Nanoparticles. Cellular and Molecular Bioengineering, 2019, 12, 389-397.	1.0	25
161	Effect of Sugar 2â€²,4â€²-Modifications on Gene Silencing Activity of siRNA Duplexes. Nucleic Acid Therapeutics, 2019, 29, 187-194.	2.0	16
162	Novel drug therapies for cardiac amyloidosis. Expert Opinion on Investigational Drugs, 2019, 28, 497-499.	1.9	2
163	Current Development of siRNA Bioconjugates: From Research to the Clinic. Frontiers in Pharmacology, 2019, 10, 444.	1.6	147
164	Contributions of Animal Models to the Mechanisms and Therapies of Transthyretin Amyloidosis. Frontiers in Physiology, 2019, 10, 338.	1.3	9
165	Time for new imaging and therapeutic approaches in cardiac amyloidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1402-1406.	3.3	12
166	Cambio de paradigma en el diagnÃ³stico y tratamiento de la amiloidosis cardiaca por transtirretina. REC: CardioClinics, 2019, 54, 9-12.	0.1	1
167	Smart-Responsive Nucleic Acid Nanoparticles (NANPs) with the Potential to Modulate Immune Behavior. Nanomaterials, 2019, 9, 611.	1.9	37
168	Systemic Delivery of Small Interfering RNA Therapeutics: Obstacles and Advances. Reviews in Agricultural Science, 2019, 7, 10-28.	0.9	8
169	Transthyretin Val122Ile amyloidosis associated with isolated gastrointestinal disease and bowel rupture in a Caucasian woman. Pathology, 2019, 51, 436-439.	0.3	0
170	Transthyretin amyloidosis in Western Europe: a snapshot from the THAOS registry and a call for further perspectives. European Heart Journal, 2019, , .	1.0	3
171	Evidence from genome wide association studies implicates reduced control of Epstein-Barr virus infection in multiple sclerosis susceptibility. Genome Medicine, 2019, 11, 26.	3.6	37

#	Article	IF	Citations
172	RNAi therapeutic and its innovative biotechnological evolution. Biotechnology Advances, 2019, 37, 801-825.	6.0	196
173	Nucleic Acid Therapeutics for Neurological Diseases. Neurotherapeutics, 2019, 16, 245-247.	2.1	16
174	Suppressing nNOS Enzyme by Small-Interfering RNAs Protects SH-SY5Y Cells and Nigral Dopaminergic Neurons from 6-OHDA Injury. Neurotoxicity Research, 2019, 36, 117-131.	1.3	13
175	IL4â€Receptorâ€Targeted Dual Antitumoral Apoptotic Peptideâ€”siRNA Conjugate Lipoplexes. Advanced Functional Materials, 2019, 29, 1900697.	7.8	26
176	Effect of Cetuximab and <i>EGFR</i> Small Interfering RNA Combination Treatment in NSCLC Cell Lines with Wild Type <i>EGFR</i> and Use of <i>KRAS</i> as a Possible Biomarker for Treatment Responsiveness. Yonago Acta Medica, 2019, 62, 085-093.	0.3	4
177	Emerging strategies to target the dysfunctional cohesin complex in cancer. Expert Opinion on Therapeutic Targets, 2019, 23, 525-537.	1.5	12
178	Lipid-Based DNA Therapeutics: Hallmarks of Non-Viral Gene Delivery. ACS Nano, 2019, 13, 3754-3782.	7.3	220
179	Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 55-65.	1.4	16
180	Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell, 2019, 35, 347-367.	7.7	533
182	ToGo-WF: prediction of RNA tertiary structures and RNAâ€“RNA/protein interactions using the KNIME workflow. Journal of Computer-Aided Molecular Design, 2019, 33, 497-507.	1.3	5
183	Huntingtin Lowering Strategies for Disease Modification in Huntingtonâ€™s Disease. Neuron, 2019, 101, 801-819.	3.8	202
184	A Quarter Century of APOE and Alzheimerâ€™s Disease: Progress to Date and the Path Forward. Neuron, 2019, 101, 820-838.	3.8	338
185	The current state and future directions of RNAi-based therapeutics. Nature Reviews Drug Discovery, 2019, 18, 421-446.	21.5	896
186	Transthyretin Amyloid Fibril Disrupting Activities of Extracts and Fractions from Juglans mandshurica Maxim. var. cordiformis (Makino) Kitam.. Molecules, 2019, 24, 500.	1.7	6
187	Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies. Neurological Sciences, 2019, 40, 661-669.	0.9	32
188	Exosome-transferred lncRNAs at the core of cancer bone lesions. Critical Reviews in Oncology/Hematology, 2019, 139, 125-127.	2.0	17
189	Safety evaluation of 2â€²-deoxy-2â€²-fluoro nucleotides in GalNAc-siRNA conjugates. Nucleic Acids Research, 2019, 47, 3306-3320.	6.5	54
190	Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis. Journal of Neuromuscular Diseases, 2019, 6, 189-199.	1.1	43

#	Article	IF	Citations
191	The molecular mechanism of dsRNA processing by a bacterial Dicer. Nucleic Acids Research, 2019, 47, 4707-4720.	6.5	9
192	Application of Locked Nucleic Acid Oligonucleotides for siRNA Preclinical Bioanalytics. Scientific Reports, 2019, 9, 3566.	1.6	31
193	Nine contemporary therapeutic directions in heart failure. Heart Asia, 2019, 11, e011150.	1.1	2
194	Multimodal Polysilsesquioxane Nanoparticles for Combinatorial Therapy and Gene Delivery in Triple-Negative Breast Cancer. ACS Applied Materials & Interfaces, 2019, 11, 12308-12320.	4.0	36
195	Towards Self-Transfecting Nucleic Acid Nanostructures for Gene Regulation. Trends in Biotechnology, 2019, 37, 983-994.	4.9	15
196	Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis. JAMA Cardiology, 2019, 4, 466.	3.0	68
197	Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. Molecular Therapy, 2019, 27, 710-728.	3.7	685
198	Spinal Stenosis in Familial Transthyretin Amyloidosis. Journal of Neuromuscular Diseases, 2019, 6, 267-270.	1.1	12
199	The Opposing Roles of PIK3R1/p85Î± and PIK3R2/p85Î² in Cancer. Trends in Cancer, 2019, 5, 233-244.	3.8	82
200	Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis. International Journal of Molecular Sciences, 2019, 20, 1287.	1.8	28
202	A transgenic mouse model reproduces human hereditary systemic amyloidosis. Kidney International, 2019, 96, 628-641.	2.6	2
203	Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease. Frontiers in Pharmacology, 2019, 10, 305.	1.6	74
204	Antisense Oligonucleotides for the Treatment of Inner Ear Dysfunction. Neurotherapeutics, 2019, 16, 348-359.	2.1	16
205	Pathology of Small Fiber Neuropathy: Skin Biopsy for the Analysis of Nociceptive Nerve Fibers. , 2019, , 11-24.		0
206	Amyloid Neuropathy. , 2019, , 83-97.		0
207	Small-fiber neuropathy definition, diagnosis, and treatment. Neurological Sciences, 2019, 40, 1343-1350.	0.9	48
208	Developing small activating RNA as a therapeutic: current challenges and promises. Therapeutic Delivery, 2019, 10, 151-164.	1.2	49
209	Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient InÂVivo Genome Editing of Multiple Therapeutic Gene Targets. Molecular Therapy, 2019, 27, 866-877.	3.7	64

#	Article	IF	Citations
210	5â€²-Morpholino modification of the sense strand of an siRNA makes it a more effective passenger. Chemical Communications, 2019, 55, 5139-5142.	2.2	21
211	Integration of target discovery, drug discovery and drug delivery: A review on computational strategies. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2019, 11, e1554.	3.3	27
212	Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). European Heart Journal, 2022, 43, 391-400.	1.0	105
213	Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?. Clinical Research in Cardiology, 2019, 108, 1324-1330.	1.5	93
214	Amyloidosis in Australia. Expert Opinion on Orphan Drugs, 2019, 7, 37-39.	0.5	0
215	Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement. Heart Failure Reviews, 2019, 24, 521-533.	1.7	23
216	Coexistence of cardiac amyloidosis with coronary artery disease and the challenges in medical management. Journal of Nuclear Cardiology, 2019, 26, 790-796.	1.4	8
217	A Systematic Review of miR-29 in Cancer. Molecular Therapy - Oncolytics, 2019, 12, 173-194.	2.0	157
218	Lungâ€Endotheliumâ€Targeted Nanoparticles Based on a pHâ€Sensitive Lipid and the GALA Peptide Enable Robust Gene Silencing and the Regression of Metastatic Lung Cancer. Advanced Functional Materials, 2019, 29, 1807677.	7.8	47
219	Targeting <scp>RNA</scp>: A Transformative Therapeutic Strategy. Clinical and Translational Science, 2019, 12, 98-112.	1.5	102
220	Dual inhibition of endothelial miR-92a-3p and miR-489-3p reduces renal injury-associated atherosclerosis. Atherosclerosis, 2019, 282, 121-131.	0.4	55
221	Targeted therapies for congenital myasthenic syndromes: systematic review and steps towards a treatabolome. Emerging Topics in Life Sciences, 2019, 3, 19-37.	1.1	47
222	Ultrastructure in Transthyretin Amyloidosis: From Pathophysiology to Therapeutic Insights. Biomedicines, 2019, 7, 11.	1.4	50
223	Skin nerve pathology: Biomarkers of premanifest and manifest amyloid neuropathy. Annals of Neurology, 2019, 85, 560-573.	2.8	33
225	Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. European Heart Journal, 2019, 40, 1287-1293.	1.0	39
226	Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 636-646.	1.3	24
227	Doxycycline and Ursodiol for ATTR Amyloidosis: Not Ready for Prime Time. Journal of Cardiac Failure, 2019, 25, 154-155.	0.7	6
228	Quantification of siRNA-Antibody Conjugates in Biological Matrices by Triplex-Forming Oligonucleotide ELISA. Nucleic Acid Therapeutics, 2019, 29, 161-166.	2.0	13

#	Article	IF	Citations
229	Onionâ€bulb patterns predict acquired or inherited demyelinating polyneuropathy. Muscle and Nerve, 2019, 59, 665-670.	1.0	14
230	Micro-RNAs in inflammatory arthritis: From physiopathology to diagnosis, prognosis and therapeutic opportunities. Biochemical Pharmacology, 2019, 165, 134-144.	2.0	11
231	The year in cardiology 2018: heart failure. European Heart Journal, 2019, 40, 651-661.	1.0	32
232	Tafamidis for the treatment of transthyretin amyloidosis. Future Cardiology, 2019, 15, 53-61.	0.5	3
233	Bottlebrush-architectured poly(ethylene glycol) as an efficient vector for RNA interference in vivo. Science Advances, 2019, 5, eaav9322.	4.7	50
234	Characteristics of ribonucleic acid. , 2019, , 43-50.		0
235	ActualitÃ©s thÃ©rapeutiques en pathologies neuromusculaires. Pratique Neurologique - FMC, 2019, 10, 187-188.	0.1	0
236	Demyelinating Neuropathy in a Patient Treated With Revusiran for Transthyretin (Thr60Ala) Amyloidosis. Journal of Clinical Neuromuscular Disease, 2019, 20, 120-128.	0.3	8
237	Amyloidosis: Systems-Based Therapies. , 2019, , .		0
238	Pathophysiology of Amyloid Fibril Formation. , 0, , .		1
239	Clinicopathological correlations of sural nerve biopsies in TTR Val30Met familial amyloid polyneuropathy. Brain Communications, 2019, 1, fcz032.	1.5	16
240	Aortic Stenosis and Cardiac Amyloidosis. Journal of the American College of Cardiology, 2019, 74, 2638-2651.	1.2	182
241	Polymeric Nanoparticles Based on Tyrosine-Modified, Low Molecular Weight Polyethylenimines for siRNA Delivery. Pharmaceutics, 2019, 11, 600.	2.0	24
242	The Role of Non-coding RNAs in Oncology. Cell, 2019, 179, 1033-1055.	13.5	952
243	Serial scanning with 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid (99mTc-DPD) for early detection of cardiac amyloid deposition and prediction of clinical worsening in subjects carrying a transthyretin gene mutation. Journal of Nuclear Cardiology, 2021, 28, 1949-1957.	1.4	15
244	Disease-modifying therapy for proteinopathies: Can the exception become the rule?. Progress in Molecular Biology and Translational Science, 2019, 168, 277-287.	0.9	5
245	Nanomedicine review: clinical developments in liposomal applications. Cancer Nanotechnology, 2019, 10, .	1.9	306
246	Noninvasive diagnosis of hereditary transthyretin-related cardiac amyloidosis. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlock	0.4	3

#	Article	IF	Citations
248	In-Vivo Gene Therapy with Foamy Virus Vectors. Viruses, 2019, 11, 1091.	1.5	16
249	Amyloidosis in Heart Failure. Current Heart Failure Reports, 2019, 16, 285-303.	1.3	26
250	Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretinâ€Mediated Amyloidosis. Journal of Clinical Pharmacology, 2020, 60, 573-585.	1.0	119
251	Amyloid and the Heart. Current Cardiology Reports, 2019, 21, 164.	1.3	6
252	DNA complexes as an efficient gene anticancer drug delivery therapy. , 2019, , 485-549.		0
254	Clinician-rated measures for distal symmetrical axonal polyneuropathy. Neurology, 2019, 93, 346-360.	1.5	19
255	Discovery of a novel deaminated metabolite of a single-stranded oligonucleotide in vivo by mass spectrometry. Bioanalysis, 2019, 11, 1955-1965.	0.6	19
256	Editorial focus: understanding off-target effects as the key to successful RNAi therapy. Cellular and Molecular Biology Letters, 2019, 24, 69.	2.7	85
257	Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry. JAMA - Journal of the American Medical Association, 2019, 322, 2191.	3.8	93
259	Update in recent clinical trials in heart failure. Current Opinion in Cardiology, 2019, 34, 307-314.	0.8	2
260	Advantages and Emerging Problems of Novel Treatments for Transthyretin Cardiac Amyloidosis. Circulation Journal, 2019, 84, 9-10.	0.7	1
261	The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nature Nanotechnology, 2019, 14, 1084-1087.	15.6	814
262	Species-Specific miRNAs in Human Brain Development and Disease. Frontiers in Cellular Neuroscience, 2019, 13, 559.	1.8	26
263	Role of miRNAs in immune responses and immunotherapy in cancer. Genes Chromosomes and Cancer, 2019, 58, 244-253.	1.5	105
264	Nano-carriers for drug routeing â€“ towards a new era. Journal of Drug Targeting, 2019, 27, 525-541.	2.1	16
265	Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis. Neurodegenerative Disease Management, 2019, 9, 25-30.	1.2	24
266	Uremic Toxins Activate Macrophages. Circulation, 2019, 139, 97-100.	1.6	7
267	Gene Silencing With siRNA (RNA Interference): A New Therapeutic Option During Ex Vivo Machine Liver Perfusion Preservation. Liver Transplantation, 2019, 25, 140-151.	1.3	47

#	Article	IF	Citations
268	RNA Interference-Based Cancer Drugs: The Roadblocks, and the â€œDeliveryâ€•of the Promise. Nucleic Acid Therapeutics, 2019, 29, 61-66.	2.0	27
269	New therapies for neuromuscular diseases in 2018. Lancet Neurology, The, 2019, 18, 12-13.	4.9	1
270	Treating Disease at the RNA Level with Oligonucleotides. New England Journal of Medicine, 2019, 380, 57-70.	13.9	223
271	RNAâ€“DNA fibers and polygons with controlled immunorecognition activate RNAi, FRET and transcriptional regulation of NF-Îº B in human cells. Nucleic Acids Research, 2019, 47, 1350-1361.	6.5	64
272	Diagnosis of amyloid neuropathy. Practical Neurology, 2019, 19, 250-258.	0.5	17
274	State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. Journal of Nuclear Cardiology, 2019, 26, 158-173.	1.4	82
275	Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 647-656.	1.3	21
276	Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegenerative Disease Management, 2019, 9, 5-23.	1.2	168
277	6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR). Neuromuscular Disorders, 2019, 29, 213-220.	0.3	14
278	Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias. Neurotherapeutics, 2019, 16, 263-286.	2.1	95
279	Zebrafish as a preclinical in vivo screening model for nanomedicines. Advanced Drug Delivery Reviews, 2019, 151-152, 152-168.	6.6	107
280	A histopathologic schema to quantify the burden of cardiac amyloidosis: Relationship with survival and echocardiographic parameters. Echocardiography, 2019, 36, 285-291.	0.3	7
281	Affordable Preeclampsia Therapeutics. Trends in Pharmacological Sciences, 2019, 40, 85-87.	4.0	11
282	The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 10-15.	0.5	23
283	When should you order genetic testing for patients with cryptogenic neuropathy? Let the data do the talking. Muscle and Nerve, 2019, 59, 280-282.	1.0	2
284	Lipids and polymers in pharmaceutical technology: Lifelong companions. International Journal of Pharmaceutics, 2019, 558, 128-142.	2.6	101
285	Tafamidis, a Noninvasive Therapy for Delaying Transthyretin Familial Amyloid Polyneuropathy:		

#	Article	IF	Citations
287	Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis. Expert Review of Clinical Pharmacology, 2019, 12, 95-99.	1.3	51
288	TTR Gene Silencers for Hereditary ATTR Amyloidosis: More than ICER Recognized. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 15-16.	0.5	1
289	Upper limb onset of hereditary transthyretin amyloidosis is common in nonâ€endemic areas. European Journal of Neurology, 2019, 26, 497.	1.7	25
290	Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation, 2019, 139, 431-443.	1.6	319
291	Molecular phenotyping of infiltrative cardiomyopathies: The future. Journal of Nuclear Cardiology, 2019, 26, 154-157.	1.4	4
292	RNA therapy: Are we using the right molecules?. , 2019, 196, 91-104.		116
293	An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy. Expert Opinion on Pharmacotherapy, 2019, 20, 473-481.	0.9	21
294	Hereditary transthyretin-related amyloidosis. Acta Neurologica Scandinavica, 2019, 139, 92-105.	1.0	35
295	Therapeutic Oligonucleotides: State of the Art. Annual Review of Pharmacology and Toxicology, 2019, 59, 605-630.	4.2	208
296	siRNA therapeutics: a clinical reality. Science China Life Sciences, 2020, 63, 485-500.	2.3	191
297	Firstâ€inâ€Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers. Clinical Pharmacology in Drug Development, 2020, 9, 115-129.	0.8	32
298	When and how do patients with cardiac amyloidosis die?. Clinical Research in Cardiology, 2020, 109, 78-88.	1.5	36
299	Corneal confocal microscopy: ready for prime time. Australasian journal of optometry, The, 2020, 103, 265-277.	0.6	73
300	Overview of treatments used in transthyretin-related hereditary amyloidosis: a systematic review. European Journal of Hospital Pharmacy, 2020, 27, 194-201.	0.5	2
301	A comprehensive, multidisciplinary, precision medicine approach to discover effective therapy for an undiagnosed, progressive, fibroinflammatory disease. Translational Research, 2020, 215, 31-40.	2.2	0
302	Cardiac manifestations and prognostic implications of hereditary transthyretin amyloidosis associated with transthyretin Ala97Ser. Journal of the Formosan Medical Association, 2020, 119, 693-700.	0.8	13
303	Shifting Paradigms Revisited: Biotechnology and the Pharmaceutical Sciences. Journal of Pharmaceutical Sciences, 2020, 109, 30-43.	1.6	8
304	A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis. Clinical Research in Cardiology, 2020, 109, 700-713.	1.5	13

#	Article	IF	Citations
305	Expanding the spectrum of transthyretin amyloidosis. Muscle and Nerve, 2020, 61, 3-4.	1.0	2
307	Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis. Internal Medicine, 2020, 59, 339-343.	0.3	0
308	A cationic amphiphilic co-polymer as a carrier of nucleic acid nanoparticles (Nanps) for controlled gene silencing, immunostimulation, and biodistribution. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 23, 102094.	1.7	44
309	Patisiran Pharmacokinetics, Pharmacodynamics, and Exposureâ€Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretinâ€Mediated (hATTR) Amyloidosis. Journal of Clinical Pharmacology, 2020, 60, 37-49.	1.0	83
310	Design of 2'-O-methyl RNA and DNA double-stranded oligonucleotides: naturally-occurring nucleotide components with strong RNA interference gene expression inhibitory activity. Nucleosides, Nucleotides and Nucleic Acids, 2020, 39, 292-309.	0.4	3
311	Lipid-based nanocarriers for delivery of small interfering RNA for therapeutic use. European Journal of Pharmaceutical Sciences, 2020, 142, 105159.	1.9	35
312	Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran. Molecular Diagnosis and Therapy, 2020, 24, 49-59.	1.6	35
313	New developments in diagnosis, risk assessment and management in systemic amyloidosis. Blood Reviews, 2020, 40, 100636.	2.8	28
314	Lipid nanocarriers for microRNA delivery. Chemistry and Physics of Lipids, 2020, 226, 104837.	1.5	63
315	Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells. Investigational New Drugs, 2020, 38, 1012-1019.	1.2	5
316	APOE polymorphism in ATTR amyloidosis patients treated with lipid nanoparticle siRNA. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 45-51.	1.4	9
317	Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 52-58.	1.4	56
318	Cellular secretion and cytotoxicity of transthyretin mutant proteins underlie late-onset amyloidosis and neurodegeneration. Cellular and Molecular Life Sciences, 2020, 77, 1421-1434.	2.4	9
319	Transthyretin amyloidosis: Putting myopathy on the map. Muscle and Nerve, 2020, 61, 95-100.	1.0	27
320	How to Image Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 1368-1383.	2.3	156
321	Emerging therapies in transthyretin amyloidosisÂâ€“Âa new wave of hope after years of stagnancy?. European Journal of Heart Failure, 2020, 22, 39-53.	2.9	55
322	Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs. Biomaterials, 2020, 240, 119742.	5.7	46
323	Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems. Canadian Journal of Cardiology, 2020, 36, 424-431.	0.8	22

#	Article	IF	Citations
324	Baroreflex Dysfunction. New England Journal of Medicine, 2020, 382, 163-178.	13.9	160
325	Double Click-Functionalized siRNA Polyplexes for Gene Silencing in Epidermal Growth Factor Receptor-Positive Tumor Cells. ACS Biomaterials Science and Engineering, 2020, 6, 1074-1089.	2.6	18
326	CRISPR/Cas9: targeted genome editing for the treatment of hereditary hearing loss. Journal of Applied Genetics, 2020, 61, 51-65.	1.0	21
327	Polyornithine-based polyplexes to boost effective gene silencing in CNS disorders. Nanoscale, 2020, 12, 6285-6299.	2.8	10
328	The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnology Advances, 2020, 40, 107502.	6.0	216
329	Regression of Bone-Tracer Uptake in Cardiac Transthyretin Amyloidosis. Mayo Clinic Proceedings, 2020, 95, 417-418.	1.4	8
330	Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis. Journal of Neurology, 2020, 267, 1070-1079.	1.8	20
331	Fractional Laser-Mediated siRNA Delivery for Mitigating Psoriasis-like Lesions via IL-6 Silencing. Molecular Therapy - Nucleic Acids, 2020, 19, 240-251.	2.3	18
332	Societal costs and burden of hereditary transthyretin amyloidosis polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 89-96.	1.4	4
333	Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Journal of Neurology, 2020, 267, 703-712.	1.8	35
334	Design and optimization strategies for the development of new drugs that treat chronic kidney disease. Expert Opinion on Drug Discovery, 2020, 15, 101-115.	2.5	13
335	Mild Innate Immune Activation Overrides Efficient Nanoparticleâ€Mediated RNA Delivery. Advanced Materials, 2020, 32, e1904905.	11.1	84
336	Amyloid Cardiomyopathy. Heart Lung and Circulation, 2020, 29, 575-583.	0.2	15
337	Improved Nucleic Acid Therapy with Advanced Nanoscale Biotechnology. Molecular Therapy - Nucleic Acids, 2020, 19, 581-601.	2.3	74
338	Use of Implantable Electronic Devices in Patients With Cardiac Amyloidosis. Canadian Journal of Cardiology, 2020, 36, 408-415.	0.8	16
339	Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. Journal of Cardiac Failure, 2020, 26, 753-759.	0.7	57
340	Amyloidosis and Ocular Involvement: an Overview. Seminars in Ophthalmology, 2020, 35, 7-26.	0.8	22
342	Alkylation enhances biocompatibility and siRNA delivery efficiency of cationic curdlan nanoparticles. International Journal of Biological Macromolecules, 2020, 143, 118-125.	3.6	17

#	Article	IF	Citations
343	Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nature Reviews Drug Discovery, 2020, 19, 93-111.	21.5	190
344	Oligonucleotides to the (Gene) Rescue: FDA Approvals 2017â€“2019. Trends in Pharmacological Sciences, 2020, 41, 27-41.	4.0	66
345	Overcoming the delivery barrier of oligonucleotide drugs and enhancing nucleoside drug efficiency: The use of nucleolipids. Medicinal Research Reviews, 2020, 40, 1178-1199.	5.0	12
346	The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosis. Clinical Cardiology, 2020, 43, 171-178.	0.7	5
347	Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis. Nucleic Acid Therapeutics, 2020, 30, 33-49.	2.0	16
348	Targeted delivery and enhanced gene-silencing activity of centrally modified folic acidâ€“siRNA conjugates. Nucleic Acids Research, 2020, 48, 75-85.	6.5	38
349	Insight into the siRNA transmembrane deliveryâ€”From cholesterol conjugating to tagging. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1606.	3.3	16
350	CD64-targeted HO-1 RNA interference enhances chemosensitivity in orthotopic model of acute myeloid leukemia and patient-derived bone marrow cells. Biomaterials, 2020, 230, 119651.	5.7	12
351	The chemistry and applications ofÂRNA 2â€²-OH acylation. Nature Reviews Chemistry, 2020, 4, 22-37.	13.8	48
352	Systems and Synthetic microRNA Biology: From Biogenesis to Disease Pathogenesis. International Journal of Molecular Sciences, 2020, 21, 132.	1.8	157
353	Pathogenicity of Shiga Toxin Type 2e Escherichia coli in Pig Colibacillosis. Frontiers in Veterinary Science, 2020, 7, 545818.	0.9	12
354	Intracellular Antibody Delivery Mediated by Lipids, Polymers, and Inorganic Nanomaterials for Therapeutic Applications. Advanced Therapeutics, 2020, 3, 2000178.	1.6	21
355	RIPK1 gene variants associate with obesity in humans and can be therapeutically silenced to reduce obesity in mice. Nature Metabolism, 2020, 2, 1113-1125.	5.1	34
356	Use of human peripheral blood mononuclear cells to define immunological properties of nucleic acid nanoparticles. Nature Protocols, 2020, 15, 3678-3698.	5.5	36
357	Expression of Amyloidogenic Transthyretin Drives Hepatic Proteostasis Remodeling in an Induced Pluripotent Stem Cell Model of Systemic AmyloidÂDisease. Stem Cell Reports, 2020, 15, 515-528.	2.3	12
358	Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery. European Journal of Internal Medicine, 2020, 82, 7-15.	1.0	32
359	Development of Prodrug Type Circular siRNA for In Vivo Knockdown by Systemic Administration. Nucleic Acid Therapeutics, 2020, 30, 346-364.	2.0	6
360	Repairing the heart: State-of the art delivery strategies for biological therapeutics. Advanced Drug Delivery Reviews, 2020, 160, 1-18.	6.6	16

#	Article	IF	Citations
361	Advances in the Diagnosis and Management of Transthyretin Amyloid Cardiomyopathy. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.4	1
362	Cancer biology functional genomics: From small RNAs to big dreams. Molecular Carcinogenesis, 2020, 59, 1343-1361.	1.3	6
363	Brave new world revisited: Focus on nanomedicine. Biochemical and Biophysical Research Communications, 2020, 533, 36-49.	1.0	18
364	Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy. Advanced Materials, 2020, 32, e2002440.	11.1	160
365	Heart failure from ATTRwt amyloid cardiomyopathy is associated with poor prognosis. ESC Heart Failure, 2020, 7, 3919-3928.	1.4	17
366	Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. ESC Heart Failure, 2020, 7, 3942-3949.	1.4	22
367	Introducing an InÂVitro Liver Stability Assay Capable of Predicting the InÂVivo Pharmacodynamic Efficacy of siRNAs for IVIVC. Molecular Therapy - Nucleic Acids, 2020, 21, 725-736.	2.3	12
368	Wild-type transthyretin cardiac amyloidosis: When is a rare disease no longer a rare disease?. Journal of Nuclear Cardiology, 2021, 28, 2857-2859.	1.4	3
369	Photoregulation of Gene Expression with Amantadineâ€Modified Caged siRNAs through Hostâ€“Guest Interactions. Chemistry - A European Journal, 2020, 26, 14002-14010.	1.7	5
370	Gene therapy: a double-edged sword with great powers. Molecular and Cellular Biochemistry, 2020, 474, 73-81.	1.4	44
371	Opportunities and challenges in commercial pharmaceutical liposome applications. Advanced Drug Delivery Reviews, 2020, 154-155, 2-12.	6.6	50
372	Continuous-Flow Synthesis of Cationic Lipid SST-01 via Safe and Scalable Aerobic Oxidation and Reductive Amination. Organic Process Research and Development, 2020, 24, 1988-1995.	1.3	8
373	Development of lipid-like materials for RNA delivery based on intracellular environment-responsive membrane destabilization and spontaneous collapse. Advanced Drug Delivery Reviews, 2020, 154-155, 210-226.	6.6	33
374	Utility of Biomarkers in Cardiac Amyloidosis. JACC: Heart Failure, 2020, 8, 701-711.	1.9	19
375	Delivering the power of nanomedicine to patients today. Journal of Controlled Release, 2020, 326, 164-171.	4.8	219
376	Trends in Therapeutic Conjugates: Bench to Clinic. Bioconjugate Chemistry, 2020, 31, 462-473.	1.8	21
378	Nanomedicine beyond tumor passive targeting: what next?. Nanomedicine, 2020, 15, 1819-1822.	1.7	11
379	Hereditary transthyretin amyloidosis caused by the rare Phe33Leu mutation. BMJ Case Reports, 2020, 13, e232756.	0.2	3

#	Article	IF	Citations
380	<scp>mNIS</scp>+7 <scp>and lower limb function in inotersen treatment of</scp> hereditary transthyretinâ€mediated amyloidosis. Muscle and Nerve, 2020, 62, 502-508.	1.0	8
381	Editorial: 18F-Fluoride PET/MR in cardiac amyloid; simple addition versus synergy?. Journal of Nuclear Cardiology, 2022, 29, 750-752.	1.4	2
382	Clinical 3-D Gait Assessment of Patients With Polyneuropathy Associated With Hereditary Transthyretin Amyloidosis. Frontiers in Neurology, 2020, 11, 605282.	1.1	6
383	Transthyretin Stabilization: An Emerging Strategy for the Treatment of Alzheimerâ€™s Disease?. International Journal of Molecular Sciences, 2020, 21, 8672.	1.8	19
384	Small Molecule-Inducible RNA-Targeting Systems for Temporal Control of RNA Regulation. ACS Central Science, 2020, 6, 1987-1996.	5.3	27
385	Nanomedicine & Nanotoxicology Future Could Be Reshaped Post-COVID-19 Pandemic. Frontiers in Nanotechnology, 2020, 2, .	2.4	9
386	Identifying Cleaved and Noncleaved Targets of Small Interfering RNAs and MicroRNAs in Mammalian Cells by SpyCLIP. Molecular Therapy - Nucleic Acids, 2020, 22, 900-909.	2.3	4
387	Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wiener Klinische Wochenschrift, 2020, 132, 742-761.	1.0	31
388	Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery. Molecules, 2020, 25, 5672.	1.7	124
389	An evidence map of randomised controlled trials evaluating genetic therapies. BMJ Evidence-Based Medicine, 2021, 26, 194-194.	1.7	4
390	Hereditary transthyretin amyloidosis overview. Neurological Sciences, 2022, 43, 595-604.	0.9	39
391	Â«Red flagsÂ» en pacientes con polineuropatÃa amiloidÃ³tica familiar relacionada con transtiretina (hATTR) en el momento del diagnÃ³stico en un Ã¡rea no endÃ©mica de EspaÃ±a. NeurologÃa, 2023, 38, 87-92.	0.3	1
392	SERPINA1 modulates expression of amyloidogenic transthyretin. Experimental Cell Research, 2020, 395, 112217.	1.2	7
393	Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era. Medicinal Research Reviews, 2020, 40, 2650-2681.	5.0	32
394	The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy. Bioconjugate Chemistry, 2020, 31, 2046-2059.	1.8	120
395	Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro. ACS Applied Materials & Interfaces, 2020, 12, 38873-38886.	4.0	38
396	Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases. Expert Opinion on Investigational Drugs, 2020, 29, 1163-1170.	1.9	44
397	Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus. Hepatology Research, 2020, 50, 1128-1140.	1.8	6

#	Article	IF	Citations
398	Humans: the ultimate animal models. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1132-1136.	0.9	7
399	Cardiac Regeneration After Myocardial Infarction: an Approachable Goal. Current Cardiology Reports, 2020, 22, 122.	1.3	28
400	Combined hybrid structure of siRNA tailed IVT mRNA (ChriST mRNA) for enhancing DC maturation and subsequent anticancer T cell immunity. Journal of Controlled Release, 2020, 327, 225-234.	4.8	11
401	The Evolution of Gene Therapy in the Treatment of Metabolic Liver Diseases. Genes, 2020, 11, 915.	1.0	3
402	Opportunities, Barriers, and a Strategy for Overcoming Translational Challenges to Therapeutic Nucleic Acid Nanotechnology. ACS Nano, 2020, 14, 9221-9227.	7.3	67
403	Managing the complexities of cardiac amyloidosis: a path for success. European Journal of Preventive Cardiology, 2020, , 2047487320928178.	0.8	1
404	The use of cardiovascular magnetic resonance for the assessment of left ventricular hypertrophy. Cardiovascular Diagnosis and Therapy, 2020, 10, 568-582.	0.7	6
405	Increased PIP3 activity blocks nanoparticle mRNA delivery. Science Advances, 2020, 6, eaba5672.	4.7	16
406	The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Frontiers in Immunology, 2020, 11, 1817.	2.2	189
407	Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses. Frontiers in Pharmacology, 2020, 11, 1024.	1.6	25
408	Hereditary ATTR Amyloidosis in Austria: Prevalence and Epidemiological Hot Spots. Journal of Clinical Medicine, 2020, 9, 2234.	1.0	10
409	Modulating the Crosstalk between the Tumor and Its Microenvironment Using RNA Interference: A Treatment Strategy for Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 5250.	1.8	12
410	Nuclear imaging approaches facilitating nanomedicine translation. Advanced Drug Delivery Reviews, 2020, 154-155, 123-141.	6.6	41
411	Transthyretin Familial Amyloid Polyneuropathy Mimicking Chronic Inflammatory Demyelinating Polyneuropathy. RRNMF Neuromuscular Journal, 2020, 1, 26-31.	0.1	0
412	Familial Oculo-Leptomeningeal Transthyretin Amyloidosis Caused by Leu55Arg Mutation. Journal of Neuromuscular Diseases, 2020, 7, 515-519.	1.1	5
413	Investigation of Strand-Selective Interaction of SNA-Modified siRNA with AGO2-MID. International Journal of Molecular Sciences, 2020, 21, 5218.	1.8	4
414	Diagnosis and treatment of transthyretinâ€related amyloidosis cardiomyopathy. Clinical Cardiology, 2020, 43, 1223-1231.	0.7	10
415	General Nanomedicine Platform by Solvent-Mediated Disassembly/Reassembly of Scalable Natural Polyphenol Colloidal Spheres. ACS Applied Materials & Interfaces, 2020, 12, 37914-37928.	4.0	25

#	Article	IF	Citations
416	Non-invasive detection and differentiation of cardiac amyloidosis using ^{99m}Tc-pyrophosphate scintigraphy and ¹¹C-Pittsburgh compound B PET imaging. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 266-274.	1.4	24
417	ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 259-265.	1.4	51
418	Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyretin Cardiac Amyloid. Current Cardiology Reports, 2020, 22, 106.	1.3	4
419	Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nature Reviews Neurology, 2020, 16, 529-546.	4.9	248
420	A Review of Patisiran (ONPATTROÂ®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis. Neurology and Therapy, 2020, 9, 301-315.	1.4	96
421	An RNAi therapeutic, DFP-10825, for intraperitoneal and intrapleural malignant cancers. Advanced Drug Delivery Reviews, 2020, 154-155, 27-36.	6.6	8
422	Disease-Modifying Pharmacological Therapies for Transthyretin Cardiac Amyloidosis. SN Comprehensive Clinical Medicine, 2020, 2, 1607-1613.	0.3	0
424	Triton X-100-Modified Adenosine Triphosphate-Responsive siRNA Delivery Agent for Antitumor Therapy. Molecular Pharmaceutics, 2020, 17, 3696-3708.	2.3	11
425	Lipid-Nucleic Acid Complexes: Physicochemical Aspects and Prospects for Cancer Treatment. Molecules, 2020, 25, 5006.	1.7	31
426	The Role of RNA Interference in Functional Cure Strategies for Chronic Hepatitis B. Current Hepatology Reports, 2020, 19, 362-369.	0.4	6
427	Patient-reported outcomes on familial amyloid polyneuropathy (FAP). Orphanet Journal of Rare Diseases, 2020, 15, 287.	1.2	2
428	Non-Viral Targeted Nucleic Acid Delivery: Apply Sequences for Optimization. Pharmaceutics, 2020, 12, 888.	2.0	13
429	Issues affecting nanomedicines on the way from the bench to the market. Journal of Materials Chemistry B, 2020, 8, 10681-10685.	2.9	14
430	SOD1-targeting therapies for neurodegenerative diseases: a review of current findings and future potential. Expert Opinion on Orphan Drugs, 2020, 8, 379-392.	0.5	2
431	Optimization of kinetic stabilizers of tetrameric transthyretin: A prospective ligand efficiency-guided approach. Bioorganic and Medicinal Chemistry, 2020, 28, 115794.	1.4	4
432	The Effects of Single Nucleotide Polymorphisms in Cancer RNAi Therapies. Cancers, 2020, 12, 3119.	1.7	6
433	In Vivo Quantification of Myocardial Amyloid Deposits in Patients with Suspected Transthyretin-Related Amyloidosis (ATTR). Journal of Clinical Medicine, 2020, 9, 3446.	1.0	19
434	Single-Stranded Phosphorothioated Regions Enhance Cellular Uptake of Cholesterol-Conjugated siRNA but Not Silencing Efficacy. Molecular Therapy - Nucleic Acids, 2020, 21, 991-1005.	2.3	22

#	Article	IF	Citations
435	Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples. Mayo Clinic Proceedings, 2020, 95, 1852-1864.	1.4	105
436	Hereditary motor neuropathies. Current Opinion in Neurology, 2020, 33, 568-574.	1.8	4
437	DNA Analogues Modified at the Nonlinking Positions of Phosphorus. Accounts of Chemical Research, 2020, 53, 2152-2166.	7.6	17
438	Potential use of noncoding RNAs and innovative therapeutic strategies to target the 5â€™UTR of SARS-CoV-2. Epigenomics, 2020, 12, 1349-1361.	1.0	34
439	Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems. Pharmaceutics, 2020, 12, 837.	2.0	99
440	Hereditary transthyretin amyloidosis: current treatment. Current Opinion in Neurology, 2020, 33, 553-561.	1.8	11
441	Specific Therapy for Transthyretin Cardiac Amyloidosis: A Systematic Literature Review and Evidenceâ€Based Recommendations. Journal of the American Heart Association, 2020, 9, e016614.	1.6	6
442	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Family Practice, 2020, 21, 198.	2.9	60
444	Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies. Neurology and Therapy, 2020, 9, 317-333.	1.4	59
445	An artificial cationic oligosaccharide combined with phosphorothioate linkages strongly improves siRNA stability. Scientific Reports, 2020, 10, 14845.	1.6	13
446	Moving Genomics to Routine Care. Circulation Genomic and Precision Medicine, 2020, 13, 406-416.	1.6	11
447	Gapmers. Methods in Molecular Biology, 2020, , .	0.4	1
448	RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges. Pharmacological Reviews, 2020, 72, 862-898.	7.1	192
449	Tyrosine-Modification of Polypropylenimine (PPI) and Polyethylenimine (PEI) Strongly Improves Efficacy of siRNA-Mediated Gene Knockdown. Nanomaterials, 2020, 10, 1809.	1.9	17
450	Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines . Therapeutics and Clinical Risk Management, 2020, Volume 16, 749-758.	0.9	18
451	Modified nucleic acids: replication, evolution, and next-generation therapeutics. BMC Biology, 2020, 18, 112.	1.7	77
452	Advanced Nuclear Medicine and Molecular Imaging in the Diagnosis of Cardiomyopathy. American Journal of Roentgenology, 2020, 215, 1208-1217.	1.0	5
453	Transthyretin Amyloidogenesis Inhibitors: From Discovery to Current Developments. Journal of Medicinal Chemistry, 2020, 63, 14228-14242.	2.9	24

#	Article	IF	Citations
454	Inter-observer reproducibility and intra-observer repeatability in 99mTc-pyrophosphate scan interpretation for diagnosis of transthyretin cardiac amyloidosis. Journal of Nuclear Cardiology, 2022, 29, 440-446.	1.4	8
455	Development of tooth regenerative medicine strategies by controlling the number of teeth using targeted molecular therapy. Inflammation and Regeneration, 2020, 40, 21.	1.5	9
456	Rare genetic causes of complex kidney and urological diseases. Nature Reviews Nephrology, 2020, 16, 641-656.	4.1	27
457	Transport Oligonucleotidesâ€"A Novel System for Intracellular Delivery of Antisense Therapeutics. Molecules, 2020, 25, 3663.	1.7	12
459	Ex vivo Improvement of a von Willebrand Disease Type 2A Phenotype Using an Allele-Specific Small-Interfering RNA. Thrombosis and Haemostasis, 2020, 120, 1569-1579.	1.8	11
460	Treating Cystic Fibrosis with mRNA and CRISPR. Human Gene Therapy, 2020, 31, 940-955.	1.4	35
461	siRNA Packaged with Neutral Cytidinyl/Cationic/PEG Lipids for Enhanced Antitumor Efficiency and Safety In Vitro and In Vivo. ACS Applied Bio Materials, 2020, 3, 6297-6309.	2.3	8
462	Treatment of Colon Cancer by Degradable rrPPC Nano-Conjugates Delivered STAT3 siRNA . International Journal of Nanomedicine, 2020, Volume 15, 9875-9890.	3.3	22
465	Investigation of Brain Functions Using Genetically Encoded Tools. Neuroscience and Behavioral Physiology, 2020, 50, 1051-1056.	0.2	1
466	RNA and Oxidative Stress in Alzheimerâ€™s Disease: Focus on microRNAs. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-16.	1.9	66
467	Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects. Brain Sciences, 2020, 10, 952.	1.1	9
468	Modulation of the Mechanisms Driving Transthyretin Amyloidosis. Frontiers in Molecular Neuroscience, 2020, 13, 592644.	1.4	24
469	Emerging Role and Therapeutic Potential of lncRNAs in Colorectal Cancer. Cancers, 2020, 12, 3843.	1.7	29
470	Decoding the Nanoenvironment in Cardiac Amyloidosis Through Proteomics. JACC: CardioOncology, 2020, 2, 644-646.	1.7	0
471	Early-Onset of Transthyretin Amyloidosis in a Young Afro-Caribbean Woman With Thr60Ala Mutation. JACC: Case Reports, 2020, 2, 2063-2067.	0.3	2
472	Disease-Modifying Therapy for Transthyretin Amyloidosis. JACC: Case Reports, 2020, 2, 2128-2130.	0.3	3
473	Cyclodextrin-Based Nanostructure Efficiently Delivers siRNA to Glioblastoma Cells Preferentially via Macropinocytosis. International Journal of Molecular Sciences, 2020, 21, 9306.	1.8	9
474	Double trouble: severe aortic stenosis and cardiac amyloidosis. Wiener Klinische Wochenschrift, 2020, 132, 705-707.	1.0	1

#	Article	IF	Citations
475	Comparison of 18F-sodium fluoride positron emission tomography imaging and 99mTc-pyrophosphate in cardiac amyloidosis. Journal of Nuclear Cardiology, 2022, 29, 1132-1140.	1.4	11
476	LncRNAs in Cancer: From garbage to Junk. Cancers, 2020, 12, 3220.	1.7	41
477	Aerosolizable Lipid Nanoparticles for Pulmonary Delivery of mRNA through Design of Experiments. Pharmaceutics, 2020, 12, 1042.	2.0	75
478	Future Perspectives. Hematology/Oncology Clinics of North America, 2020, 34, 1205-1214.	0.9	4
479	Emerging siRNA Design Principles and Consequences for Biotransformation and Disposition in Drug Development. Journal of Medicinal Chemistry, 2020, 63, 6407-6422.	2.9	16
480	Validation of RESP and PRESERVE score for ARDS patients with pumpless extracorporeal lung assist (pECLA). BMC Anesthesiology, 2020, 20, 102.	0.7	2
481	Patisiran, an RNAi therapeutic for patients with hereditary transthyretinâ€mediated amyloidosis: Subâ€analysis in Japanese patients from the APOLLO study. Neurology and Clinical Neuroscience, 2020, 8, 251-260.	0.2	3
482	Machine Learning Enables Prediction of Cardiac Amyloidosis by Routine Laboratory Parameters: A Proof-of-Concept Study. Journal of Clinical Medicine, 2020, 9, 1334.	1.0	13
483	Protein and mRNA Delivery Enabled by Cholesterylâ€Based Biodegradable Lipidoid Nanoparticles. Angewandte Chemie - International Edition, 2020, 59, 14957-14964.	7.2	44
484	Gene Therapy for the Heart Lessons Learned and Future Perspectives. Circulation Research, 2020, 126, 1394-1414.	2.0	81
485	Nanoparticles containing constrained phospholipids deliver <scp>mRNA</scp> to liver immune cells in vivo without targeting ligands. Bioengineering and Translational Medicine, 2020, 5, e10161.	3.9	36
486	Delivery of RNAi-Based Therapeutics for Bone Regeneration. Current Osteoporosis Reports, 2020, 18, 312-324.	1.5	17
487	Acquired and inherited amyloidosis: Knowledge driving patients' care. Journal of the Peripheral Nervous System, 2020, 25, 85-101.	1.4	12
488	Quantification of cardiac amyloid with [¹⁸F]Flutemetamol in patients with V30M hereditary transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 191-199.	1.4	14
489	The Clinical and Economic Burden of Newly Diagnosed Hereditary Transthyretin (ATTRv) Amyloidosis: A Retrospective Analysis of Claims Data. Neurology and Therapy, 2020, 9, 473-482.	1.4	5
491	TTRMDB: A database for structural and functional analysis on the impact of SNPs over transthyretin (TTR) using bioinformatic tools. Computational Biology and Chemistry, 2020, 87, 107290.	1.1	8
492	Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis. Journal of the American College of Cardiology, 2020, 75, 2851-2862.	1.2	131
493	Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation, 2020, 142, e7-e22.	1.6	338

#	Article	IF	Citations
494	The sensitivity of DPD scintigraphy to detect transthyretin cardiac amyloidosis in V30M mutation depends on the phenotypic expression of the disease. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 174-183.	1.4	16
495	Screening for genetic mutations in patients with neuropathy without definite etiology is useful. Journal of Neurology, 2020, 267, 2648-2654.	1.8	8
496	Cardiac Care of Patients with Cardiac Amyloidosis. Acta Haematologica, 2020, 143, 343-351.	0.7	9
497	Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities. Nature Communications, 2020, 11, 2517.	5.8	60
498	Significance of Single-Nucleotide Variants in Long Intergenic Non-protein Coding RNAs. Frontiers in Cell and Developmental Biology, 2020, 8, 347.	1.8	30
499	Protein and mRNA Delivery Enabled by Cholesterylâ€Based Biodegradable Lipidoid Nanoparticles. Angewandte Chemie, 2020, 132, 15067-15074.	1.6	15
500	Regulatory function of <scp>microRNAs</scp> in microglia. Glia, 2020, 68, 1631-1642.	2.5	44
501	MicroRNA Regulation of the Small Rho GTPase Regulatorsâ€"Complexities and Opportunities in Targeting Cancer Metastasis. Cancers, 2020, 12, 1092.	1.7	16
502	Experience of patisiran with transthyretin stabilizers in patients with hereditary transthyretin-mediated amyloidosis. Neurodegenerative Disease Management, 2020, 10, 289-300.	1.2	7
503	â€œElectrifying dysmorphologyâ€• Potassium channelopathies causing dysmorphic syndromes. Advances in Genetics, 2020, 105, 137-174.	0.8	18
504	Nanotechnology for COVID-19: Therapeutics and Vaccine Research. ACS Nano, 2020, 14, 7760-7782.	7.3	289
505	Therapeutic siRNA: state of the art. Signal Transduction and Targeted Therapy, 2020, 5, 101.	7.1	674
506	Silencing of MYH7 ameliorates disease phenotypes in human iPSC-cardiomyocytes. Physiological Genomics, 2020, 52, 293-303.	1.0	29
507	Selfâ€Degradable Lipidâ€Like Materials Based on â€œHydrolysis accelerated by the intraâ€Particle Enrichment of Reactant (HyPER)â€•for Messenger RNA Delivery. Advanced Functional Materials, 2020, 30, 1910575.	7.8	65
508	Catheter ablation of atrial fibrillation in cardiac amyloidosis. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 913-921.	0.5	14
509	Parallel evolution of polymer chemistry and immunology: Integrating mechanistic biology with materials design. Advanced Drug Delivery Reviews, 2020, 156, 65-79.	6.6	15
510	Genetically Encoded Split-Luciferase Biosensors to Measure Endosome Disruption Rapidly in Live Cells. ACS Sensors, 2020, 5, 1929-1936.	4.0	14
511	Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German/Austrian position and review of the literature. Journal of Neurology, 2021, 268, 3610-3625.	1.8	19

#	Article	IF	Citations
512	Poor Yield of Routine Transthyretin Screening in Patients with Idiopathic Neuropathy. Canadian Journal of Neurological Sciences, 2020, 47, 816-819.	0.3	5
513	Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection. Pharmaceutics, 2020, 12, 520.	2.0	16
514	Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics. Advanced Functional Materials, 2020, 30, 2003054.	7.8	83
515	Targeting the oncogene LSF with either the small molecule inhibitor FQI1 or siRNA causes mitotic delays with unaligned chromosomes, resulting in cell death or senescence. BMC Cancer, 2020, 20, 552.	1.1	8
517	Molecular Imaging of Amyloid Deposits for Early Diagnosis of CardiacÂAmyloidosis andÂMonitoringÂTreatment Response. JACC: Cardiovascular Imaging, 2020, 13, 1348-1352.	2.3	5
518	Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury. Pharmacological Reviews, 2020, 72, 639-667.	7.1	45
519	Solid Organ Transplantation in Amyloidosis. Acta Haematologica, 2020, 143, 352-364.	0.7	10
520	Particle-Size-Dependent Delivery of Antitumoral miRNA Using Targeted Mesoporous Silica Nanoparticles. Pharmaceutics, 2020, 12, 505.	2.0	27
521	Givosiran â€" Running RNA Interference to Fight Porphyria Attacks. New England Journal of Medicine, 2020, 382, 2366-2367.	13.9	15
522	From a misdiagnosis of anorexia nervosa to a dramatic patisiran-induced improvement in a patient with ATTRE89Q amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 279-280.	1.4	3
523	Quantitative Bone-Avid Tracer SPECT/CT for CardiacÂAmyloidosis: AÂCrucial Step Forward. JACC: Cardiovascular Imaging, 2020, 13, 1364-1367.	2.3	12
524	Population Pharmacokineticâ€“Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration. Nucleic Acid Therapeutics, 2020, 30, 143-152.	2.0	14
525	Fetal gene therapy and pharmacotherapy to treat congenital hearing loss and vestibular dysfunction. Hearing Research, 2020, 394, 107931.	0.9	16
526	Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. New England Journal of Medicine, 2020, 382, 1507-1519.	13.9	758
527	Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors . Drug Design, Development and Therapy, 2020, Volume 14, 1057-1081.	2.0	15
528	Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study. Orphanet Journal of Rare Diseases, 2020, 15, 67.	1.2	15
529	Osteoblasts mineralization and collagen matrix are conserved upon specific Col1a2 silencing. Matrix Biology Plus, 2020, 6-7, 100028.	1.9	6
530	Modulating the immune response with liposomal delivery. , 2020, , 159-211.		2

#	Article	IF	Citations
531	Inborn errors of apolipoprotein A-I metabolism. Current Opinion in Lipidology, 2020, 31, 62-70.	1.2	17
532	Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 153-162.	1.4	47
533	The success of nanomedicine. Nano Today, 2020, 31, 100853.	6.2	69
534	RT-qPCR Methods to Support Pharmacokinetics and Drug Mechanism of Action to Advance Development of RNAi Therapeutics. Nucleic Acid Therapeutics, 2020, 30, 133-142.	2.0	10
535	Characterization of Cationic Bolaamphiphile Vesicles for siRNA Delivery into Tumors and Brain. Molecular Therapy - Nucleic Acids, 2020, 20, 359-372.	2.3	24
537	Targeted gene silencing in vivo by platelet membraneâ€“coated metal-organic framework nanoparticles. Science Advances, 2020, 6, eaaz6108.	4.7	208
538	Chemical Synthesis and Biological Application of Modified Oligonucleotides. Bioconjugate Chemistry, 2020, 31, 1213-1233.	1.8	50
539	Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy. Neurology and Therapy, 2020, 9, 135-149.	1.4	3
540	Chimeric siRNAs with chemically modified pentofuranose and hexopyranose nucleotides: altritol-nucleotide (ANA) containing GalNAcâ€“siRNA conjugates: in vitro and in vivo RNAi activity and resistance to 5â€²-exonuclease. Nucleic Acids Research, 2020, 48, 4028-4040.	6.5	27
541	Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care . Therapeutics and Clinical Risk Management, 2020, Volume 16, 109-123.	0.9	78
542	Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis. Canadian Journal of Cardiology, 2020, 36, 322-334.	0.8	68
543	Compression of Vectors for Small Interfering RNAs Delivery: Toward Oral Administration of siRNA Lipoplexes in Tablet Forms. Molecular Pharmaceutics, 2020, 17, 1159-1169.	2.3	8
544	Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS). Expert Opinion on Therapeutic Targets, 2020, 24, 295-310.	1.5	49
545	POE Immunoassay: Plate-based oligonucleotide electro-chemiluminescent immunoassay for the quantification of nucleic acids in biological matrices. Scientific Reports, 2020, 10, 10425.	1.6	11
546	Noncoding RNAs in Cardiovascular Disease: Current Knowledge, Tools and Technologies for Investigation, and Future Directions: A Scientific Statement From the American Heart Association. Circulation Genomic and Precision Medicine, 2020, 13, e000062.	1.6	61
547	Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. Journal of Clinical Medicine, 2020, 9, 2004.	1.0	239
548	Systemic Amyloidosis Recognition, Prognosis, and Therapy. JAMA - Journal of the American Medical Association, 2020, 324, 79.	3.8	152
549	Nanoparticle-siRNA: A potential strategy for rheumatoid arthritis therapy?. Journal of Controlled Release, 2020, 325, 380-393.	4.8	26

#	Article	IF	Citations
550	TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 250-253.	1.4	19
551	Bioinformatics analysis reveals four major hexon variants of human adenovirus type-3 (HAdV-3) as the potential strains for development of vaccine and siRNA-based therapeutics against HAdV-3 respiratory infections. Infection, Genetics and Evolution, 2020, 85, 104439.	1.0	2
552	Role of Lipid-Based and Polymer-Based Non-Viral Vectors in Nucleic Acid Delivery for Next-Generation Gene Therapy. Molecules, 2020, 25, 2866.	1.7	118
553	Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug. Molecular Therapy, 2020, 28, 1759-1771.	3.7	177
554	A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Orphanet Journal of Rare Diseases, 2020, 15, 179.	1.2	33
555	Nucleic acid therapeutics in neurodevelopmental disease. Current Opinion in Genetics and Development, 2020, 65, 112-116.	1.5	7
556	Lipid nanoparticle technology for therapeutic gene regulation in the liver. Advanced Drug Delivery Reviews, 2020, 159, 344-363.	6.6	187
557	V122I Transthyretin Cardiomyopathy. Journal of the American College of Cardiology, 2020, 76, 93-95.	1.2	3
558	Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nature Reviews Clinical Oncology, 2020, 17, 251-266.	12.5	408
559	The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy. Current Medical Research and Opinion, 2020, 36, 799-808.	0.9	4
561	Multimodality Imaging in the Evaluation and Management of Cardiac Amyloidosis. Seminars in Nuclear Medicine, 2020, 50, 295-310.	2.5	6
562	Diagnostic imaging of cardiac amyloidosis. Nature Reviews Cardiology, 2020, 17, 413-426.	6.1	84
563	Multivalent Peptide-Functionalized Bioreducible Polymers for Cellular Delivery of Various RNAs. Biomacromolecules, 2020, 21, 1613-1624.	2.6	16
564	Artificial peptides for antitumoral siRNA delivery. Journal of Materials Chemistry B, 2020, 8, 2020-2031.	2.9	8
565	Options in extracorporeal support of multiple organ failure. Medizinische Klinik - Intensivmedizin Und Notfallmedizin, 2020, 115, 28-36.	0.4	13
566	Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives. Nanomaterials, 2020, 10, 364.	1.9	138
567	Hereditary Transthyretin Amyloidosis: Clinical Presentation and Management Updates. Journal of Clinical Neuromuscular Disease, 2020, 21, 144-156.	0.3	7
568	Amyloid cardiomyopathy. Herz, 2020, 45, 267-271.	0.4	10

#	Article	IF	Citations
569	Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovascular Drugs and Therapy, 2020, 34, 357-370.	1.3	55
570	Synthesis and mechanistic investigations of pH-responsive cationic poly(aminoester)s. Chemical Science, 2020, 11, 2951-2966.	3.7	26
571	Small interfering RNA from the lab discovery to patients' recovery. Journal of Controlled Release, 2020, 321, 616-628.	4.8	42
572	Cyclodextrins in drug delivery: applications in gene and combination therapy. Drug Delivery and Translational Research, 2020, 10, 661-677.	3.0	57
573	Downregulation of the Arg/N-degron Pathway Sensitizes Cancer Cells to Chemotherapy InÂVivo. Molecular Therapy, 2020, 28, 1092-1104.	3.7	19
574	Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles InÂVitro and InÂVivo. Molecular Therapy - Nucleic Acids, 2020, 19, 1357-1367.	2.3	53
575	An antibody against pre-amyloid oligomers: a potential clinical tool or merely an intriguing observation?. European Heart Journal, 2020, 41, 1271-1272.	1.0	1
576	Long non-coding RNAs in immune regulation and their potential as therapeutic targets. International Immunopharmacology, 2020, 81, 106279.	1.7	18
577	MicroRNA-195 Functions as a Tumor Suppressor by Directly Targeting Fatty Acid Synthase in Malignant Meningioma. World Neurosurgery, 2020, 136, e355-e364.	0.7	23
578	Chemoenzymatic Preparation of Functional Clickâ€Labeled Messenger RNA. ChemBioChem, 2020, 21, 1641-1646.	1.3	15
579	Functional extracellular vesicles aplenty. Nature Biomedical Engineering, 2020, 4, 9-11.	11.6	23
580	Targeting the Oncogenic Long Non-coding RNA SLNCR1 by Blocking Its Sequence-Specific Binding to the Androgen Receptor. Cell Reports, 2020, 30, 541-554.e5.	2.9	47
581	Emerging Concepts and Challenges in Rheumatoid Arthritis Gene Therapy. Biomedicines, 2020, 8, 9.	1.4	28
582	Should the Reporting of Bone Marrow Positivity for Amyloid Be Revised?: A Critical Assessment Based on 66 Biopsies From a Single Institution. Archives of Pathology and Laboratory Medicine, 2020, 144, 967-973.	1.2	5
583	Amyloidosis as a Systemic Disease in Context. Canadian Journal of Cardiology, 2020, 36, 396-407.	0.8	28
584	Diagnostic delay in wild type transthyretin cardiac amyloidosis â€“ A clinical challenge. International Journal of Cardiology, 2020, 304, 138-143.	0.8	38
585	Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. Annual Review of Medicine, 2020, 71, 203-219.	5.0	82
586	Determinants and Prognostic Significance of Serial Right Heart Function Changes in Patients With Cardiac Amyloidosis. Canadian Journal of Cardiology, 2020, 36, 432-440.	0.8	10

#	Article	IF	Citations
587	Bone Scintigraphy Imaging for Transthyretin Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 1322-1324.	2.3	4
588	Reappraising the role of inflammation in heart failure. Nature Reviews Cardiology, 2020, 17, 269-285.	6.1	389
589	RNA Interference for the Masses? siRNA Targeting PCSK9 Promises Prevention of Cardiovascular Disease. Nucleic Acid Therapeutics, 2020, 30, 1-3.	2.0	7
590	Pharmacological treatment for familial amyloid polyneuropathy. The Cochrane Library, 2020, 4, CD012395.	1.5	8
591	Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis. Current Heart Failure Reports, 2020, 17, 77-83.	1.3	6
592	Improving Molecular Therapy in the Kidney. Molecular Diagnosis and Therapy, 2020, 24, 375-396.	1.6	18
593	Generation and validation of structurally defined antibodyâ€“siRNA conjugates. Nucleic Acids Research, 2020, 48, 5281-5293.	6.5	26
594	Grand Challenges in Gene and Epigenetic Editing for Neurologic Disease. Frontiers in Genome Editing, 2020, 1, 1.	2.7	2
595	Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies. Journal of the Neurological Sciences, 2020, 414, 116813.	0.3	19
596	From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases. European Heart Journal, 2020, 41, 3884-3899.	1.0	58
597	Gene delivery into cells and tissues. , 2020, , 519-554.		3
598	Disparities, Uncertainties, and Societal Cost: Precision Medicine and Transthyretin Amyloidosis. American Journal of Medicine, 2020, 133, 892-894.	0.6	2
599	Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis. Cell Metabolism, 2020, 31, 969-986.e7.	7.2	117
600	Follow-up in transthyretin familial amyloid polyneuropathy: Useful investigations. Journal of the Neurological Sciences, 2020, 413, 116776.	0.3	5
601	Systemic amyloidosis: moving into the spotlight. Leukemia, 2020, 34, 1215-1228.	3.3	22
602	Particle-mediated delivery of frataxin plasmid to a human sensory neuronal model of Friedreich's ataxia. Biomaterials Science, 2020, 8, 2398-2403.	2.6	6
603	Amyloid in the Lung. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 299-310.	0.8	9
604	MYCN Silencing by RNAi Induces Neurogenesis and Suppresses Proliferation in Models of Neuroblastoma with Resistance to Retinoic Acid. Nucleic Acid Therapeutics, 2020, 30, 237-248.	2.0	9

#	Article	IF	Citations
605	The Changing Face of Nuclear Cardiology: Guiding Cardiovascular Care Toward Molecular Medicine. Journal of Nuclear Medicine, 2020, 61, 951-961.	2.8	31
606	The Delivery of RNA-Interference Therapies Based on Engineered Hydrogels for Bone Tissue Regeneration. Frontiers in Bioengineering and Biotechnology, 2020, 8, 445.	2.0	23
607	Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Revue Neurologique, 2020, 176, 507-515.	0.6	71
608	Advances in the Treatment of Cardiac Amyloidosis. Current Treatment Options in Oncology, 2020, 21, 36.	1.3	39
609	Long Non-Coding RNAs in Biliary Tract Cancerâ€"An Up-to-Date Review. Journal of Clinical Medicine, 2020, 9, 1200.	1.0	14
610	Trimeric Small Interfering RNAs and Their Cholesterol-Containing Conjugates Exhibit Improved Accumulation in Tumors, but Dramatically Reduced Silencing Activity. Molecules, 2020, 25, 1877.	1.7	6
611	Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis. Annals of Clinical and Translational Neurology, 2020, 7, 799-807.	1.7	20
612	RNAi-Based Gene Therapy Rescues Developmental and Epileptic Encephalopathy in a Genetic Mouse Model. Molecular Therapy, 2020, 28, 1706-1716.	3.7	15
613	Naturally occurring modified ribonucleosides. Wiley Interdisciplinary Reviews RNA, 2020, 11, e1595.	3.2	108
614	Epidemiologic and Survival Trends in Amyloidosis, 1987â€"2019. New England Journal of Medicine, 2020, 382, 1567-1568.	13.9	77
615	The Use of Genomics to Drive Kidney Disease Drug Discovery and Development. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1342-1351.	2.2	5
616	Lipid Nanoparticles for Cell-Specific <i>in Vivo</i> Targeted Delivery of Nucleic Acids. Biological and Pharmaceutical Bulletin, 2020, 43, 584-595.	0.6	43
617	The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinsonâ€™s Disease. Cells, 2020, 9, 841.	1.8	51
618	Phasic left atrial strain analysis to discriminate cardiac amyloidosis in patients with unclear thick heart pathology. European Heart Journal Cardiovascular Imaging, 2021, 22, 680-687.	0.5	26
619	Pharmacodynamic and Pharmacokinetic Properties of Full Phosphorothioate Small Interfering RNAs for Gene Silencing In Vivo. Nucleic Acid Therapeutics, 2021, 31, 237-244.	2.0	10
620	Optimizing synthetic nucleic acid and protein nanocarriers: The chemical evolution approach. Advanced Drug Delivery Reviews, 2021, 168, 30-54.	6.6	49
621	Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center. Revista Espanola De Cardiologia (English Ed), 2021, 74, 149-158.	0.4	10
622	Non-coding RNA therapeutics for cardiac regeneration. Cardiovascular Research, 2021, 117, 674-693.	1.8	56

#	Article	IF	Citations
623	Opportunities and challenges for antisense oligonucleotide therapies. Journal of Inherited Metabolic Disease, 2021, 44, 72-87.	1.7	86
624	Cardiac Amyloidosis in Patients Undergoing TAVR: Why We Need to Think About It. Cardiovascular Revascularization Medicine, 2021, 22, 109-114.	0.3	8
625	Editorial Commentary: Advances in transthyretin amyloid cardiomyopathy. Trends in Cardiovascular Medicine, 2021, 31, 67-68.	2.3	0
626	The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types. Blood Reviews, 2021, 45, 100720.	2.8	15
627	BIOANALYSIS AND BIOTRANSFORMATION OF OLIGONUCLEOTIDE THERAPEUTICS BY LIQUID CHROMATOGRAPHYâ€MASS SPECTROMETRY. Mass Spectrometry Reviews, 2021, 40, 334-358.	2.8	23
628	Singleâ€Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting Nâ€acetylgalactosamineâ€“Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects. Clinical Pharmacology and Therapeutics, 2021, 109, 372-382.	2.3	88
629	Targeted Engineering of Medicinal Chemistry for Cancer Therapy: Recent Advances and Perspectives. Angewandte Chemie - International Edition, 2021, 60, 5626-5643.	7.2	47
630	Zielgerichtete Wirkstoffe fÃ¼r die Krebstherapie: Aktuelle Entwicklungen und Perspektiven. Angewandte Chemie, 2021, 133, 5686-5705.	1.6	3
631	Examining the sensitivity of 18F-NaF PET for the imaging of cardiac amyloidosis. Journal of Nuclear Cardiology, 2021, 28, 209-218.	1.4	36
632	Diagnosing cardiac amyloidosis: A wealth of new possibilities with nuclear cardiac imaging. Journal of Nuclear Cardiology, 2021, 28, 219-224.	1.4	2
633	Autophagy in cardiovascular diseases: role of noncoding RNAs. Molecular Therapy - Nucleic Acids, 2021, 23, 101-118.	2.3	27
634	In Search of the Holy Grail. JACC: Cardiovascular Imaging, 2021, 14, 200-202.	2.3	1
635	Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. JACC: Cardiovascular Imaging, 2021, 14, 189-199.	2.3	113
636	Prevalence and Outcomes of Concomitant Aortic Stenosis and CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2021, 77, 128-139.	1.2	187
637	Targeting transthyretin â€•Mechanismâ€based treatment approaches and future perspectives in hereditary amyloidosis. Journal of Neurochemistry, 2021, 156, 802-818.	2.1	16
638	Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers. Journal of Neurology, 2021, 268, 189-198.	1.8	38
640	Nanoplatforms for mRNA Therapeutics. Advanced Therapeutics, 2021, 4, .	1.6	62
641	Treating PMP22 gene duplication-related Charcot-Marie-Tooth disease: the past, the present and the future. Translational Research, 2021, 227, 100-111.	2.2	30

#	Article	IF	Citations
642	Clinical Translation of Selfâ€Assembled Cancer Nanomedicines. Advanced Therapeutics, 2021, 4, .	1.6	34
643	Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation. Journal of Controlled Release, 2021, 329, 676-695.	4.8	111
644	Analytical characterization of liposomes and other lipid nanoparticles for drug delivery. Journal of Pharmaceutical and Biomedical Analysis, 2021, 192, 113642.	1.4	165
645	Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis. Neurology, 2021, 96, e412-e422.	1.5	52
646	Antisense Drugs Make Sense for Neurological Diseases. Annual Review of Pharmacology and Toxicology, 2021, 61, 831-852.	4.2	54
647	Advances in pharmacotherapy for cardiac amyloidosis. Expert Opinion on Pharmacotherapy, 2021, 22, 469-481.	0.9	3
648	Branched Antisense and siRNA Coâ€Assembled Nanoplatform for Combined Gene Silencing and Tumor Therapy. Angewandte Chemie - International Edition, 2021, 60, 1853-1860.	7.2	48
649	Branched Antisense and siRNA Coâ€Assembled Nanoplatform for Combined Gene Silencing and Tumor Therapy. Angewandte Chemie, 2021, 133, 1881-1888.	1.6	10
650	Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model. American Journal of Hematology, 2021, 96, 251-257.	2.0	5
651	Targeted delivery of small noncoding RNA for glioblastoma. Cancer Letters, 2021, 500, 274-280.	3.2	12
652	RNA interference-mediated suppression of TNF-Î± converting enzyme as an alternative anti-TNF-Î± therapy for rheumatoid arthritis. Journal of Controlled Release, 2021, 330, 1300-1312.	4.8	14
653	Genetic mechanisms of peripheral nerve disease. Neuroscience Letters, 2021, 742, 135357.	1.0	25
654	Reference Ranges, Diagnostic and Prognostic Utility of Native <scp>T1</scp> Mapping and Extracellular Volume for Cardiac Amyloidosis: A Metaâ€Analysis. Journal of Magnetic Resonance Imaging, 2021, 53, 1458-1468.	1.9	13
655	New immunoprobe: Dual-labeling ZIF-8 embellished with multifunctional bovine serum albumin lamella for electrochemical immunoassay of tumor marker. Biosensors and Bioelectronics, 2021, 175, 112853.	5.3	25
656	Bone fracture healing: perspectives according to molecular basis. Journal of Bone and Mineral Metabolism, 2021, 39, 311-331.	1.3	17
657	New treatment for myocardial diseases. Journal of Cardiology, 2021, 77, 620-625.	0.8	3
658	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurology, The, 2021, 20, 49-59.	4.9	93
659	Patisiran in hereditary transthyretin-mediated amyloidosis. Lancet Neurology, The, 2021, 20, 21-23.	4.9	9

#	Article	IF	Citations
660	Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 91-99.	1.4	8
661	Association of Low Plasma Transthyretin Concentration With Risk of Heart Failure in the General Population. JAMA Cardiology, 2021, 6, 258.	3.0	12
662	Tenosynovial complications identify TTR cardiac amyloidosis among patients with hypertrophic cardiomyopathy phenotype. Journal of Internal Medicine, 2021, 289, 831-839.	2.7	12
663	Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Failure, 2021, 8, 652-661.	1.4	43
664	Nucleic acids therapeutics using PolyPurine Reverse Hoogsteen hairpins. Biochemical Pharmacology, 2021, 189, 114371.	2.0	13
665	To Conjugate or to Package? A Look at Targeted siRNA Delivery Through Folate Receptors. Nucleic Acid Therapeutics, 2021, 31, 21-38.	2.0	5
666	Distribution of amyloidosis subtypes based on tissue biopsy site â^' Consecutive analysis of 729 patients at a single amyloidosis center in Japan. Pathology International, 2021, 71, 70-79.	0.6	18
667	Vincristine- and bortezomib-induced neuropathies â€“ from bedside to bench and back. Experimental Neurology, 2021, 336, 113519.	2.0	18
668	Rod-shaped polypeptide nanoparticles for siRNA delivery. International Journal of Biological Macromolecules, 2021, 166, 401-408.	3.6	5
669	Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 24-29.	1.4	22
670	Oligonucleotideâ€Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases. Hepatology, 2021, 73, 1581-1593.	3.6	4
671	Antisense drug discovery and development technology considered in a pharmacological context. Biochemical Pharmacology, 2021, 189, 114196.	2.0	55
672	Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 50-55.	1.4	28
673	Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy. Expert Opinion on Pharmacotherapy, 2021, 22, 121-129.	0.9	12
674	Systemic amyloidosis from A (AA) to T (ATTR): a review. Journal of Internal Medicine, 2021, 289, 268-292.	2.7	133
675	Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. Journal of Neurology, 2021, 268, 2109-2122.	1.8	141
676	Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction. Trends in Cardiovascular Medicine, 2021, 31, 59-66.	2.3	14
677	SelecciÃ³n de lo mejor del aÃ±o 2020 en cardiopatÃas familiares y genÃ©tica cardiovascular. REC: CardioClinics, 2021, 56, 9-14.	0.1	0

#	Article	IF	Citations
678	Optimizing the Intracellular Delivery of Therapeutic Anti-inflammatory TNF-Î± siRNA to Activated Macrophages Using Lipidoid-Polymer Hybrid Nanoparticles. Frontiers in Bioengineering and Biotechnology, 2020, 8, 601155.	2.0	11
679	The emerging role of long noncoding RNAs in esophageal carcinoma: from underlying mechanisms to clinical implications. Cellular and Molecular Life Sciences, 2021, 78, 3403-3422.	2.4	8
680	Application of Nanotechnology in the COVID-19 Pandemic. International Journal of Nanomedicine, 2021, Volume 16, 623-649.	3.3	60
681	Epigenetics and regenerative medicine. , 2021, , 853-872.		0
682	Identification of a potent ionizable lipid for efficient macrophage transfection and systemic anti-interleukin-1Î² siRNA delivery against acute liver failure. Journal of Materials Chemistry B, 2021, 9, 5136-5149.	2.9	10
683	Modified internucleoside linkages for nuclease-resistant oligonucleotides. RSC Chemical Biology, 2021, 2, 94-150.	2.0	35
684	Computational and Experimental Approaches to Investigate Lipid Nanoparticles as Drug and Gene Delivery Systems. Current Topics in Medicinal Chemistry, 2021, 21, 92-114.	1.0	16
685	Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clinical Research in Cardiology, 2021, 110, 479-506.	1.5	57
686	Modulation of noncoding RNAs (ncRNAs) and their potential role as therapeutics. , 2021, , 721-740.		0
687	Selection of Chemical Modifications in the siRNA Seed Region That Repress Off-Target Effect. Methods in Molecular Biology, 2021, 2282, 17-30.	0.4	5
688	Therapeutic strategies for modulating epigenetic mechanisms in cardiovascular disease. , 2021, , 349-373.		0
690	Early changes of nerve integrity in preclinical carriers of hereditary transthyretin Ala117Ser amyloidosis with polyneuropathy. European Journal of Neurology, 2021, 28, 982-991.	1.7	9
691	Recent progress in non-native nucleic acid modifications. Chemical Society Reviews, 2021, 50, 5126-5164.	18.7	155
692	Cardiac Amyloidosis. , 2021, , 37-69.		0
693	Harnessing nanotechnology to expand the toolbox of chemical biology. Nature Chemical Biology, 2021, 17, 129-137.	3.9	24
694	Preparation and Characterization of siRNA-Loaded Liposomes. Methods in Molecular Biology, 2021, 2282, 159-169.	0.4	4
695	Primary Restrictive, Infiltrative, and Storage Cardiomyopathies. , 2021, , 290-307.		0
696	Ionizable lipid nanoparticles for in utero mRNA delivery. Science Advances, 2021, 7, .	4.7	110

#	Article	IF	Citations
697	Novel Lipid-Oligonucleotide Conjugates Containing Long-Chain Sulfonyl Phosphoramidate Groups: Synthesis and Biological Properties. Applied Sciences (Switzerland), 2021, 11, 1174.	1.3	12
698	Cell and gene therapiesâ€"Emerging technologies and drug delivery systems for treating brain cancer. , 2021, , 431-446.		0
699	Does protein aggregation drive postmitotic tissue degeneration?. Science Translational Medicine, 2021, 13, .	5.8	12
700	In Vitro Silencing of lncRNA Expression Using siRNAs. Methods in Molecular Biology, 2021, 2348, 141-156.	0.4	3
701	PFRED: A computational platform for siRNA and antisense oligonucleotides design. PLoS ONE, 2021, 16, e0238753.	1.1	22
702	A perspective on RNA interference-based therapeutics for metabolic liver diseases. Expert Opinion on Investigational Drugs, 2021, 30, 237-244.	1.9	7
703	Case Study 12: Roadmap to Quantifying Ago2-Mediated siRNA Metabolic Kinetics. Methods in Molecular Biology, 2021, 2342, 825-841.	0.4	1
704	MicroRNAs Regulating Autophagy in Neurodegeneration. Advances in Experimental Medicine and Biology, 2021, 1208, 191-264.	0.8	1
706	Orthopaedic Manifestations of Amyloidosis. Journal of the American Academy of Orthopaedic Surgeons, The, 2021, 29, e488-e496.	1.1	11
707	Genomic Screening Identifies Individuals at High Risk for Hereditary Transthyretin Amyloidosis. Journal of Personalized Medicine, 2021, 11, 49.	1.1	8
709	Neuromuscular Complications of General Medical Disorders. , 2021, , 1057-1084.		0
710	Synthesis and evaluation of modified siRNA molecules containing a novel glucose derivative. RSC Advances, 2021, 11, 9285-9289.	1.7	1
711	Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis. Clinical Research in Cardiology, 2021, 110, 579-590.	1.5	3
712	New Enkephalin Nanomedicines for Pain Alleviation, Overcoming the Side Effects of Morphine. , 2021, , 191-212.		0
713	Targeted delivery of therapeutic agents to the heart. Nature Reviews Cardiology, 2021, 18, 389-399.	6.1	51
714	Illuminating endosomal escape of polymorphic lipid nanoparticles that boost mRNA delivery. Biomaterials Science, 2021, 9, 4289-4300.	2.6	52
715	Development of siRNA Therapeutics for the Treatment of Liver Diseases. Methods in Molecular Biology, 2021, 2282, 57-75.	0.4	7
716	Neuromuscular amyloidosis: Unmasking the master of disguise. Muscle and Nerve, 2021, 64, 23-36.	1.0	23

#	Article	IF	Citations
717	Frameworks for targeting RNA with small molecules. Journal of Biological Chemistry, 2021, 296, 100191.	1.6	35
718	Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles. ACS Nano, 2021, 15, 9627-9637.	7.3	66
719	Autonomic neuropathies and gastroparesis. , 2021, , 109-121.		0
720	Transthyretin amyloid cardiomyopathy. Medicina ClÃnica (English Edition), 2021, 156, 126-134.	0.1	6
721	Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA. ACS Pharmacology and Translational Science, 2021, 4, 703-712.	2.5	7
722	Development of an AAV9-RNAi-mediated silencing strategy to abrogate TRPM4 expression in the adult heart. Pflugers Archiv European Journal of Physiology, 2021, 473, 533-546.	1.3	5
724	Photocrosslinked Bioreducible Polymeric Nanoparticles for Enhanced Systemic siRNA Delivery as Cancer Therapy. Advanced Functional Materials, 2021, 31, 2009768.	7.8	29
725	Use of biomarkers to diagnose and manage cardiac amyloidosis. European Journal of Heart Failure, 2021, 23, 217-230.	2.9	33
726	Implementing genomic screening in diverse populations. Genome Medicine, 2021, 13, 17.	3.6	38
727	Late-onset Hereditary ATTR Amyloidosis with a Novel p.P63S (P43S) Transthyretin Variant. Internal Medicine, 2021, 60, 557-561.	0.3	0
728	New effective treatment options reinforce disease awareness: the case of transthyretin cardiac amyloidosis. European Journal of Heart Failure, 2021, 23, 290-292.	2.9	1
729	Perfil clÃnico y evoluciÃ³n de la amiloidosis cardiaca en un centro espaÃ±ol de referencia. Revista Espanola De Cardiologia, 2021, 74, 149-158.	0.6	33
730	Structural tuning of oligonucleotides for enhanced blood circulation properties of unit polyion complexes prepared from two-branched poly(ethylene glycol)-block-poly(l-lysine). Journal of Controlled Release, 2021, 330, 812-820.	4.8	15
731	A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	15
732	Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Failure Reviews, 2022, 27, 785-793.	1.7	31
733	Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management. Canadian Journal of Neurological Sciences, 2022, 49, 7-18.	0.3	9
734	Amiloidosis cardÃaca por transtiretina. Medicina ClÃnica, 2021, 156, 126-134.	0.3	22
735	Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis. BMC Neurology, 2021, 21, 70.	0.8	11

#	Article	IF	Citations
736	Targeting Beclin1 as an Adjunctive Therapy against HIV Using Mannosylated Polyethylenimine Nanoparticles. Pharmaceutics, 2021, 13, 223.	2.0	5
737	The Implications of ncRNAs in the Development of Human Diseases. Non-coding RNA, 2021, 7, 17.	1.3	28
738	Nerve biopsy: Current indications and decision tools. Muscle and Nerve, 2021, 64, 125-139.	1.0	25
739	Molecular Mechanisms of MYCN Dysregulation in Cancers. Frontiers in Oncology, 2020, 10, 625332.	1.3	22
740	A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis. Journal of Cardiovascular Pharmacology, 2021, 77, 544-548.	0.8	11
741	Enhanced detection of ATTR amyloid using a nanofibril-based assay. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 158-167.	1.4	4
742	Clinical approach to genetic testing in amyloid cardiomyopathy: from mechanism to effective therapies. Current Opinion in Cardiology, 2021, 36, 309-317.	0.8	3
743	In Vivo Production of RNA Aptamers and Nanoparticles: Problems and Prospects. Molecules, 2021, 26, 1422.	1.7	3
744	Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 967-973.	0.7	2
745	Nanomedicine-driven molecular targeting, drug delivery, and therapeutic approaches to cancer chemoresistance. Drug Discovery Today, 2021, 26, 724-739.	3.2	25
746	Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A. Communications Biology, 2021, 4, 317.	2.0	31
747	Management of genetic diseases: Present and future. Revista De La Facultad De Medicina Humana, 2021, 21, 399-416.	0.1	2
748	Updates in Cardiac Amyloidosis Diagnosis and Treatment. Current Oncology Reports, 2021, 23, 47.	1.8	17
749	Nanotechnologyâ€Based Strategies to Evaluate and Counteract Cancer Metastasis and Neoangiogenesis. Advanced Healthcare Materials, 2021, 10, e2002163.	3.9	14
750	Clinical comparison of V122I genotypic variant of transthyretin amyloid cardiomyopathy with wild-type and other hereditary variants: a systematic review. Heart Failure Reviews, 2022, 27, 849-856.	1.7	6
751	A cardiology fellowâ€™s take-home points from ASNCâ€™s Webinar: Cases in Tc 99m-PYP evaluation of ATTR cardiac amyloidosis - interpretation and reporting. Journal of Nuclear Cardiology, 2021, 28, 604-609.	1.4	2
752	Gene therapy strategies for idiopathic pulmonary fibrosis: recent advances, current challenges, and future directions. Molecular Therapy - Methods and Clinical Development, 2021, 20, 483-496.	1.8	21
753	Recent advances in the diagnosis and management of amyloid cardiomyopathy. Faculty Reviews, 2021, 10, 31.	1.7	4

#	Article	IF	Citations
754	Cardiac Amyloidosis Wild Type (ATTR-CAwt) and Associated Cardiac Arrhythmias: A Case Report and Literature Review. Indian Journal of Clinical Cardiology, 2021, 2, 80-85.	0.3	1
755	Emerging Therapeutic Approaches to Combat COVID-19: Present Status and Future Perspectives. Frontiers in Molecular Biosciences, 2021, 8, 604447.	1.6	28
756	RNA-based therapies: A cog in the wheel of lung cancer defense. Molecular Cancer, 2021, 20, 54.	7.9	53
757	Transthyretin Amyloid Cardiomyopathyâ€"Current and Future Therapies. Annals of Pharmacotherapy, 2021, 55, 1502-1514.	0.9	12
758	Cardiac Amyloidosis. , 0, , .		0
759	Viral Mimicry as a Design Template for Nucleic Acid Nanocarriers. Frontiers in Chemistry, 2021, 9, 613209.	1.8	9
760	Narrative review of pharmacotherapy for transthyretin cardiac amyloid. Annals of Translational Medicine, 2021, 9, 519-519.	0.7	5
761	Therapeutic RNA Delivery for COVID and Other Diseases. Advanced Healthcare Materials, 2021, 10, e2002022.	3.9	31
762	Novel approaches for vaccine development. Cell, 2021, 184, 1589-1603.	13.5	145
763	Diphenyl-Methane Based Thyromimetic Inhibitors for Transthyretin Amyloidosis. International Journal of Molecular Sciences, 2021, 22, 3488.	1.8	5
764	Nanotechnology for modern medicine: next step towards clinical translation. Journal of Internal Medicine, 2021, 290, 486-498.	2.7	88
765	iRGDâ€Liposomes Enhance Tumor Delivery and Therapeutic Efficacy of Antisense Oligonucleotide Drugs against Primary Prostate Cancer and Bone Metastasis. Advanced Functional Materials, 2021, 31, 2100478.	7.8	32
766	Adipocyte, Immune Cells, and miRNA Crosstalk: A Novel Regulator of Metabolic Dysfunction and Obesity. Cells, 2021, 10, 1004.	1.8	35
767	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568.	1.0	434
768	Polycatechol Mediated Small Interfering RNA Delivery for the Treatment of Ulcerative Colitis. Advanced Functional Materials, 2021, 31, 2101646.	7.8	30
769	Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis. Current Cardiovascular Risk Reports, 2021, 15, 1.	0.8	9
770	Recent Advances and Current Dilemmas in the Diagnosis and Management of Transthyretin Cardiac Amyloidosis. Journal of the American Heart Association, 2021, 10, e019840.	1.6	10
771	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp>orking <scp>G</scp>roup on <scp>M</scp>yocardial and <scp>P</scp>ericardial <scp>D</scp>iseases. European Journal of Heart Failure, 2021, 23, 512-526.	2.9	153

#	Article	IF	Citations
772	Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy. Brain Sciences, 2021, 11, 515.	1.1	8
773	Delivery of oligonucleotideâ€based therapeutics: challenges and opportunities. EMBO Molecular Medicine, 2021, 13, e13243.	3.3	181
774	Patisiran for advanced heart failure with hereditary transthyretin cardiac amyloidosis. Journal of Cardiology Cases, 2021, 23, 177-180.	0.2	3
775	RNA therapeutics in ophthalmology - translation to clinical trials. Experimental Eye Research, 2021, 205, 108482.	1.2	23
776	Use of Drugs for ATTRv Amyloidosis in the Real World: How Therapy Is Changing Survival in a Non-Endemic Area. Brain Sciences, 2021, 11, 545.	1.1	17
777	Transforming ATTR cardiac amyloidosis into a chronic disease: The enormous potential of quantitative SPECT to improve diagnosis, prognosis, and monitoring of disease progression. Journal of Nuclear Cardiology, 2021, 28, 1846-1850.	1.4	1
779	Glucocorticoid-induced leucine zipper regulates liver fibrosis by suppressing CCL2-mediated leukocyte recruitment. Cell Death and Disease, 2021, 12, 421.	2.7	9
780	Caveolae-Mediated Endocytosis Drives Robust siRNA Delivery of Polymeric Nanoparticles to Macrophages. ACS Nano, 2021, 15, 8267-8282.	7.3	42
781	Automated high-throughput preparation and characterization of oligonucleotide-loaded lipid nanoparticles. International Journal of Pharmaceutics, 2021, 599, 120392.	2.6	29
782	Transthyretin contributes to insulin resistance and diminishes exercise-induced insulin sensitivity in obese mice by inhibiting AMPK activity in skeletal muscle. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E808-E821.	1.8	4
783	ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. Orphanet Journal of Rare Diseases, 2021, 16, 204.	1.2	11
784	Current Challenges of Cardiac Amyloidosis Awareness among Romanian Cardiologists. Diagnostics, 2021, 11, 834.	1.3	3
785	Carpal Tunnel Syndrome Due to Iatrogenic Amyloidosis After Domino Liver Transplantation From Hereditary Transthyretin Amyloidosis: A Case Report. Transplantation Proceedings, 2021, 53, 1313-1316.	0.3	0
786	Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines. Pharmaceutics, 2021, 13, 644.	2.0	17
787	Very Early Onset of ATTRE89Q Amyloidosis in a Homozygous Patient. The Open Neurology Journal, 2021, 15, 21-24.	0.4	0
788	ASSOCIATION BETWEEN CHOROIDAL CHARACTERISTICS AND SYSTEMIC SEVERITY IN AMYLOIDOSIS. Retina, 2021, 41, 1037-1046.	1.0	10
789	Extension in the approaches to treat cancer through siRNA system: a beacon of hope in cancer therapy. Drug Delivery and Translational Research, 2022, 12, 1002-1016.	3.0	4
790	Cardiac Amyloidosis-Challenging Diagnosis and Unclear Clinical Picture. Medicina (Lithuania), 2021, 57, 450.	0.8	4

#	Article	IF	Citations
791	Multifunctional Liposomes Enable Active Targeting and Twinfilin 1 Silencing to Reverse Paclitaxel Resistance in Brain Metastatic Breast Cancer. ACS Applied Materials & Interfaces, 2021, 13, 23396-23409.	4.0	24
792	Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. European Journal of Clinical Investigation, 2021, 51, e13598.	1.7	16
793	Neurological involvement in Ile68Leu (p.Ile88Leu) ATTR amyloidosis: not only a cardiogenic mutation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 173-181.	1.4	5
794	ActualitÃ©s dans les neuropathies amyloÃ¯des. Pratique Neurologique - FMC, 2021, 12, 149-157.	0.1	0
795	Single AAV-mediated CRISPR-Nme2Cas9 efficiently reduces mutant hTTR expression in a transgenic mouse model of transthyretin amyloidosis. Molecular Therapy, 2022, 30, 164-174.	3.7	12
796	Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. Heart, 2022, 108, 474-478.	1.2	8
797	The current landscape of nucleic acid therapeutics. Nature Nanotechnology, 2021, 16, 630-643.	15.6	578
798	Polymeric Delivery of Therapeutic Nucleic Acids. Chemical Reviews, 2021, 121, 11527-11652.	23.0	138
799	Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis. Circulation Research, 2021, 128, 1554-1575.	2.0	52
800	Removing the idiopathic from the chronic sensory neuropathies. Brain, 2021, 144, 1291-1292.	3.7	1
801	Incidental cardiac uptake in bone scintigraphy: increased importance and association with cardiac amyloidosis. BJR|case Reports, 2021, 7, 20200161.	0.1	0
802	RNA interference activity of single-stranded oligonucleotides linked between the passenger strand and the guide strand with an aryl phosphate linker. Nucleosides, Nucleotides and Nucleic Acids, 2021, 40, 647-664.	0.4	1
803	Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance. Molecular Pharmaceutics, 2021, 18, 2218-2232.	2.3	12
804	Syntheses of Morpholine-Based Nucleotide Analogs for Hepatic siRNA Targeting and Stabilization. Journal of Medicinal Chemistry, 2021, 64, 6838-6855.	2.9	1
805	A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nature Communications, 2021, 12, 3142.	5.8	42
806	Cardiac Amyloidosis for the Primary Care Provider: A Practical Review to Promote Earlier Recognition of Disease. American Journal of Medicine, 2021, 134, 587-595.	0.6	5
807	Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry. Scientific Reports, 2021, 11, 11645.	1.6	15
808	Level of Murine DDX3 RNA Helicase Determines Phenotype Changes of Hepatocytes In Vitro and In Vivo. International Journal of Molecular Sciences, 2021, 22, 6958.	1.8	2

#	Article	IF	Citations
809	Amyloidosis with Cardiac Involvement: Identification, Characterization, and Management. Current Hematologic Malignancy Reports, 2021, 16, 357-366.	1.2	6
810	Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice. Npj Vaccines, 2021, 6, 84.	2.9	52
811	CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. New England Journal of Medicine, 2021, 385, 493-502.	13.9	807
812	Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. ESC Heart Failure, 2021, 8, 2380-2396.	1.4	29
813	Updated review of therapeutic strategies for Charcot-Marie-Tooth disease and related neuropathies. Expert Review of Neurotherapeutics, 2021, 21, 701-713.	1.4	16
814	Centyrin ligands for extrahepatic delivery of siRNA. Molecular Therapy, 2021, 29, 2053-2066.	3.7	23
815	Wild-type ATTR amyloidosis of the prostate: a case review. Journal of Clinical Urology, 0, , 205141582110237.	0.1	0
816	Towards precision medicine in heart failure. Nature Reviews Cardiology, 2021, 18, 745-762.	6.1	34
817	Multidisciplinary Approaches for Transthyretin Amyloidosis. Cardiology and Therapy, 2021, 10, 289-311.	1.1	28
818	Critical contribution of macrophage scavenger receptor 1 to the uptake of nanostructured DNA by immune cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 34, 102386.	1.7	7
819	Engineering Gene Therapy: Advances and Barriers. Advanced Therapeutics, 2021, 4, 2100040.	1.6	23
820	Ligand conjugateÂSAR and enhanced delivery in NHP. Molecular Therapy, 2021, 29, 2910-2919.	3.7	10
821	How has nanomedical innovation contributed to the COVID-19 vaccine development?. Nanomedicine, 2021, 16, 1179-1181.	1.7	11
822	A Focus on â€œBioâ€•in Bioâ€“Nanoscience: The Impact of Biological Factors on Nanomaterial Interactions. Advanced Healthcare Materials, 2021, 10, e2100574.	3.9	23
823	miRNA in cardiac development and regeneration. Cell Regeneration, 2021, 10, 14.	1.1	34
824	Spherical Nucleic Acids for Near-Infrared Light-Responsive Self-Delivery of Small-Interfering RNA and Antisense Oligonucleotide. ACS Nano, 2021, 15, 11929-11939.	7.3	54
825	A new combination strategy to enhance apoptosis in cancer cells by using nanoparticles as biocompatible drug delivery carriers. Scientific Reports, 2021, 11, 13027.	1.6	18
826	Responder analysis for neuropathic impairment and quality-of-life assessment in patients with hereditary transthyretin amyloidosis with polyneuropathy in the NEURO-TTR study. Journal of Neurology, 2022, 269, 323-335.	1.8	3

#	Article	IF	Citations
827	Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein. Molecular Therapy - Nucleic Acids, 2021, 24, 369-384.	2.3	47
828	Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria. British Journal of Clinical Pharmacology, 2022, 88, 2525-2538.	1.1	17
829	An Overview of the Role of Long Non-Coding RNAs in Human Choriocarcinoma. International Journal of Molecular Sciences, 2021, 22, 6506.	1.8	8
830	Cardiac Amyloidosis: Multimodal Imaging of Disease Activity and Response to Treatment. Circulation: Cardiovascular Imaging, 2021, 14, e009025.	1.3	24
831	RECURRENT PLEURAL EFFUSION IN PRIMARY SYSTEMIC AMYLOIDOSIS â€“ A RARE MANIFESTATION OF A RARE DISEASE. British Journal of Medical and Health Research, 2021, 8, 13-21.	0.1	0
832	Mesenchymal Stem Cells as a Gene Delivery Tool: Promise, Problems, and Prospects. Pharmaceutics, 2021, 13, 843.	2.0	15
833	Lipid Nanoparticlesâ”€From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano, 2021, 15, 16982-17015.	7.3	730
834	Ultrasound image-guided gene delivery using three-dimensional diagnostic ultrasound and lipid-based microbubbles. Journal of Drug Targeting, 2022, 30, 200-207.	2.1	11
835	Identification and Optimization of a Minor Allele-Specific siRNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease. Nucleic Acid Therapeutics, 2021, 31, 324-340.	2.0	9
836	Nanotherapeutic-directed approaches to analgesia. Trends in Pharmacological Sciences, 2021, 42, 527-550.	4.0	7
837	Improved CRISPR genome editing using small highly active and specific engineered RNA-guided nucleases. Nature Communications, 2021, 12, 4219.	5.8	29
838	Non-coding RNAs: Emerging from the discovery to therapeutic applications. Biochemical Pharmacology, 2021, 189, 114469.	2.0	29
839	Diagnostic yield of advanced genetic testing in patients with hereditary neuropathies: A retrospective singleâ€site study. Muscle and Nerve, 2021, 64, 454-461.	1.0	5
840	Electro-clinical presentation of hereditary transthyretin related amyloidosis when presenting as a polyneuropathy of unknown origin in northern France. Revue Neurologique, 2021, 177, 1160-1167.	0.6	4
841	Local application of Usag-1 siRNA can promote tooth regeneration in Runx2-deficient mice. Scientific Reports, 2021, 11, 13674.	1.6	10
842	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€”Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029.	1.3	48
843	Therapeutic siRNAs Targeting the JAK/STAT Signalling Pathway in Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2022, 16, 286-300.	0.6	5
844	Pulmonary Aerosol Delivery of Letâ€7b microRNA Confers a Striking Inhibitory Effect on Lung Carcinogenesis through Targeting the Tumor Immune Microenvironment. Advanced Science, 2021, 8, e2100629.	5.6	17

#	Article	IF	Citations
845	Gene Silencing Therapeutics in Cardiology: A Review Article. International Journal of Cardiovascular Sciences, 2021, , .	0.0	0
846	Engineering Microâ€“Nanomaterials for Biomedical Translation. Advanced NanoBiomed Research, 2021, 1, 2100002.	1.7	20
847	Disease-Modifying Treatments for Transthyretin Amyloidosis. Journal of Cardiovascular Pharmacology, 2021, 78, e641-e647.	0.8	3
848	Hereditary Transthyretin Amyloidosis- Clinical and Genetic Characteristics of a Multiracial South-East Asian Cohort in Singapore. Journal of Neuromuscular Diseases, 2021, 8, 723-733.	1.1	11
849	Genetics in Drug Discovery. Trends in Genetics, 2021, 37, 603-605.	2.9	0
850	Renal Involvement in Hereditary Transthyretin Amyloidosis: An Italian Single-Centre Experience. Brain Sciences, 2021, 11, 980.	1.1	18
851	Association between spinal stenosis and wild-type ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 226-233.	1.4	23
852	Bioinspired artificial exosomes based on lipid nanoparticles carrying let-7b-5p promote angiogenesis inÂvitro and inÂvivo. Molecular Therapy, 2021, 29, 2239-2252.	3.7	42
853	From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Molecular Aspects of Medicine, 2021, 81, 101003.	2.7	13
854	The growth of siRNA-based therapeutics: Updated clinical studies. Biochemical Pharmacology, 2021, 189, 114432.	2.0	249
855	Variant Transthyretin Amyloidosis (ATTRv) in Hungary: First Data on Epidemiology and Clinical Features. Genes, 2021, 12, 1152.	1.0	4
856	An optimized imaging protocol for [99mTc]Tc-DPD scintigraphy and SPECT/CT quantification in cardiac transthyretin (ATTR) amyloidosis. Journal of Nuclear Cardiology, 2021, 28, 2483-2496.	1.4	6
857	Osteopontin silencing attenuates bleomycin-induced murine pulmonary fibrosis by regulating epithelialâ€“mesenchymal transition. Biomedicine and Pharmacotherapy, 2021, 139, 111633.	2.5	24
858	The Ultrastructure of Tissue Damage by Amyloid Fibrils. Molecules, 2021, 26, 4611.	1.7	17
859	Nanotechnologyâ€Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVIDâ€19 Vaccines. Small Methods, 2021, 5, 2100402.	4.6	45
860	Cardiac Amyloidosis â€“ An Underdiagnosed Cause of Heart Failure with Preserved Ejection Fraction â€“ Updated Diagnosis and Treatment Options. Revista Romana De Cardiologie, 2021, 31, 283-302.	0.0	1
861	lncRNAs as Hallmarks for Individualized Treatment of Gastric Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, .	0.9	1
862	Emerging gene therapies for enhancing the hemostatic potential of platelets. Transfusion, 2021, 61, S275-S285.	0.8	1

#	Article	IF	Citations
864	Lipids and Lipid Derivatives for RNA Delivery. Chemical Reviews, 2021, 121, 12181-12277.	23.0	227
865	Comparison of the United Kingdom and United States approaches to approval of new neuromuscular therapies. Muscle and Nerve, 2021, 64, 641-650.	1.0	2
866	Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. , 2022, 230, 107967.		40
867	Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment. Molecules, 2021, 26, 5091.	1.7	23
868	Value of Longitudinal Strain to Identify Wild-Type Transthyretin Amyloidosis in Patients With Aortic Stenosis. Circulation Journal, 2021, 85, 1494-1504.	0.7	9
869	CRISPR Hits Home in a First-in-Human Study. CRISPR Journal, 2021, 4, 460-461.	1.4	4
870	Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic Review. Circulation Genomic and Precision Medicine, 2021, 14, e003356.	1.6	25
871	Synthesis and validation of DOPY: A new gemini dioleylbispyridinium based amphiphile for nucleic acid transfection. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 165, 279-292.	2.0	7
872	Gene Editing â€" A Cure for Transthyretin Amyloidosis?. New England Journal of Medicine, 2021, 385, 558-559.	13.9	8
874	Immunohistochemical typing of amyloid in fixed paraffin-embedded samples by an automatic procedure: Comparison with immunofluorescence data on fresh-frozen tissue. PLoS ONE, 2021, 16, e0256306.	1.1	10
875	An Update on mRNA-Based Viral Vaccines. Vaccines, 2021, 9, 965.	2.1	14
876	Role of RNA Motifs in RNA Interaction with Membrane Lipid Rafts: Implications for Therapeutic Applications of Exosomal RNAs. International Journal of Molecular Sciences, 2021, 22, 9416.	1.8	13
877	Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery. Small, 2021, 17, e2103025.	5.2	29
878	Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis. Cardiology Clinics, 2021, 39, 389-402.	0.9	7
879	Capturing the RNA castle: Exploiting MicroRNA inhibition for wound healing. FEBS Journal, 2022, 289, 5137-5151.	2.2	8
880	Transthyretin Cardiac Amyloidosis and Novel Therapies to Treat This Not-so-rare Cause of Cardiomyopathy. Cardiology in Review, 2021, 29, 263-273.	0.6	2
881	Alpha1-antitrypsin deficiency: New therapies on the horizon. Current Opinion in Pharmacology, 2021, 59, 149-156.	1.7	20
882	Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis. Journal of Neurology, 2022, 269, 1905-1912.	1.8	13

#	Article	IF	Citations
884	Treatment of Melanoma by Nano-conjugate-Delivered Wee1 siRNA. Molecular Pharmaceutics, 2021, 18, 3387-3400.	2.3	13
885	Cationic lipid nanoparticle production by microfluidization for siRNA delivery. International Journal of Pharmaceutics, 2021, 605, 120772.	2.6	7
886	Echocardiographic assessment of cardiac amyloidosis. Heart Failure Reviews, 2022, 27, 1505-1513.	1.7	7
887	Symptomatic Val122del mutated hereditary transthyretin amyloidosis: Need for early diagnosis and prioritization for heart and liver transplantation. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 323-329.	0.6	1
888	Transthyretin Amyloidosis Therapies: Guiding the Future. Revista De Investigacion Clinica, 2021, 73, 310-315.	0.2	0
890	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 14344-14357.	2.9	8
891	Variable differences of nerve conduction amplitudes versus velocities and distal latencies of healthy subjects assessed in ethnic cohorts. Muscle and Nerve, 2022, 65, 162-170.	1.0	2
892	From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta Biomaterialia, 2021, 131, 16-40.	4.1	140
893	RNA Therapeutics - Research and Clinical Advancements. Frontiers in Molecular Biosciences, 2021, 8, 710738.	1.6	39
894	Combining gene therapy with other therapeutic strategies and imaging agents for cancer theranostics. International Journal of Pharmaceutics, 2021, 606, 120905.	2.6	5
895	First in man: gene editing for the treatment of transthyretin amyloidosis. European Heart Journal, 2021, 42, 3597-3598.	1.0	0
898	Age-related amyloidosis outside the brain: A state-of-the-art review. Ageing Research Reviews, 2021, 70, 101388.	5.0	14
899	Pharmacotherapy review: Emerging treatment modalities in transthyretin cardiac amyloidosis. American Journal of Health-System Pharmacy, 2022, 79, 52-62.	0.5	8
900	Role of different types of nanomaterials against diagnosis, prevention and therapy of COVID-19. Sustainable Cities and Society, 2021, 72, 103046.	5.1	25
901	Posicionamento sobre DiagnÃ³stico e Tratamento da Amiloidose CardÃaca â€“ 2021. Arquivos Brasileiros De Cardiologia, 2021, 117, 561-598.	0.3	35
902	High-throughput screening of nanoparticles in drug delivery. APL Bioengineering, 2021, 5, 031511.	3.3	11
903	Regulation of pyroptosis in cardiovascular pathologies: Role of noncoding RNAs. Molecular Therapy - Nucleic Acids, 2021, 25, 220-236.	2.3	25
904	Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs). Advanced Drug Delivery Reviews, 2021, 176, 113835.	6.6	50

#	Article	IF	Citations
905	Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles. ACS Nano, 2021, 15, 13993-14021.	7.3	74
906	Irf5 siRNA-loaded biodegradable lipid nanoparticles ameliorate concanavalin A-induced liver injury. Molecular Therapy - Nucleic Acids, 2021, 25, 708-715.	2.3	10
907	The tumor suppressor miR-642a-5p targets Wilms Tumor 1 gene and cell-cycle progression in prostate cancer. Scientific Reports, 2021, 11, 18003.	1.6	10
908	Secret messengers: Extracellular RNA communication in the immune system*. Immunological Reviews, 2021, 304, 62-76.	2.8	12
909	A 79-year-old man with unexplained recurrent syncope and severe orthostatic hypotension. Internal and Emergency Medicine, 2021, , 1.	1.0	0
910	Non-Viral Gene Delivery Systems for Treatment of Myocardial Infarction: Targeting Strategies and Cardiac Cell Modulation. Pharmaceutics, 2021, 13, 1520.	2.0	4
911	OCULAR ANGIOGRAPHIC FEATURES IN JAPANESE PATIENTS WITH VAL30MET HEREDITARY TRANSTHYRETIN AMYLOIDOSIS. Retina, 2022, 42, 210-215.	1.0	8
912	Tumor-targeting pH/redox dual-responsive nanosystem epigenetically reverses cancer drug resistance by co-delivering doxorubicin and GCN5 siRNA. Acta Biomaterialia, 2021, 135, 556-566.	4.1	30
913	Nucleic acid delivery for therapeutic applications. Advanced Drug Delivery Reviews, 2021, 178, 113834.	6.6	122
914	InÂvivo gene editing works in humans: Results of a phase 1 clinical trial for TTR amyloidosis. Molecular Therapy, 2021, 29, 2633-2634.	3.7	6
915	Angiopathie rÃ©tinienne sÃ©vÃ¨re survenue sous patisiran. La Presse MÃ©dicale Formation, 2021, 2, 536-536.	0.1	0
916	Long non-coding RNAs and circular RNAs in tumor angiogenesis: From mechanisms to clinical significance. Molecular Therapy - Oncolytics, 2021, 22, 336-354.	2.0	14
917	New Therapeutics in Endometriosis: A Review of Hormonal, Non-Hormonal, and Non-Coding RNA Treatments. International Journal of Molecular Sciences, 2021, 22, 10498.	1.8	23
918	Management Strategies for Atrial Fibrillation and Flutter in Patients with Transthyretin Cardiac Amyloidosis. American Journal of Cardiology, 2021, 157, 107-114.	0.7	8
919	Cardiac Amyloidosis: Presentations, Diagnostic Work-up and Collaborative Approach for Comprehensive Clinical Management. Current Problems in Cardiology, 2021, 46, 100910.	1.1	7
920	RNA interference therapeutics for cardiac regeneration. Current Opinion in Genetics and Development, 2021, 70, 48-53.	1.5	5
921	Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson's disease. , 2021, 227, 107873.		17
922	Delivery of therapeutic oligonucleotides in nanoscale. Bioactive Materials, 2022, 7, 292-323.	8.6	29

#	Article	IF	Citations
923	Delivery strategies for ex vivo and in vivo T-cell reprogramming. , 2022, , 31-62.		0
924	Autonomic Dysfunction in Neuromuscular Disorders. , 2022, , 97-117.		0
925	Molecular and Genetic Therapies. , 2022, , 225-246.		0
926	Nanotargeting to the kidney. , 2022, , 439-449.		1
927	Detection of subclinical heart failure. , 2022, , 20-50.		1
928	Miscellaneous Interstitial Lung Diseases. , 2022, , 475-485.		0
929	Treatment and Management of Hereditary Neuropathies. , 2022, , 278-311.		0
930	From uncovering the mechanism of transthyretin aggregation to the drug tafamidis for ameliorating neurodegeneration and cardiomyopathy. , 2021, , 65-103.		1
931	Cardiac Amyloid Heart Disease in Racial/Ethnic Minorities: Focus on Transthyretin Amyloid Cardiomyopathy. Contemporary Cardiology, 2021, , 201-215.	0.0	0
932	Boosting ionizable lipid nanoparticle-mediated in vivo mRNA delivery through optimization of lipid amine-head groups. Biomaterials Science, 2021, 9, 7534-7546.	2.6	19
933	Carbon-based nanomaterials for viral infection management. Biomicrofluidics, 2021, 15, 011501.	1.2	12
935	siRNA Therapeutics in Ocular Diseases. Methods in Molecular Biology, 2021, 2282, 417-442.	0.4	5
936	Precision Medicine: Enabling Healthcare Progress in the Twenty-First Century. , 2021, , 9-19.		0
937	Antisense oligonucleotides in oncology: prospects and limitations of use in clinical practice. Onkologiya Zhurnal Imeni P A Gertsena, 2021, 10, 59.	0.0	0
938	siRNA Therapeutics against Respiratory Viral Infectionsâ€"What Have We Learned for Potential COVIDâ€19 Therapies?. Advanced Healthcare Materials, 2021, 10, e2001650.	3.9	47
939	Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis. Heart Failure Reviews, 2021, 26, 861-879.	1.7	16
940	Advancements in research and development to combat COVID-19 using nanotechnology. Nanotechnology for Environmental Engineering, 2021, 6, 1.	2.0	58
941	A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes. Advanced Materials, 2020, 32, e1906128.	11.1	126

#	Article	IF	Citations
942	Plasma growth differentiation factor 15: a novel tool to detect early changes of hereditary transthyretin amyloidosis. ESC Heart Failure, 2021, 8, 1178-1185.	1.4	3
943	Chemical Modifications in RNA Interference and CRISPR/Cas Genome Editing Reagents. Methods in Molecular Biology, 2020, 2115, 23-55.	0.4	7
944	Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis. Methods in Molecular Biology, 2020, 2176, 87-98.	0.4	12
945	Emerging Concepts for RNA Therapeutics for Inherited Retinal Disease. Advances in Experimental Medicine and Biology, 2019, 1185, 85-89.	0.8	4
946	Non-viral Vectors for Gene Therapy. , 2020, , 23-37.		2
947	MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside. Targeted Oncology, 2020, 15, 261-278.	1.7	183
948	A Narrative Review of the Role of Transthyretin in Health and Disease. Neurology and Therapy, 2020, 9, 395-402.	1.4	47
949	Therapie der Polyneuropathien. , 2019, , 494-510.		1
950	Gene therapies for axonal neuropathies: Available strategies, successes to date, and what to target next. Brain Research, 2020, 1732, 146683.	1.1	10
951	The Process of Amyloid Formation due to Monoclonal Immunoglobulins. Hematology/Oncology Clinics of North America, 2020, 34, 1041-1054.	0.9	8
952	Diagnostic Accuracy of [11C]PIB Positron Emission Tomography for Detection of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 1337-1347.	2.3	49
954	Liver-targeted RNAi Therapeutics: Principles and Applications. RSC Drug Discovery Series, 2019, , 233-265.	0.2	5
955	Cardiac sympathetic denervation in wild-type transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 237-243.	1.4	10
956	Roadmap on nanomedicine. Nanotechnology, 2021, 32, 012001.	1.3	17
962	Gene therapy in wound healing using nanotechnology. Wound Repair and Regeneration, 2021, 29, 225-239.	1.5	11
963	Conjunctival lymphangiectasia as a biomarker of severe systemic disease in Ser77Tyr hereditary transthyretin amyloidosis. British Journal of Ophthalmology, 2020, 104, 1363-1367.	2.1	8
964	Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight, 2019, 4, .	2.3	53
965	Interacting hepatic PAI-1/tPA gene regulatory pathways influence impaired fibrinolysis severity in obesity. Journal of Clinical Investigation, 2020, 130, 4348-4359.	3.9	20

#	Article	IF	Citations
966	Sustained depletion of FXIII-A by inducing acquired FXIII-B deficiency. Blood, 2020, 136, 2946-2954.	0.6	17
967	Autonomic Peripheral Neuropathy. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 58-71.	0.4	3
968	JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis. Circulation Journal, 2020, 84, 1610-1671.	0.7	98
969	Recent advances in the treatment of chronic heart failure. F1000Research, 2019, 8, 2134.	0.8	7
970	Cardiac amyloidosis: A case report and review of literature. World Journal of Clinical Cases, 2019, 7, 742-752.	0.3	10
971	Gastrointestinal Manifestations in Hereditary Transthyretin Amyloidosis: a Single-Centre Experience. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 339-343.	0.5	10
972	Becoming familiar with hereditary transthyretin amyloidosis, a treatable neuropathy. Arquivos De Neuro-Psiquiatria, 2018, 76, 573-574.	0.3	1
973	Lipid-based Vehicles for siRNA Delivery in Biomedical Field. Current Pharmaceutical Biotechnology, 2020, 21, 3-22.	0.9	8
974	A Review of Gene Therapy Delivery Systems for Intervertebral Disc Degeneration. Current Pharmaceutical Biotechnology, 2020, 21, 194-205.	0.9	24
975	Challenges in optimizing RNA nanostructures for large-scale production and controlled therapeutic properties. Nanomedicine, 2020, 15, 1331-1340.	1.7	24
976	Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines. Pharmaceutics, 2021, 13, 45.	2.0	45
977	Untangling Amyloidosis: Recent Advances in Cardiac Amyloidosis. International Journal of Heart Failure, 2020, 2, 231.	0.9	11
978	RNA Therapy: Current Status and Future Potential. Chonnam Medical Journal, 2020, 56, 87.	0.5	64
979	Multi-modality imaging of cardiac amyloidosis: Contemporary update. World Journal of Radiology, 2020, 12, 87-100.	0.5	4
980	Multi-modality imaging in transthyretin amyloid cardiomyopathy. World Journal of Cardiology, 2019, 11, 266-276.	0.5	1
981	Rationale for a Singapore Transthyretin Amyloidosis Registry. Annals of the Academy of Medicine, Singapore, 2020, 49, 411-414.	0.2	2
982	A microfluidic approach for sequential assembly of siRNA polyplexes with a defined structure-activity relationship. , 0, 1, e1.		5
983	Regulation of microglia polarization via mannose receptor-mediated delivery of siRNA by ligand-functionalized DoGo LNP. RSC Advances, 2021, 11, 32549-32558.	1.7	5

#	Article	IF	Citations
984	Transthyretin amyloid cardiomyopathy: Treatment pipeline, clinical trials, and challenges. Journal of Public Health and Primary Care, 2021, 2, 32.	0.1	0
985	A nanodrug incorporating siRNA PD-L1 and Birinapant for enhancing tumor immunotherapy. Biomaterials Science, 2021, 9, 8007-8018.	2.6	7
986	Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nature Biomedical Engineering, 2021, 5, 1059-1068.	11.6	165
987	RNA-Based Therapeutics: Current Developments in Targeted Molecular Therapy of Triple-Negative Breast Cancer. Pharmaceutics, 2021, 13, 1694.	2.0	17
988	The Roles of Non-coding RNA in the Development and Regeneration of Hair Follicles: Current Status and Further Perspectives. Frontiers in Cell and Developmental Biology, 2021, 9, 720879.	1.8	12
989	Nucleic Acid Drugsâ€"Current Status, Issues, and Expectations for Exosomes. Cancers, 2021, 13, 5002.	1.7	42
990	Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis. Hemato, 2021, 2, 645-659.	0.2	9
991	Editorial: Nanomedicine in Cancer Targeting and Therapy. Frontiers in Oncology, 2021, 11, 788210.	1.3	2
992	Delivery of synthetic mRNAs for tissue regeneration. Advanced Drug Delivery Reviews, 2021, 179, 114007.	6.6	18
993	The discovery and development of transthyretin amyloidogenesis inhibitors: what are the lessons?. Future Medicinal Chemistry, 2021, 13, 2083-2105.	1.1	0
994	The International Society of RNA Nanotechnology and Nanomedicine (ISRNN): The Present and Future of the Burgeoning Field. ACS Nano, 2021, 15, 16957-16973.	7.3	19
995	Lateâ€onset hematological complications post <scp>COVID</scp>â€19: An emerging medical problem for the hematologist. American Journal of Hematology, 2022, 97, 119-128.	2.0	36
996	Electrophysiological Manifestations of Cardiac Amyloidosis. JACC: CardioOncology, 2021, 3, 506-515.	1.7	28
997	Genome silencer therapy leading to â€˜regressionâ€™ of cardiac amyloid load on cardiovascular magnetic resonance: a case report. European Heart Journal - Case Reports, 2021, 5, ytab415.	0.3	1
998	Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression. Orphanet Journal of Rare Diseases, 2021, 16, 411.	1.2	24
999	Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies. Journal of Heart and Lung Transplantation, 2022, 41, 199-207.	0.3	9
1000	Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs. Drug Metabolism and Pharmacokinetics, 2021, 41, 100424.	1.1	114
1001	Aging, Aortic Stenosis, and Transthyretin Cardiac Amyloidosis. JACC: CardioOncology, 2021, 3, 577-579.	1.7	3

#	Article	IF	Citations
1002	Cardiac Amyloidosis. JACC: CardioOncology, 2021, 3, 617-618.	1.7	0
1003	Engineering programmable RNA synthetic circuits in mammalian cells. Current Opinion in Systems Biology, 2021, 28, 100395.	1.3	1
1004	Cardiovascular Involvement in Transthyretin Cardiac Amyloidosis. Heart Failure Clinics, 2022, 18, 73-87.	1.0	12
1007	Misconceptions and Facts About Cardiac Amyloidosis. American Journal of Cardiology, 2021, 160, 99-105.	0.7	7
1008	Delivery of small interfering RNAs by nanovesicles for cancer therapy. Drug Metabolism and Pharmacokinetics, 2022, 42, 100425.	1.1	11
1009	Conduction abnormalities and role of cardiac pacing in cardiac amyloidosis: A systematic review. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 2092-2099.	0.5	3
1010	Optimization of Synthesis of the Amino Lipid ECO for Effective Delivery of Nucleic Acids. Pharmaceuticals, 2021, 14, 1016.	1.7	4
1011	Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies. Pharmacotherapy, 2021, 41, 1081-1091.	1.2	6
1012	Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery. Pharmaceutics, 2021, 13, 1675.	2.0	33
1013	A quinoline derived D-A-D type fluorescent probe for sensing tetrameric transthyretin. Bioorganic and Medicinal Chemistry Letters, 2021, 52, 128408.	1.0	4
1014	Amyloid Heart Disease. US Cardiology Review, 2018, 12, 113.	0.5	2
1017	Neue Arzneimittel 2018. , 2019, , 61-175.		1
1018	3. Recent Advance of Neurology-related Amyloidosis. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 144b-144b.	0.0	0
1022	Domino Liver Transplantation: Where are we Now?. Reviews on Recent Clinical Trials, 2019, 14, 183-188.	0.4	3
1023	VI. Familial Amyloid Polyneuropathy (Hereditary Transthyretin Amyloidosis). The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1552-1561.	0.0	0
1024	3. Recent Advance of Neurology-related Amyloidosis. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1873-1882.	0.0	0
1025	A 63-Year-Old Man with Nausea, Vomiting, Orthostatic Dizziness, and Distal Limb Paresthesia. , 2020, , 319-327.		0
1026	Epigenetics: rethinking of drug research and development. Future Medicinal Chemistry, 2019, , .	1.1	1

#	Article	IF	Citations
1027	Amyloidosis and the lung. , 2019, , 296-318.		0
1028	Advances in diagnostics and therapy of systemic amyloidoses. Reumatologia, 2020, 58, 343-344.	0.5	1
1029	SelecciÃ³n de lo mejor del aÃ±o 2019 en insuficiencia cardiaca. REC: CardioClinics, 2020, 55, 44-50.	0.1	0
1030	Amyloid cardiomyopathy in the elderly: clinical options, difficulties in diagnosis and treatment. Rossiiskii Meditsinskii Zhurnal: Organ Ministerstva Zdravookhraneniia RSFSR, 2020, 26, 45-66.	0.1	0
1031	(Transthyretin amyloidosis). Cor Et Vasa, 2020, 62, 267-271.	0.1	0
1032	Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?. Cardiac Failure Review, 2020, 6, e21.	1.2	2
1034	CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. New England Journal of Medicine, 2021, 385, 1721-1723.	13.9	13
1035	Synthetic molecule libraries for nucleic acid delivery: Design parameters in cationic/ionizable lipids and polymers. Drug Metabolism and Pharmacokinetics, 2022, 42, 100428.	1.1	8
1036	The role of serial ^{99m}Tc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 38-49.	1.4	8
1037	AMP functionalized curdlan nanoparticles as a siRNA carrier: Synthesis, characterization and targeted delivery via adenosine A2B receptor. International Journal of Biological Macromolecules, 2021, 193, 866-873.	3.6	7
1038	RNA and Protein Delivery by Cellâ€Secreted and Bioengineered Extracellular Vesicles. Advanced Healthcare Materials, 2022, 11, e2101557.	3.9	5
1039	99mTechnetium-labeled cardiac scintigraphy for suspected amyloidosis: a review of current and future directions. Heart Failure Reviews, 2022, 27, 1493-1503.	1.7	3
1040	Machine learning-derived electrocardiographic algorithm for the detection of cardiac amyloidosis. Heart, 2022, 108, 1137-1147.	1.2	9
1041	New Keys to Early Diagnosis: Muscle Echogenicity, Nerve Ultrasound Patterns, Electrodiagnostic, and Clinical Parameters in 150 Patients with Hereditary Polyneuropathies. Neurotherapeutics, 2021, 18, 2425-2435.	2.1	5
1043	Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis. Neurological Research and Practice, 2021, 3, 57.	1.0	9
1044	Synthetic cells in biomedical applications. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, e1761.	3.3	30
1045	Amyloidosis and 30-Day Outcomes Among Patients With HeartÂFailure. JACC: CardioOncology, 2020, 2, 710-718.	1.7	5
1046	StratÃ©gies thÃ©rapeutiques pour lâ€™application clinique des ARN interfÃ©rents. Bulletin De L'Academie Nationale De Medecine, 2020, 204, 1088-1097.	0.0	0

#	Article	IF	Citations
1048	Cardiac Amyloidosis. , 2020, , 167-177.		0
1050	Neuropathy Associated with Hereditary Transthyretin Amyloidosisâ€"Diagnosis and Management. US Neurology, 2020, 16, 103.	0.2	0
1051	Antisense oligonucleotide drugs for neurological and neuromuscular disease. , 2020, , 221-245.		0
1053	Interactions between noncoding RNAs as epigenetic regulatory mechanisms in cardiovascular diseases. Methods in Cell Biology, 2021, 166, 309-348.	0.5	3
1054	Amyloidosisâ€"the Diagnosis and Treatment of an Underdiagnosed Disease. Deutsches Ärzteblatt International, 2020, 117, 159-166.	0.6	30
1055	ATTR Amyloidosis: Current and Emerging Management Strategies. JACC: CardioOncology, 2021, 3, 488-505.	1.7	56
1056	Genomic Screening for Pathogenic Transthyretin Variants Finds Evidence of Underdiagnosed Amyloid Cardiomyopathy From Health Records. JACC: CardioOncology, 2021, 3, 550-561.	1.7	4
1057	The promise of microRNA-based therapies in Alzheimerâ€™s disease: challenges and perspectives. Molecular Neurodegeneration, 2021, 16, 76.	4.4	52
1058	Mechanisms and Treatments in Demyelinating CMT. Neurotherapeutics, 2021, 18, 2236-2268.	2.1	16
1059	Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis. Journal of the American Heart Association, 2021, 10, e022859.	1.6	19
1060	4â€²-C-Aminoethoxy modification enhanced nuclease resistance of RNAs and improved thermal stability of RNA duplexes. Results in Chemistry, 2021, 3, 100231.	0.9	2
1061	RNA-binding proteins and their role in kidney disease. Nature Reviews Nephrology, 2022, 18, 153-170.	4.1	27
1062	New Frontiers for Site-Directed RNA Editing: Harnessing Endogenous ADARs. Methods in Molecular Biology, 2021, 2181, 331-349.	0.4	7
1067	TÃ³picos Emergentes em InsuficiÃªncia CardÃaca: Novos Paradigmas na Amiloidose CardÃaca. Arquivos Brasileiros De Cardiologia, 2020, 115, 945-948.	0.3	2
1068	Mechanistic analysis of the enhanced RNAi activity by 6-mCEPh-purine at the 5â€² end of the siRNA guide strand. Rna, 2021, 27, 151-162.	1.6	6
1069	siRNA potency enhancement via chemical modifications of nucleotide bases at the 5â€²-end of the siRNA guide strand. Rna, 2021, 27, 163-173.	1.6	8
1071	UNDERSTANDING NOVEL POLYMER AND LIPID BASED CARRIER SYSTEMS IN CLINICIAN PERSPECTIVE. International Journal of Medical Science and Diagnosis Research, 2020, 4, .	0.0	1
1072	Approach to a patient with cardiac amyloidosis. Journal of Geriatric Cardiology, 2019, 16, 567-574.	0.2	7

#	Article	IF	Citations
1073	The Role of Non-coding RNAs in the Pathogenesis of Glial Tumors. Acta Naturae, 2021, 13, 38-51.	1.7	0
1074	MicroRNAs and their delivery in diabetic fibrosis. Advanced Drug Delivery Reviews, 2022, 182, 114045.	6.6	17
1075	The Role of Non-coding RNAs in the Pathogenesis of Glial Tumors. Acta Naturae, 2021, 13, 38-51.	1.7	3
1076	Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic. Advanced Drug Delivery Reviews, 2022, 181, 114033.	6.6	5
1077	An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis. Molecular Therapy, 2022, 30, 1329-1342.	3.7	18
1078	Changes in nerve conduction studies predate clinical symptoms onset in early onset Val30Met hereditary ATTR amyloidosis. European Journal of Neurology, 2022, 29, 826-832.	1.7	9
1079	Tips and Tools to Understand Direct Membrane Translocation of siRNA-Loaded WRAP-Based Nanoparticles. Methods in Molecular Biology, 2022, 2383, 475-490.	0.4	1
1080	Targeted Therapeutics for Transthyretin Amyloid Cardiomyopathy. American Journal of Therapeutics, 2023, 30, e447-e453.	0.5	1
1081	Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future. Neurotherapeutics, 2021, 18, 2286-2302.	2.1	8
1082	Kardiale Beteiligung bei Amyloidose. Springer Reference Medizin, 2022, , 1-12.	0.0	0
1083	Non-coding RNAs and their bioengineering applications for neurological diseases. Bioengineered, 2021, 12, 11675-11698.	1.4	14
1084	Dual-Echo Turbo Spin Echo and 12-Echo Multi Spin Echo Sequences as Equivalent Techniques for Obtaining T2-Relaxometry Data. Investigative Radiology, 2022, 57, 301-307.	3.5	5
1085	Targeted treatments of AL and ATTR amyloidosis. Heart Failure Reviews, 2021, , 1.	1.7	3
1086	pH-Dependent Phase Behavior and Stability of Cationic Lipidâ€“mRNA Nanoparticles. Journal of Pharmaceutical Sciences, 2022, 111, 690-698.	1.6	12
1087	Further Studies on Cationic Gemini Amphiphiles as Carriers for Gene Deliveryâ”€The Effect of Linkers in the Structure and Other Factors Affecting the Transfection Efficacy of These Amphiphiles. ACS Omega, 2021, 6, 33370-33388.	1.6	1
1088	Translation of New and Emerging Therapies for Genetic Cardiomyopathies. JACC Basic To Translational Science, 2022, 7, 70-83.	1.9	20
1089	Posttranscriptional regulation of Nrf2 through miRNAs and their role in Alzheimer's disease. Pharmacological Research, 2022, 175, 106018.	3.1	14
1090	The functional and structural evaluation of small fibers in asymptomatic carriers of TTR p.Val50Met (Val30Met) mutation. Neuromuscular Disorders, 2022, 32, 50-56.	0.3	8

#	Article	IF	Citations
1091	Non-liver mRNA Delivery. Accounts of Chemical Research, 2022, 55, 13-23.	7.6	61
1092	Therapeutic inhibition of RBM20 improves diastolic function in a murine heart failure model and human engineered heart tissue. Science Translational Medicine, 2021, 13, eabe8952.	5.8	14
1094	Primary hyperoxaluria type 1: novel therapies at a glance. CKJ: Clinical Kidney Journal, 2022, 15, i17-i22.	1.4	10
1095	Antisense therapies in neurological diseases. Brain, 2022, 145, 816-831.	3.7	10
1096	Transthyretin Gene Variants and Associated Phenotypes in Danish Patients with Amyloid Cardiomyopathy. Neurology International, 2022, 12, 1-11.	0.2	1
1097	Nanoparticle Mediated Gene Therapy: A Trailblazer Armament to Fight CNS Disorders. Current Medicinal Chemistry, 2023, 30, 304-315.	1.2	3
1098	Small molecule protein binding to correct cellular folding or stabilize the native state against misfolding and aggregation. Current Opinion in Structural Biology, 2022, 72, 267-278.	2.6	21
1099	Mechanism of action of hepatitis B virus S antigen transport-inhibiting oligonucleotide polymer, STOPS, molecules. Molecular Therapy - Nucleic Acids, 2022, 27, 335-348.	2.3	13
1100	Peripheral sensory neuropathies â€“ pain loss vs. pain gain. Medizinische Genetik, 2020, 32, 233-241.	0.1	4
1101	Heart Failure Due to Cardiac Transthyretin Amyloidosis. , 2021, 1, 161-166.		0
1102	Disease Modifying Therapies for Transthyretin Amyloid Cardiomyopathy. , 2021, 1, 144-146.		0
1103	Variable Presentation of Hereditary Transthyretin-Mediated Amyloidosis at a Single Center. Journal of Clinical Neuromuscular Disease, 2021, 23, 7-17.	0.3	3
1104	Magnetic Resonance Neurography: Improved Diagnosis of Peripheral Neuropathies. Neurotherapeutics, 2021, 18, 2368-2383.	2.1	14
1105	Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making. Journal of Personalized Medicine, 2021, 11, 1348.	1.1	5
1106	miRNAs as Biomarkers and Possible Therapeutic Strategies in Rheumatoid Arthritis. Cells, 2022, 11, 452.	1.8	28
1107	Oral mRNA delivery using capsule-mediated gastrointestinal tissue injections. Matter, 2022, 5, 975-987.	5.0	48
1108	Unique Phenotypes With Corresponding Pathology in Late-Onset Hereditary Transthyretin Amyloidosis of A97S vs. V30M. Frontiers in Aging Neuroscience, 2021, 13, 786322.	1.7	8
1109	Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma: Applications and Challenges in Cancer Therapeutics. Pharmaceutics, 2022, 14, 137.	2.0	4

#	Article	IF	Citations
1110	Patient-specific induced pluripotent stem cells for understanding and assessing novel therapeutics for multisystem transthyretin amyloid disease. , 2022, , 105-122.		1
1111	Early Detection of Cardiac Amyloidosis in Transthyretin Mutation Carriers. International Heart Journal, 2022, 63, 168-175.	0.5	7
1112	Neuromuscular Complications of Systemic Amyloidosis. American Journal of Medicine, 2022, 135, S13-S19.	0.6	2
1113	Noncoding ribonucleic acids in gallbladder cancer patients. , 2022, , 391-408.		0
1114	Drug delivery systems for RNA therapeutics. Nature Reviews Genetics, 2022, 23, 265-280.	7.7	417
1115	Non-Viral Delivery of RNA Gene Therapy to the Central Nervous System. Pharmaceutics, 2022, 14, 165.	2.0	6
1116	Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis. European Journal of Neurology, 2022, 29, 1477-1487.	1.7	18
1117	Application of New Materials in Auditory Disease Treatment. Frontiers in Cellular Neuroscience, 2021, 15, 831591.	1.8	0
1118	In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy. Science Advances, 2022, 8, eabj6901.	4.7	75
1119	Crosstalk between Long Non Coding RNAs, microRNAs and DNA Damage Repair in Prostate Cancer: New Therapeutic Opportunities?. Cancers, 2022, 14, 755.	1.7	12
1120	Vitreous involvement as initial presentation of hereditary transthyretin amyloidosis related to the rare TTR Ile107Met (p.Ile127Met) pathogenic variant. Ophthalmic Genetics, 2022, , 1-7.	0.5	0
1121	Elderly patients with suspected Charcot-Marie-Tooth disease should be tested for the TTR gene for effective treatments. Journal of Human Genetics, 2022, , .	1.1	4
1122	Toward Gene Transfer Nanoparticles as Therapeutics. Advanced Healthcare Materials, 2022, 11, e2102145.	3.9	17
1123	Developing Therapy for Transthyretin Amyloidosis. American Journal of Medicine, 2022, , .	0.6	4
1124	Treatment of transthyretin His88Arg amyloidosis with RNA interference therapy: A case report. Journal of Cardiology Cases, 2022, 25, 363-366.	0.2	3
1125	Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 92-101.	1.4	6
1126	Liver Fibrosisâ€"From Mechanisms of Injury to Modulation of Disease. Frontiers in Medicine, 2021, 8, 814496.	1.2	9
1127	Applying diagnosis support systems in electronic health records to identify wild-type transthyretin amyloid cardiomyopathy risk. Future Cardiology, 2022, , .	0.5	1

#	Article	IF	Citations
1128	State-of-the-art review on management of end-stage heart failure in amyloidosis: transplant and beyond. Heart Failure Reviews, 2022, 27, 1567-1578.	1.7	5
1129	A self-assembly reproducible nanoplatform enables cancer phenotypic lethality in solid tumors. Materials and Design, 2022, 214, 110408.	3.3	0
1130	Delivery strategies of RNA therapeutics to leukocytes. Journal of Controlled Release, 2022, 342, 362-371.	4.8	9
1131	Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis. Journal of Controlled Release, 2022, 343, 175-186.	4.8	37
1132	Performance of nanoparticles for biomedical applications: The in vitro/in vivo discrepancy. Biophysics Reviews, 2022, 3, .	1.0	10
1133	Pearls from the First Gulf Cardiac Amyloidosis Summit 2021. Emirates Medical Journal, 2022, 3, 1-11.	0.3	0
1134	Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing. Nanoscale Advances, 2022, 4, 2107-2123.	2.2	21
1135	Pharmacological Aspects of Clinically Approved Gene Therapy Drugs and Products. , 2022, , .		0
1136	Species-dependent in vivo mRNA delivery and cellular responses to nanoparticles. Nature Nanotechnology, 2022, 17, 310-318.	15.6	56
1137	Amyloid Cardiomyopathy in Older Adults. Current Geriatrics Reports, 2022, 11, 1.	1.1	0
1138	Nucleic Acids for Potential Treatment of Rheumatoid Arthritis. ACS Applied Bio Materials, 2022, 5, 1990-2008.	2.3	3
1139	Clinical improvement after change of therapy from tafamidis to patisiran in progressive TTR amyloidosis post-liver transplantation. Journal of Neurology, 2022, 269, 3912-3914.	1.8	3
1140	Anhydrous Nucleic Acid Nanoparticles for Storage and Handling at Broad Range of Temperatures. Small, 2022, 18, e2104814.	5.2	13
1141	Amyloidosis from the patient perspective: the French daily impact of amyloidosis study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 165-174.	1.4	17
1142	Future Developments in the Treatment of AL Amyloidosis. Hemato, 2022, 3, 131-152.	0.2	2
1143	Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 156-164.	1.4	5
1144	The potential of long noncoding RNA therapies. Trends in Pharmacological Sciences, 2022, 43, 269-280.	4.0	28
1145	Current state of the art in peptide-based gene delivery. Journal of Controlled Release, 2022, 343, 600-619.	4.8	45

#	Article	IF	Citations
1146	Three patients of transthyretin amyloidosis in a Japanese family with amyloidogenic transthyretin Thr49Ser (p.Thr69Ser) variant. European Journal of Medical Genetics, 2022, 65, 104451.	0.7	0
1147	A nanoconfined loading strategy for highly efficient siRNA delivery and cancer therapy. Nano Today, 2022, 43, 101418.	6.2	13
1148	Recent advance in nanomaterials for cancer immunotherapy. Chemical Engineering Journal, 2022, 435, 134145.	6.6	16
1149	Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nature Communications, 2021, 12, 7101.	5.8	100
1150	On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	285
1151	mRNA, a Revolution in Biomedicine. Pharmaceutics, 2021, 13, 2090.	2.0	26
1152	Advances in the Diagnosis and Management of Cardiac Amyloidosis. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 308-314.	0.0	0
1153	Orphan drugs in treatment of rare neuromuscular disorders. Neurologie Pro Praxi, 2021, 22, 104-112.	0.0	2
1154	Cardiac Amyloidosis Treatment. Methodist DeBakey Cardiovascular Journal, 2022, 18, 59-72.	0.5	18
1155	Clinical Clues and Diagnostic Workup of Cardiac Amyloidosis. Methodist DeBakey Cardiovascular Journal, 2022, 18, 36-46.	0.5	5
1156	ATTR Epidemiology, Genetics, and Prognostic Factors. Methodist DeBakey Cardiovascular Journal, 2022, 18, 17-26.	0.5	26
1157	Cardiac amyloidosis: an update on diagnosis, current therapy, and future directions. Current Opinion in Cardiology, 2022, 37, 272-284.	0.8	4
1158	Non-Alzheimers Amyloidoses of the Neurological System: Cerebral Amyloid Angiopathy and Familial Amyloid Polyneuropathy. , 0, , .		0
1159	Therapeutic RNA-silencing oligonucleotides in metabolic diseases. Nature Reviews Drug Discovery, 2022, 21, 417-439.	21.5	24
1160	RNA interference as a novel treatment strategy for chronic hepatitis B infection. Clinical and Molecular Hepatology, 2022, 28, 408-424.	4.5	32
1161	Cytosolic Delivery of Small Protein Scaffolds Enables Efficient Inhibition of Ras and Myc. Molecular Pharmaceutics, 2022, 19, 1104-1116.	2.3	6
1162	Role of miRNAs in Neurodegeneration: From Disease Cause to Tools of Biomarker Discovery and Therapeutics. Genes, 2022, 13, 425.	1.0	39
1164	Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics. Pharmaceutics, 2022, 14, 398.	2.0	31

#	Article	IF	Citations
1165	Magnetic Solid Nanoparticles and Their Counterparts: Recent Advances towards Cancer Theranostics. Pharmaceutics, 2022, 14, 506.	2.0	13
1166	Ultraviolet Photodissociation and Activated Electron Photodetachment Mass Spectrometry for Top-Down Sequencing of Modified Oligoribonucleotides. Journal of the American Society for Mass Spectrometry, 2022, 33, 510-520.	1.2	9
1167	The Effect of Dicer Knockout on RNA Interference Using Various Dicer Substrate Small Interfering RNA (DsiRNA) Structures. Genes, 2022, 13, 436.	1.0	1
1168	The Transthyretin/Oleuropein Aglycone Complex: A New Tool against TTR Amyloidosis. Pharmaceuticals, 2022, 15, 277.	1.7	3
1169	Suppression of fibrin(ogen)-driven pathologies in diseaseÂmodels through controlled knockdown byÂlipidÂnanoparticle delivery of siRNA. Blood, 2022, 139, 1302-1311.	0.6	9
1170	Implication of microRNA as a potential biomarker of myocarditis. Clinical and Experimental Pediatrics, 2022, 65, 230-238.	0.9	7
1171	Progressive Multiple Mononeuropathy in a Patient With Familial Transthyretin Amyloidosis After Liver Transplantation. Journal of Clinical Neuromuscular Disease, 2022, 23, 143-147.	0.3	0
1172	Current approaches of nanomedicines in the market and various stage of clinical translation. Acta Pharmaceutica Sinica B, 2022, 12, 3028-3048.	5.7	103
1173	Research and development of oligonucleotide therapeutics in Japan for rare diseases. Future Rare Diseases, 2022, 2, .	0.1	10
1174	Suspicion, screening, and diagnosis of wildâ€type transthyretin amyloid cardiomyopathy: a systematic literature review. ESC Heart Failure, 2022, 9, 1524-1541.	1.4	8
1175	Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist. Internal and Emergency Medicine, 2022, 17, 957-969.	1.0	6
1176	A compound score to screen patients with hereditary transthyretin amyloidosis. Journal of Neurology, 2022, , .	1.8	3
1177	Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation. American Journal of Transplantation, 2022, 22, 1646-1657.	2.6	30
1178	Realâ€life experience with inotersen in hereditary transthyretin amyloidosis with lateâ€onset phenotype: Data from an earlyâ€access program in Italy. European Journal of Neurology, 2022, 29, 2148-2155.	1.7	13
1179	SiRNAs with Neutral Phosphate Triester Hydrocarbon Tails Exhibit Carrier-Free Gene-Silencing Activity. ACS Medicinal Chemistry Letters, 2022, 13, 695-700.	1.3	6
1180	Enclosure of siRNA in Alternately Hydrophilicâ€“Hydrophobic Double-Layered Nanoarchitectures for Promoted RNAi. ACS Applied Polymer Materials, 2022, 4, 2262-2268.	2.0	0
1181	Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine. Cancers, 2022, 14, 1588.	1.7	27
1182	Cerebellar and Cerebral Amyloid Visualized by [18F]flutemetamol PET in Long-Term Hereditary V30M (p.V50M) Transthyretin Amyloidosis Survivors. Frontiers in Neurology, 2022, 13, 816636.	1.1	3

#	Article	IF	Citations
1183	LncRNA: A Potential Target for Host-Directed Therapy of Candida Infection. Pharmaceutics, 2022, 14, 621.	2.0	4
1185	Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 668-678.	0.9	35
1186	When fibrin(ogen) is too loud, silence it!Â. Blood, 2022, 139, 1261-1262.	0.6	0
1187	Current Advances in RNA Therapeutics for Human Diseases. International Journal of Molecular Sciences, 2022, 23, 2736.	1.8	78
1188	Liposomal siRNA Formulations for the Treatment of Herpes Simplex Virus-1: In Vitro Characterization of Physicochemical Properties and Activity, and In Vivo Biodistribution and Toxicity Studies. Pharmaceutics, 2022, 14, 633.	2.0	5
1189	CSF/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 190-196.	1.4	6
1190	Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications. RNA Biology, 2022, 19, 452-467.	1.5	26
1191	RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nature Reviews Cardiology, 2022, 19, 655-667.	6.1	64
1192	Anionic Lipid Nanoparticles Preferentially Deliver mRNA to the Hepatic Reticuloendothelial System. Advanced Materials, 2022, 34, e2201095.	11.1	66
1193	Ventricular arrhythmia burden and implantable cardioverterâ€defibrillator outcomes in transthyretin cardiac amyloidosis. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 443-451.	0.5	9
1194	Non-viral siRNA delivery to T cells: Challenges and opportunities in cancer immunotherapy. Biomaterials, 2022, 286, 121510.	5.7	11
1195	Navigating the Complex Web of Prescribing Amyloidosis Therapeutics: A Primer. Journal of the American Heart Association, 2022, 11, e023895.	1.6	1
1196	CRISPR and cardiovascular diseases. Cardiovascular Research, 2023, 119, 79-93.	1.8	10
1197	Harnessing Rift Valley fever virus NSs gene for cancer gene therapy. Cancer Gene Therapy, 2022, 29, 1477-1486.	2.2	2
1198	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR0000000000001063.	1.6	756
1199	Nanomaterials and Bioactive Compounds against SARS-CoV-2. Journal of Nanomaterials, 2022, 2022, 1-13.	1.5	3
1200	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2022, 79, e263-e421.	1.2	774
1201	Transthyretin: Its function and amyloid formation. Neurochemistry International, 2022, 155, 105313.	1.9	11

#	Article	IF	Citations
1202	Cardiac Amyloidosis: A Review of Current Imaging Techniques. Frontiers in Cardiovascular Medicine, 2021, 8, 751293.	1.1	16
1203	Molecular Mechanisms of Cardiac Amyloidosis. International Journal of Molecular Sciences, 2022, 23, 25.	1.8	20
1204	Enhancing knowledge and awareness of transthyretin cardiac amyloidosis and shared decision-making among cardiology team members in Colorado, USA via an online educational initiative. Hospital Practice (1995), 2022, 50, 37-41.	0.5	1
1206	Investigating changes of proteome in the bovine milk serum after retort processing using proteomics techniques. Food Science and Nutrition, 2022, 10, 307-316.	1.5	1
1207	Targeting Inflammasome Activation in COVID-19: Delivery of RNA Interference-Based Therapeutic Molecules. Biomedicines, 2021, 9, 1823.	1.4	7
1208	miRNA- and lncRNA-Based Therapeutics for Non-Hodgkinâ€™s Lymphoma: Moving towards an RNA-Guided Precision Medicine. Cancers, 2021, 13, 6324.	1.7	3
1210	An ionizable lipid toolbox for RNA delivery. Nature Communications, 2021, 12, 7233.	5.8	182
1211	A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis). International Journal of Molecular Sciences, 2021, 22, 13158.	1.8	10
1212	Improvement of mRNA Delivery Efficiency to a T Cell Line by Modulating PEG-Lipid Content and Phospholipid Components of Lipid Nanoparticles. Pharmaceutics, 2021, 13, 2097.	2.0	11
1213	Microinjection of antisense oligonucleotides into living mouse testis enables lncRNA function study. Cell and Bioscience, 2021, 11, 213.	2.1	10
1214	Extrahepatic delivery of RNA to immune cells. , 2022, , 57-86.		1
1215	RNA delivery for cancer gene therapy. , 2022, , 375-424.		0
1216	CMC and regulatory aspects of oligonucleotide therapeutics. , 2022, , 263-320.		0
1217	Targeted delivery to macrophages and dendritic cells by chemically modified mannose ligand-conjugated siRNA. Nucleic Acids Research, 2022, 50, 4840-4859.	6.5	22
1218	The Impact of mRNA Technology in Regenerative Therapy: Lessons for Oral Tissue Regeneration. Journal of Dental Research, 2022, 101, 1015-1024.	2.5	3
1219	Phenotype of a second Irish variant causing hereditary amyloidogenic transthyretin amyloidosis. Journal of Neurology, 2022, , .	1.8	0
1220	Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice. Molecular Therapy - Nucleic Acids, 2022, 28, 500-513.	2.3	8
1221	Incidental cardiac uptake of 99mTc-diphosphonates is predictive of poor outcome: data from 9616 bone scintigraphies. Journal of Nuclear Cardiology, 2022, 29, 3419-3425.	1.4	5

#	Article	IF	Citations
1223	Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges. Journal of Clinical Medicine, 2022, 11, 2148.	1.0	19
1224	RNA therapy: rich history, various applications and unlimited future prospects. Experimental and Molecular Medicine, 2022, 54, 455-465.	3.2	92
1225	The revolution of ATTR amyloidosis in cardiology: certainties, gray zones and perspectives. Minerva Cardiology and Angiology, 2022, 70, 248-257.	0.4	2
1226	Engineered Neutral Phosphorous Dendrimers Protect Mouse Cortical Neurons and Brain Organoids from Excitotoxic Death. International Journal of Molecular Sciences, 2022, 23, 4391.	1.8	6
1227	Nano-vectors for CRISPR/Cas9-mediated genome editing. Nano Today, 2022, 44, 101482.	6.2	15
1228	Targeting nucleic acid-based therapeutics to tumors: Challenges and strategies for polyplexes. Journal of Controlled Release, 2022, 346, 110-135.	4.8	23
1229	Development of in silico methodology for siRNA lipid nanoparticle formulations. Chemical Engineering Journal, 2022, 442, 136310.	6.6	7
1234	Overcoming the challenge of long-term storage of mRNA-lipid nanoparticle vaccines. Molecular Therapy, 2022, 30, 1792-1793.	3.7	7
1235	Advances in COVID-19 mRNA vaccine development. Signal Transduction and Targeted Therapy, 2022, 7, 94.	7.1	177
1236	Lung perfusion during veno-venous extracorporeal membrane oxygenation in a model of hypoxemic respiratory failure. Intensive Care Medicine Experimental, 2022, 10, 15.	0.9	3
1239	Preparation of Chimeric Polymersomes for Gene Delivery. Biomaterial Engineering, 2022, , 309-333.	0.1	0
1240	Retinitis Pigmentosa: Progress in Molecular Pathology and Biotherapeutical Strategies. International Journal of Molecular Sciences, 2022, 23, 4883.	1.8	40
1241	New Advanced Imaging Parameters and Biomarkersâ€"A Step Forward in the Diagnosis and Prognosis of TTR Cardiomyopathy. Journal of Clinical Medicine, 2022, 11, 2360.	1.0	4
1243	CRISPR/Cas therapeutic strategies for autosomal dominant disorders. Journal of Clinical Investigation, 2022, 132, .	3.9	8
1244	Italian Real-Life Experience of Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran. Pharmacogenomics and Personalized Medicine, 2022, Volume 15, 499-514.	0.4	8
1245	Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug. Pharmaceuticals, 2022, 15, 575.	1.7	11
1246	Normothermic liver machine perfusion as a dynamic platform for regenerative purposes: What does the future have in store for us?. Journal of Hepatology, 2022, 77, 825-836.	1.8	27
1247	The Progress and Promise of RNA Medicineâ"€An Arsenal of Targeted Treatments. Journal of Medicinal Chemistry, 2022, 65, 6975-7015.	2.9	42

#	Article	IF	Citations
1248	Reflections on Alnylam. Nature Biotechnology, 2022, 40, 641-650.	9.4	5
1249	Imaging-Guided Treatment for Cardiac Amyloidosis. Current Cardiology Reports, 2022, 24, 839-850.	1.3	13
1250	Trends and Hotspots in Nanoparticles for the Targeted Delivery of Nucleic Acids: A Ten-Year Bibliometric Study. Frontiers in Pharmacology, 2022, 13, .	1.6	6
1251	Givosiran for the treatment of acute hepatic porphyria. Expert Review of Clinical Pharmacology, 2022, 15, 383-393.	1.3	10
1252	Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients. CKJ: Clinical Kidney Journal, 2022, 15, 1747-1754.	1.4	10
1253	The clinical progress of mRNA vaccines and immunotherapies. Nature Biotechnology, 2022, 40, 840-854.	9.4	248
1254	Chemical and Biophysical Signatures of the Protein Corona in Nanomedicine. Journal of the American Chemical Society, 2022, 144, 9184-9205.	6.6	98
1255	Disrupting autorepression circuitry generates â€œopen-loop lethalityâ€•to yield escape-resistant antiviral agents. Cell, 2022, 185, 2086-2102.e22.	13.5	7
1256	Aerosol delivery of star polymer-siRNA nanoparticles as a therapeutic strategy to inhibit lung tumor growth. Biomaterials, 2022, 285, 121539.	5.7	14
1257	Virus-like siRNA construct dynamically responsive to sequential microenvironments for potent RNA interference. Journal of Colloid and Interface Science, 2022, 622, 938-949.	5.0	0
1258	Transthyretin Amyloid Cardiomyopathy: Impact of Transthyretin Amyloid Deposition in Myocardium on Cardiac Morphology and Function. Journal of Personalized Medicine, 2022, 12, 792.	1.1	2
1259	Unusual presentation of rare Phe33Leu mutation hereditary TTR cardiac amyloidosis. Future Cardiology, 2022, , .	0.5	1
1260	Assessment and Management of Older Patients With Transthyretin Amyloidosis Cardiomyopathy: Geriatric Cardiology, Frailty Assessment and Beyond. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	8
1261	Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy. Frontiers in Cell and Developmental Biology, 2022, 10, .	1.8	4
1262	Modern therapeutic approaches to liver-related disorders. Journal of Hepatology, 2022, 76, 1392-1409.	1.8	22
1263	Exciting Times for Lipid Nanoparticles: How Canadian Discoveries Are Enabling Gene Therapies. Molecular Pharmaceutics, 2022, 19, 1663-1668.	2.3	11
1264	Treatment With Diflunisal in Domino Liver Transplant Recipients With Acquired Amyloid Neuropathy. Transplant International, 2022, 35, 10454.	0.8	1
1266	Simultaneous quantification of oligo-nucleic acids and a ferritin nanocage by size-exclusion chromatography hyphenated to inductively coupled plasma mass spectrometry for developing drug delivery systems. Analytical Methods, 2022, 14, 2219-2226.	1.3	2

#	Article	IF	Citations
1267	LncRNAs as the Regulators of Brain Function and Therapeutic Targets for Alzheimerâ€™s Disease. , 2022, 13, 837.		10
1268	Blood biomarkers of peripheral neuropathy. Acta Neurologica Scandinavica, 2022, 146, 325-331.	1.0	14
1269	Neurological update: hereditary neuropathies. Journal of Neurology, 2022, 269, 5187-5191.	1.8	6
1270	Brain Gene Silencing with Cationic Amino-Capped Poly(Ethylene Glycol) Polyplexes. SSRN Electronic Journal, 0, , .	0.4	0
1271	Development of Therapeutic RNA Manipulation for Muscular Dystrophy. Frontiers in Genome Editing, 0, 4, .	2.7	5
1272	Chemical Conjugation in Drug Delivery Systems. Frontiers in Chemistry, 2022, 10, .	1.8	12
1273	A Rare Case of I127V Heterozygous Transthyretin Amyloidosis With Atypical Transthoracic Echocardiogram Findings Presenting As Upper Extremity Sensorimotor Polyneuropathy. Cureus, 2022, , .	0.2	0
1274	miR-204-5p in vivo inhibition cause diminished CD45RO cells rate in lungs of melanoma B16-bearing mice. Non-coding RNA Research, 2022, , .	2.4	0
1275	Therapeutic significance of nano- and biosensor technology in combating SARS-CoV-2: a review. Applied Nanoscience (Switzerland), 2022, 12, 3127-3140.	1.6	3
1276	Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 143-155.	1.4	55
1277	Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates. Nature Biotechnology, 2022, 40, 1500-1508.	9.4	79
1278	Genetic therapeutic advancements for Dravet Syndrome. Epilepsy and Behavior, 2022, 132, 108741.	0.9	10
1279	Recent Progress in Amyloidosis Therapy. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 1170-1177.	0.0	0
1280	Diagnostics and Prevention: Landscape for Technology Innovation in Precision Cardiovascular Medicine. , 2022, , 603-624.		0
1281	Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components. Molecular Pharmaceutics, 2022, 19, 1669-1686.	2.3	58
1282	The Landscape of Noncoding RNA in Pulmonary Hypertension. Biomolecules, 2022, 12, 796.	1.8	8
1283	Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. Orphanet Journal of Rare Diseases, 2022, 17, .	1.2	22
1284	Peptidomimetic Lipid-Nanoparticle-Mediated Knockdown of TLR4 in CNS Protects against Cerebral Ischemia/Reperfusion Injury in Mice. Nanomaterials, 2022, 12, 2072.	1.9	7

#	Article	IF	Citations
1285	Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy. Journal of Human Genetics, 2023, 68, 131-152.	1.1	39
1286	Long Noncoding RNAs as Orchestrators of CD4+ T-Cell Fate. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	3
1287	Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy. Drug Design, Development and Therapy, 0, Volume 16, 1827-1845.	2.0	12
1288	CHOROIDAL AMYLOID DEPOSITION. Retina, 2022, 42, 1989-1994.	1.0	2
1289	Hereditary transthyretin amyloidosis: aÂcase report. Journal of Medical Case Reports, 2022, 16, .	0.4	2
1290	Considerations and recommendations for assessment of plasma protein binding and drugâ€“drug interactions for siRNA therapeutics. Nucleic Acids Research, 2022, 50, 6020-6037.	6.5	20
1291	Lipid Nanoparticle Technologies for Nucleic Acid Delivery: A Nanoarchitectonics Perspective. Advanced Functional Materials, 2022, 32, .	7.8	36
1293	Universal Barcoding Predicts In Vivo ApoE-Independent Lipid Nanoparticle Delivery. Nano Letters, 2022, 22, 4822-4830.	4.5	16
1294	Correlation Between Cardiac Images, Biomarkers, and Amyloid Load in Wildâ€Type Transthyretin Amyloid Cardiomyopathy. Journal of the American Heart Association, 2022, 11, .	1.6	4
1295	Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and metaâ€analysis. European Journal of Heart Failure, 2022, 24, 1677-1696.	2.9	25
1296	YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation. Clinical and Translational Medicine, 2022, 12, .	1.7	24
1298	Lipid nanoparticle-mediated silencing of osteogenic suppressor GNAS leads to osteogenic differentiation of mesenchymal stem cells inÂvivo. Molecular Therapy, 2022, 30, 3034-3051.	3.7	10
1299	Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging. Clinical Research in Cardiology, 2023, 112, 353-362.	1.5	8
1300	Cardiac amyloidosisâ€”interdisciplinary approach to diagnosis and therapy. Herz, 2022, 47, 324-331.	0.4	2
1301	Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways. European Journal of Pharmaceutical Sciences, 2022, 176, 106234.	1.9	14
1302	PK-modifying anchors significantly alter clearance kinetics, tissue distribution, and efficacy of therapeutics siRNAs. Molecular Therapy - Nucleic Acids, 2022, 29, 116-132.	2.3	7
1303	RNA therapies for cardiovascular disease. , 2022, , 413-425.		0
1304	Beyond GalNAc! Drug delivery systems comprising complex oligosaccharides for targeted use of nucleic acid therapeutics. RSC Advances, 2022, 12, 20432-20446.	1.7	5

#	Article	IF	Citations
1305	Clinical Profile and Prognosis of Hereditary Transthyretin Amyloid Cardiomyopathy: A Single-Center Study in South China. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	5
1306	Knockdown of 15-bp Deletion-Type v-raf Murine Sarcoma Viral Oncogene Homolog B1 mRNA in Pancreatic Ductal Adenocarcinoma Cells Repressed Cell Growth In Vitro and Tumor Volume In Vivo. Cancers, 2022, 14, 3162.	1.7	1
1307	Nonviral vector system for cancer immunogene therapy. , 2022, 1, .		2
1308	RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies. Journal of Pharmacology and Experimental Therapeutics, 2023, 384, 133-154.	1.3	52
1309	Nanoparticle single-cell multiomic readouts reveal that cell heterogeneity influences lipid nanoparticle-mediated messenger RNA delivery. Nature Nanotechnology, 2022, 17, 871-879.	15.6	31
1310	Analyzing siRNA Concentration, Complexation and Stability in Cationic Dendriplexes by Stem-Loop Reverse Transcription-qPCR. Pharmaceutics, 2022, 14, 1348.	2.0	2
1312	The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era. Journal of Cardiac Failure, 2022, 28, 1509-1518.	0.7	3
1313	Gait Characterization and Analysis of Hereditary Amyloidosis Associated with Transthyretin Patients: A Case Series. Journal of Clinical Medicine, 2022, 11, 3967.	1.0	2
1315	Does [99mTc]-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) soft tissue uptake allow the identification of patients with the diagnosis of cardiac transthyretin-related (ATTR) amyloidosis with higher risk for polyneuropathy?. Journal of Nuclear Cardiology, 2023, 30, 357-367.	1.4	6
1316	RNA-targeting strategies as a platform for ocular gene therapy. Progress in Retinal and Eye Research, 2023, 92, 101110.	7.3	10
1318	Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 0, , 1-11.	1.4	1
1319	Next RNA Therapeutics: The Mine of Non-Coding. International Journal of Molecular Sciences, 2022, 23, 7471.	1.8	34
1320	Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics â€“ a Minireview. Pharmaceutical Research, 2022, 39, 1749-1759.	1.7	19
1321	Beta-Adrenergic Antagonist Tolerance in Amyloid Cardiomyopathy. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
1322	In Cellulo and In Vivo Comparison of Cholesterol, Beta-Sitosterol and Dioleylphosphatidylethanolamine for Lipid Nanoparticle Formulation of mRNA. Nanomaterials, 2022, 12, 2446.	1.9	6
1323	mRNA-based therapy proves superior to the standard of care for treating hereditary tyrosinemia 1 in a mouse model. Molecular Therapy - Methods and Clinical Development, 2022, 26, 294-308.	1.8	4
1324	Therapeutic inÂvivo delivery of gene editing agents. Cell, 2022, 185, 2806-2827.	13.5	131
1325	Grand Challenges in Vaccine Delivery: Lessons Learned From the COVID-19 Vaccine Rollout. Frontiers in Drug Delivery, 0, 2, .	0.4	1

#	Article	IF	Citations
1326	Factors associated with increased <scp>healthâ€related</scp> qualityâ€ofâ€life benefits in hereditary transthyretin amyloidosis polyneuropathy patients treated with inotersen. Muscle and Nerve, 2022, 66, 319-328.	1.0	0
1327	RNA solutions to treat inborn errors of metabolism. Molecular Genetics and Metabolism, 2022, 136, 289-295.	0.5	6
1328	Lipid nanocapsules for intracellular delivery of microRNA: A first step towards intervertebral disc degeneration therapy. International Journal of Pharmaceutics, 2022, 624, 121941.	2.6	10
1329	The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Advanced Drug Delivery Reviews, 2022, 188, 114416.	6.6	192
1330	Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapy. Journal of Controlled Release, 2022, 349, 174-183.	4.8	10
1331	RNA-based therapeutics: an overview and prospectus. Cell Death and Disease, 2022, 13, .	2.7	137
1332	Bone scintigraphy imaging and transthyretin-related (ATTR) cardiac amyloidosis: New tricks from an old tool?. Journal of Nuclear Cardiology, 2023, 30, 368-370.	1.4	1
1333	Multi-step screening of DNA/lipid nanoparticles and co-delivery with siRNA to enhance and prolong gene expression. Nature Communications, 2022, 13, .	5.8	25
1334	Myeloid leukocytesâ€™ diverse effects on cardiovascular and systemic inflammation in chronic kidney disease. Basic Research in Cardiology, 2022, 117, .	2.5	3
1335	Extracellular Vesicle Mimetics: Preparation from Topâ€Down Approaches and Biological Functions. Advanced Healthcare Materials, 2022, 11, .	3.9	6
1336	Nanoparticles-Based Strategies to Improve the Delivery of Therapeutic Small Interfering RNA in Precision Oncology. Pharmaceutics, 2022, 14, 1586.	2.0	12
1337	HELIOS-A: Vutrisiran meets exploratory endpoints. , 0, , .		0
1338	siRNA therapeutics and its challenges: Recent advances in effective delivery for cancer therapy. OpenNano, 2022, 7, 100063.	1.8	13
1339	Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 18-26.	1.4	97
1340	Cutaneous amyloid is a biomarker in early <scp>ATTRv</scp> neuropathy and progresses across disease stages. Annals of Clinical and Translational Neurology, 2022, 9, 1370-1383.	1.7	10
1341	Ascendancy of semi-synthetic biomaterials from design towards democratization. Nature Materials, 2022, 21, 989-992.	13.3	7
1342	Modulating glioblastoma chemotherapy response: Evaluating long non-coding RNA effects on DNA damage response, glioma stem cell function, and hypoxic processes. Neuro-Oncology Advances, 2022, 4, .	0.4	2
1343	mRNA-Loaded Lipid Nanoparticles Targeting Immune Cells in the Spleen for Use as Cancer Vaccines. Pharmaceuticals, 2022, 15, 1017.	1.7	12

#	Article	IF	Citations
1344	Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo. Nature Communications, 2022, 13, .	5.8	47
1345	Trading places: Peptide and small molecule alternatives to oligonucleotide-based modulation of microRNA expression. Drug Discovery Today, 2022, 27, 103337.	3.2	2
1346	RNA-As-Graphs Motif Atlasâ€"Dual Graph Library of RNA Modules and Viral Frameshifting-Element Applications. International Journal of Molecular Sciences, 2022, 23, 9249.	1.8	1
1347	Update on Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis. Current Heart Failure Reports, 2022, 19, 356-363.	1.3	3
1348	Vutrisiran: First Approval. Drugs, 2022, 82, 1419-1425.	4.9	41
1349	A Comprehensive Review on COVID-19: Emphasis on Current Vaccination and Nanotechnology Aspects. Recent Patents on Nanotechnology, 2022, 16, .	0.7	0
1350	Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets. International Journal of Molecular Sciences, 2022, 23, 8875.	1.8	9
1351	Polymeric Carriers for Delivery of RNA Cancer Therapeutics. Non-coding RNA, 2022, 8, 58.	1.3	3
1352	Using RNAi in the treatment of cardiovascular diseases - therapeutics based on siRNA overview. Journal of Education, Health and Sport, 2022, 12, 890-896.	0.0	0
1353	Development of siRNA Delivery System by Lipid Nanoparticles Modified with Functional Materials for Cancer Treatment. Biological and Pharmaceutical Bulletin, 2022, 45, 972-977.	0.6	2
1354	Therapeutic siRNA: State-of-the-Art and Future Perspectives. BioDrugs, 2022, 36, 549-571.	2.2	88
1356	Transthyretin cardiac amyloidosis. Cardiovascular Research, 2023, 118, 3517-3535.	1.8	39
1357	Nerve Conduction Studies of Dorsal Sural Nerve: Normative Data and Its Potential Application in ATTRv Pre-Symptomatic Subjects. Brain Sciences, 2022, 12, 1037.	1.1	4
1358	Development of 5-FU-modified tumor suppressor microRNAs as a platform for novel microRNA-based cancer therapeutics. Molecular Therapy, 2022, 30, 3450-3461.	3.7	6
1359	Short interfering RNA: a rapidly developing drug class. European Heart Journal, 2022, 43, 4772-4774.	1.0	1
1360	Tracking the Endosomal Escape: A Closer Look at Calcein and Related Reporters. Macromolecular Bioscience, 2022, 22, .	2.1	6
1361	The current state of amyloidosis therapeutics and the potential role of fluorine in their treatment. Biochimie, 2022, 202, 123-135.	1.3	1
1362	Engineered ionizable lipid siRNA conjugates enhance endosomal escape but induce toxicity in vivo. Journal of Controlled Release, 2022, 349, 831-843.	4.8	13

#	Article	IF	Citations
1363	Downregulation of hepatic lipopolysaccharide binding protein improves lipogenesis-induced liver lipid accumulation. Molecular Therapy - Nucleic Acids, 2022, 29, 599-613.	2.3	8
1364	Clinical manifestations and healthcare utilization before diagnosis of transthyretin amyloidosis. Journal of Comparative Effectiveness Research, 2022, 11, 1031-1044.	0.6	2
1365	Spheroplexes: Hybrid PLGA-cationic lipid nanoparticles, for in vitro and oral delivery of siRNA. Journal of Controlled Release, 2022, 350, 228-243.	4.8	14
1366	Nucleic acid-based therapy for brain cancer: Challenges and strategies. Journal of Controlled Release, 2022, 350, 80-92.	4.8	11
1367	Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. Journal of Controlled Release, 2022, 350, 298-307.	4.8	19
1368	Optimization of nucleotides dephosphorylation for RNA structural characterization by tandem mass spectrometry hyphenated with separation methods. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2022, 1208, 123396.	1.2	1
1369	Amyloidosis and Other Protein Deposition Diseases. , 2023, , 213-235.		0
1370	Multifunctional Therapeutic Cyclodextrin-Appended Dendrimer Complex for Treatment of Systemic and Localized Amyloidosis. ACS Applied Materials & Interfaces, 2022, 14, 40599-40611.	4.0	2
1371	Treatment of acquired transthyretin amyloidosis in domino liver transplantation. Clinical Transplantation, 2023, 37, .	0.8	2
1372	LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea. Journal of Controlled Release, 2022, 350, 401-413.	4.8	18
1373	siRNA modification and delivery for drug development. Trends in Molecular Medicine, 2022, 28, 892-893.	3.5	9
1374	Nucleic acid therapy in pediatric cancer. Pharmacological Research, 2022, 184, 106441.	3.1	3
1375	Biogenesis, classification, and role of LncRNAs in tumor angiogenesis: A focus on tumor and its neighbouring cells, and interaction with miRNAs. Process Biochemistry, 2022, 122, 347-355.	1.8	3
1376	Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells. Molecular Therapy - Nucleic Acids, 2022, 30, 49-61.	2.3	6
1377	Lipid Nanoparticle-Mediated Delivery of Therapeutic and Prophylactic mRNA: Immune Activation by Ionizable Cationic Lipids. RNA Technologies, 2022, , 237-255.	0.2	1
1378	Synthetic mRNA Gene Therapies and Hepatotropic Non-viral Vectors for the Treatment of Chronic HBV Infections. RNA Technologies, 2022, , 157-179.	0.2	0
1379	Biomaterials in Their Role in Creating New Approaches for the Delivery of Drugs, Proteins, Nucleic Acids, and Mammalian Cells in Safety Pharmacology. , 2022, , 1-27.		0
1380	Small Interfering RNA in Colorectal Cancer Liver Metastasis Therapy. Technology in Cancer Research and Treatment, 2022, 21, 153303382211033.	0.8	1

#	Article	IF	Citations
1381	Development and application of ribonucleic acid therapy strategies against COVID-19. International Journal of Biological Sciences, 2022, 18, 5070-5085.	2.6	18
1382	Biotechnology applications in clinical trials. , 2022, , 163-195.		0
1383	Treatment of the metabolic syndrome by siRNA targeting apolipoprotein CIII. BioFactors, 2023, 49, 153-172.	2.6	1
1384	Applications and challenges of biomaterial mediated mRNA delivery. Exploration of Targeted Anti-tumor Therapy, 0, , 428-444.	0.5	5
1385	Using ncRNAs as Tools in Cancer Diagnosis and Treatmentâ€"The Way towards Personalized Medicine to Improve Patientsâ€™ Health. International Journal of Molecular Sciences, 2022, 23, 9353.	1.8	21
1386	Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 49-58.	1.4	10
1387	Directing the Wayâ€"Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery. Pharmaceutical Research, 2023, 40, 47-76.	1.7	10
1388	Influence of diverse storage conditions of doubleâ€stranded <scp>RNA</scp>in vitro on the <scp>RNA</scp> interference efficiency in vivo insect Tribolium castaneum. Pest Management Science, 2023, 79, 45-54.	1.7	0
1389	Treating hereditary transthyretin amyloidosis: Present & future challenges. Revue Neurologique, 2022, , .	0.6	2
1391	Brain Gene Silencing with Cationic Amino-Capped Poly(ethylene glycol) Polyplexes. Biomedicines, 2022, 10, 2182.	1.4	3
1392	High Hereditary Transthyretin-Related Amyloidosis Prevalence in Crete. Neurology: Genetics, 2022, 8, .	0.9	1
1393	mRNA nanomedicine: Design and recent applications. Exploration, 2022, 2, .	5.4	37
1394	Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study. Journal of Neurology, 2023, 270, 328-339.	1.8	3
1395	Transcriptomics and RNA-Based Therapeutics as Potential Approaches to Manage SARS-CoV-2 Infection. International Journal of Molecular Sciences, 2022, 23, 11058.	1.8	2
1396	Lipidâ€based nucleic acid therapeutics with in vivo efficacy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2023, 15, .	3.3	3
1397	Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. Cancers, 2022, 14, 4543.	1.7	9
1398	Small non-coding RNA therapeutics for cardiovascular disease. European Heart Journal, 2022, 43, 4548-4561.	1.0	24
1399	Hereditary Transthyretin-Related Amyloidosis: Genetic Heterogeneity and Early Personalized Gene Therapy. Biomedicines, 2022, 10, 2394.	1.4	2

#	Article	IF	Citations
1400	The emerging role of long non-coding RNAs in schizophrenia. Frontiers in Psychiatry, 0, 13, .	1.3	1
1401	CRISPR/Cas9 in the era of nanomedicine and synthetic biology. Drug Discovery Today, 2023, 28, 103375.	3.2	2
1402	Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 81-95.	1.4	3
1403	Distribution and progression of cerebral amyloid angiopathy in early-onset V30M (p.V50M) hereditary ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 109-118.	1.4	3
1404	Sustained Drug Release from Smart Nanoparticles in Cancer Therapy: A Comprehensive Review. Micromachines, 2022, 13, 1623.	1.4	23
1405	Liver Gene Therapy. Human Gene Therapy, 2022, 33, 879-888.	1.4	9
1406	Modeling the Cost and Health Impacts of Diagnostic Strategies in Patients with Suspected Transthyretin Cardiac Amyloidosis. Journal of the American Heart Association, 2022, 11, .	1.6	4
1407	Phenylalanine hydroxylase mRNA rescues the phenylketonuria phenotype in mice. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	9
1408	MicroRNAs: emerging biomarkers and therapeutic targets of bone fragility in chronic kidney disease. CKJ: Clinical Kidney Journal, 2023, 16, 408-421.	1.4	2
1411	Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntingtonâ€™s disease models. Nature Communications, 2022, 13, .	5.8	11
1413	Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy. Journal of Controlled Release, 2022, 351, 713-726.	4.8	12
1414	Transthyretin Cardiac Amyloidosis. Cardiology Clinics, 2022, 40, 541-558.	0.9	3
1415	The Outlook for Novel Pharmaceutics. Future of Business and Finance, 2022, , 301-315.	0.3	1
1416	Regulation der Transkription â€“ Aktivierung und Inaktivierung der Genexpression. , 2022, , 765-781.		0
1417	Bioresponsive Nanomaterials for CNS Disease. , 2022, , 189-227.		0
1418	Toxicity Evaluation of Nanomedicine. , 2022, , 323-345.		1
1419	TREAT: Therapeutic RNAs exploration inspired by artificial intelligence technology. Computational and Structural Biotechnology Journal, 2022, 20, 5680-5689.	1.9	1
1420	Light-responsive RNA delivery. Drug Delivery System, 2022, 37, 229-236.	0.0	0

#	Article	IF	Citations
1421	Leptomeningeal Disease Secondary to Thr60Ala Transthyretin Amyloidosis: Case Report and Review of the Literature. Neurohospitalist, The, 0, , 194187442211278.	0.3	1
1422	Lipid Nanoparticles: A Novel Gene Delivery Technique for Clinical Application. Current Issues in Molecular Biology, 2022, 44, 5013-5027.	1.0	17
1423	Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy. Bioengineering, 2022, 9, 576.	1.6	4
1424	Noncoding RNAs Emerging as Drugs or Drug Targets: Their Chemical Modification, Bio-Conjugation and Intracellular Regulation. Molecules, 2022, 27, 6717.	1.7	4
1425	Portable RGB-D Camera-Based System for Assessing Gait Impairment Progression in ATTRv Amyloidosis. Applied Sciences (Switzerland), 2022, 12, 10203.	1.3	2
1426	A review of transthyretin cardiac amyloidosis. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 2023, 61, 28-34.	0.3	1
1427	Synergistic siRNA Loading of Extracellular Vesicles Enables Functional Delivery into Cells. Small Methods, 2022, 6, .	4.6	10
1428	Genetically modified organisms: adapting regulatory frameworks for evolving genome editing technologies. Biological Research, 2022, 55, .	1.5	10
1429	Endometriosis-associated infertility: From pathophysiology to tailored treatment. Frontiers in Endocrinology, 0, 13, .	1.5	31
1430	Multidisciplinary amyloidosis care in the era of personalized medicine. Frontiers in Neurology, 0, 13, .	1.1	3
1431	Photoacoustic image-guided biomimetic nanoparticles targeting rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	22
1432	Small Interfering RNAs Containing Dioxane- and Morpholino-Derived Nucleotide Analogues Show Improved Off-Target Profiles and Chirality-Dependent In Vivo Knock-Down. Journal of Medicinal Chemistry, 2022, 65, 13736-13752.	2.9	2
1433	Current and potential therapeutic strategies for transthyretin cardiac amyloidosis. Frontiers in Drug Discovery, 0, 2, .	1.1	0
1434	Contaminating transfection complexes can masquerade as small extracellular vesicles and impair their delivery of RNA. Journal of Extracellular Vesicles, 2022, 11, .	5.5	9
1435	Small interfering RNA: Discovery, pharmacology and clinical developmentâ€"An introductory review. British Journal of Pharmacology, 2023, 180, 2697-2720.	2.7	29
1436	^{99m}Technetiumâ€pyrophosphate bone scan: A potential biomarker for the burden of transthyretin amyloidosis in skeletal muscle: A preliminary study. Muscle and Nerve, 2023, 67, 111-116.	1.0	4
1437	CRISPR/Cas systems usher in a new era of disease treatment and diagnosis. Molecular Biomedicine, 2022, 3, .	1.7	5
1438	Clinical pharmacology of siRNA therapeutics: current status and future prospects. Expert Review of Clinical Pharmacology, 2022, 15, 1327-1341.	1.3	7

#	Article	IF	Citations
1439	Extracellular Volume Fraction by Computed Tomography Predicts Long-Term Prognosis Among PatientsÂWith Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2022, 15, 2082-2094.	2.3	15
1441	RNA interference (RNAi)-based therapeutics for treatment of rare neurologic diseases. Molecular Aspects of Medicine, 2023, 91, 101148.	2.7	5
1442	Diverse and Composite Roles of miRNA in Non-Neuronal Cells and Neuronal Synapses in Alzheimerâ€™s Disease. Biomolecules, 2022, 12, 1505.	1.8	1
1443	Suppression and Replacement Gene Therapy for KCNH2 -Mediated Arrhythmias. Circulation Genomic and Precision Medicine, 2022, 15, .	1.6	2
1444	Noninvasive Diagnostics of Renal Amyloidosis: Current State and Perspectives. International Journal of Molecular Sciences, 2022, 23, 12662.	1.8	3
1445	Focal Segmental Glomerulosclerosis Complicating Therapy With Inotersen, an Antisense Oligonucleotide Inhibitor: A Case Report. American Journal of Kidney Diseases, 2022, , .	2.1	2
1446	Unlocking the promise of mRNA therapeutics. Nature Biotechnology, 2022, 40, 1586-1600.	9.4	107
1447	A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis. EBioMedicine, 2022, 85, 104304.	2.7	28
1449	Targeted therapy and molecular genetics. , 2023, , 464-488.e11.		0
1450	Amyloidosis: Clinical Manifestations and Treatment. , 2022, , 113-125.		0
1451	Synthesis and characterization of ZnOâ€“TiO₂â€“chitosanâ€“escin metallic nanocomposites: Evaluation of their antimicrobial and anticancer activities. Green Processing and Synthesis, 2022, 11, 1026-1039.	1.3	3
1452	Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology. Pharmaceutics, 2022, 14, 2389.	2.0	10
1453	Cholesterolâ€conjugated siRNAs silence gene expression in mucosal dendritic cells in cervicovaginal tissue in mice. Journal of the European Academy of Dermatology and Venereology, 2023, 37, 615-626.	1.3	4
1454	Bio-Orthogonal Chemistry Conjugation Strategy Facilitates Investigation of N-methyladenosine and Thiouridine Guide RNA Modifications on CRISPR Activity. CRISPR Journal, 2022, 5, 787-798.	1.4	4
1455	Red flags in patients with hereditary transthyretin amyloidosis at diagnosis in a non-endemic area of Spain. NeurologÃa (English Edition), 2022, , .	0.2	0
1456	A Î²-Cyclodextrin-Based Nanoparticle with Very High Transfection Efficiency Unveils siRNA-Activated TLR3 Responses in Human Prostate Cancer Cells. Pharmaceutics, 2022, 14, 2424.	2.0	4
1457	Liverâ€directed drugs for t<scp>ransthyretinâ€mediated</scp> amyloidosis. Journal of the Peripheral Nervous System, 2022, 27, 228-237.	1.4	4
1458	Genetics of Kidney Disease: The Unexpected Role of Rare Disorders. Annual Review of Medicine, 2023, 74, 353-367.	5.0	3

#	Article	IF	Citations
1459	Analysis of lumbar spine stenosis for identification of amyloid. Journal of the American Geriatrics Society, 2022, 70, 3356-3358.	1.3	1
1460	Recent Advances in Gene Therapy for Familial Hypercholesterolemia: An Update Review. Journal of Clinical Medicine, 2022, 11, 6773.	1.0	7
1461	An Enzymatically Gated Catalytic Hairpin Assembly Delivered by Lipid Nanoparticles for the Tumorâ€Specific Activation of Signal Amplification in miRNA Imaging. Angewandte Chemie, 2022, 134, .	1.6	0
1462	Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy. American Journal of Cardiology, 2022, 185, S23-S34.	0.7	6
1463	Skeletal muscle 99mTechnetiumâ€pyrophosphate scan: more questions than answers. Muscle and Nerve, 0, , .	1.0	0
1465	An Enzymatically Gated Catalytic Hairpin Assembly Delivered by Lipid Nanoparticles for the Tumorâ€Specific Activation of Signal Amplification in miRNA Imaging. Angewandte Chemie - International Edition, 2022, 61, .	7.2	23
1466	Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy. Current Neuropharmacology, 2023, 21, 471-481.	1.4	3
1467	Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics. Journal of Controlled Release, 2022, 352, 861-878.	4.8	21
1469	A treatment strategy of elderly patients with heart failure. [Fukushima Igaku Zasshi] Fukushima Medical Journal, 2022, 72, 103-108.	0.1	0
1470	Future Impact of mRNA Therapy on Cardiovascular Diseases. Methodist DeBakey Cardiovascular Journal, 2022, 18, 64-73.	0.5	1
1471	Combinatorial screening for therapeutics in ATTRv amyloidosis identifies naphthoquinone analogues as TTR-selective amyloid disruptors. Journal of Pharmacological Sciences, 2023, 151, 54-62.	1.1	0
1472	Substituting racemic ionizable lipids with stereopure ionizable lipids can increase mRNA delivery. Journal of Controlled Release, 2023, 353, 270-277.	4.8	11
1473	siRNA delivery to lymphatic endothelial cells via ApoE-mediated uptake by lipid nanoparticles. Journal of Controlled Release, 2023, 353, 125-133.	4.8	3
1474	Engineering poly- and micelleplexes for nucleic acid delivery â€“ A reflection on their endosomal escape. Journal of Controlled Release, 2023, 353, 518-534.	4.8	15
1475	Protein corona: Friend or foe? Co-opting serum proteins for nanoparticle delivery. Advanced Drug Delivery Reviews, 2023, 192, 114635.	6.6	22
1476	Opportunities for Earlier Diagnosis and Treatment of Cardiac Amyloidosis. Methodist DeBakey Cardiovascular Journal, 2022, 18, 27-39.	0.5	2
1477	In vivo gene therapy with CRISPRâ€“Cas9: A promising therapeutic strategy to cure inherited diseases. , 2022, 1, .		1
1478	Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, .	3.3	12

#	Article	IF	Citations
1479	MicroRNA29B induces fetal hemoglobin via inhibition of the HBG repressor protein MYB in vitro and in humanized sickle cell mice. Frontiers in Medicine, 0, 9, .	1.2	2
1481	Microhook ab interno trabeculotomy for secondary glaucoma in patients with hereditary transthyretin amyloidosis. Japanese Journal of Ophthalmology, 0, , .	0.9	1
1482	The flutemetamol analogue cyano-flutemetamol detects myocardial AL and ATTR amyloid deposits: a post-mortem histofluorescence analysis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 169-187.	1.4	1
1483	Roles and mechanisms of CircRNAs in ovarian cancer. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	4
1484	Is There a Role for Immunoregulatory and Antiviral Oligonucleotides Acting in the Extracellular Space? A Review and Hypothesis. International Journal of Molecular Sciences, 2022, 23, 14593.	1.8	1
1485	Innovative approaches in transforming <scp>microRNAs</scp> into therapeutic tools. Wiley Interdisciplinary Reviews RNA, 2023, 14, .	3.2	18
1486	mRNA therapy for myocardial infarction: A review of targets and delivery vehicles. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	3
1487	Advances in Lipidâ€Based Codelivery Systems for Cancer and Inflammatory Diseases. Advanced Healthcare Materials, 2023, 12, .	3.9	5
1489	MicroRNAs: a crossroad that connects obesity to immunity and aging. Immunity and Ageing, 2022, 19, .	1.8	9
1490	Influence of Lipid Composition of Cationic Liposomes 2X3-DOPE on mRNA Delivery into Eukaryotic Cells. Pharmaceutics, 2023, 15, 8.	2.0	4
1491	Serum neurofilament light chain as a reliable biomarker of hereditary transthyretinâ€related amyloidosisâ€”A Swiss reference center experience. Journal of the Peripheral Nervous System, 2023, 28, 86-97.	1.4	7
1492	High Prevalence of Cardiac Amyloidosis in Clinically Significant Aortic Stenosis: A Meta-Analysis. Cardiology Research, 2022, 13, 357-371.	0.5	3
1493	The tumor therapeutic potential of long non-coding RNA delivery and targeting. Acta Pharmaceutica Sinica B, 2023, 13, 1371-1382.	5.7	5
1495	Follow-up regimens for carriers of hereditary transthyretin variants. Medicina ClÃ¬nica, 2023, 160, 213-217.	0.3	0
1496	Nanoparticles-mediated CRISPR-Cas9 gene therapy in inherited retinal diseases: applications, challenges, and emerging opportunities. Journal of Nanobiotechnology, 2022, 20, .	4.2	10
1497	Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy. International Journal of Molecular Sciences, 2022, 23, 16145.	1.8	3
1498	Current Understanding of Systemic Amyloidosis and Underlying Disease Mechanisms. American Journal of Cardiology, 2022, 185, S2-S10.	0.7	1
1499	Chlorinated Naringenin Analogues as Potential Inhibitors of Transthyretin Amyloidogenesis. Journal of Medicinal Chemistry, 2022, 65, 16218-16233.	2.9	5

#	Article	IF	Citations
1500	The Extent to Which Lipid Nanoparticles Require Apolipoprotein E and Low-Density Lipoprotein Receptor for Delivery Changes with Ionizable Lipid Structure. Nano Letters, 2022, 22, 10025-10033.	4.5	10
1501	Therapeutic tools for inherited neuropathies. Revue Neurologique, 2023, 179, 5-9.	0.6	2
1502	Inhibition of c-Rel expression in myeloid and lymphoid cells with distearoyl -phosphatidylserine (DSPS) liposomal nanoparticles encapsulating therapeutic siRNA. PLoS ONE, 2022, 17, e0276905.	1.1	0
1503	Hereditary Transthyretin Amyloidosis with Polyneuropathy: Monitoring and Management. International Journal of General Medicine, 0, Volume 15, 8677-8684.	0.8	0
1505	Gene Therapy and Cardiovascular Diseases. Advances in Experimental Medicine and Biology, 2023, , 235-254.	0.8	1
1506	Transthyretin Cardiac Amyloidosis: A Cardio-Orthopedic Disease. Biomedicines, 2022, 10, 3226.	1.4	3
1507	Strategy for genetic analysis in hereditary neuropathy. Revue Neurologique, 2023, 179, 10-29.	0.6	5
1508	^{99m}Tc Bone-Avid Tracer Cardiac Scintigraphy: Role in Noninvasive Diagnosis of Transthyretin Cardiac Amyloidosis. Radiology, 2023, 306, .	3.6	8
1509	Current approaches to the diagnosis and management of amyloidosis. Internal Medicine Journal, 2022, 52, 2046-2067.	0.5	3
1510	Modified fibrin hydrogel for sustained delivery of RNAi lipopolyplexes in skeletal muscle. International Journal of Energy Production and Management, 0, , .	1.9	0
1511	Care of Patients With Transthyretin Amyloidosis: the Roles of Nutrition, Supplements, Exercise, and Mental Health. American Journal of Cardiology, 2022, 185, S35-S42.	0.7	1
1512	Interaction Kinetics of Individual mRNA-Containing Lipid Nanoparticles with an Endosomal Membrane Mimic: Dependence on pH, Protein Corona Formation, and Lipoprotein Depletion. ACS Nano, 2022, 16, 20163-20173.	7.3	22
1513	Gene therapy review: Duchenne muscular dystrophy case study. Revue Neurologique, 2023, 179, 90-105.	0.6	1
1514	Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen. Neurology and Therapy, 2023, 12, 267-287.	1.4	14
1515	Editorial: Novel phenotyping and risk stratification strategies for heart failure. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
1516	Epigenetics in Cancer Biology. , 2022, , .		0
1517	Non-coding RNAs in human health and disease: potential function as biomarkers and therapeutic targets. Functional and Integrative Genomics, 2023, 23, .	1.4	39
1518	Amphiphilic Phosphorus Dendrons Associated with Anti-inflammatory siRNA Reduce Symptoms in Murine Collagen-Induced Arthritis. Biomacromolecules, 2023, 24, 667-677.	2.6	1

#	Article	IF	Citations
1519	Nonchromatographic Purification of Synthetic RNA. , 2023, , 1-18.		0
1520	Outcomes in patients with cardiac amyloidosis undergoing heart transplantation: the eurotransplant experience. Journal of Heart and Lung Transplantation, 2023, 42, 778-785.	0.3	2
1521	Structural Modifications of siRNA Improve Its Performance In Vivo. International Journal of Molecular Sciences, 2023, 24, 956.	1.8	4
1522	Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates. Science Advances, 2023, 9, .	4.7	52
1523	Lipid nanoparticle-mediated mRNA delivery in lung fibrosis. European Journal of Pharmaceutical Sciences, 2023, 183, 106370.	1.9	9
1524	Nucleic acid drug vectors for diagnosis and treatment of brain diseases. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	19
1525	Elimination of Cancer Cells in Co-Culture: Role of Different Nanocarriers in Regulation of CD47 and Calreticulin-Induced Phagocytosis. ACS Applied Materials & Interfaces, 2023, 15, 3791-3803.	4.0	5
1526	CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	73
1527	Bioinspired Lipid Nanocarriers for RNA Delivery. ACS Bio & Med Chem Au, 2023, 3, 114-136.	1.7	8
1528	Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2. Biomedical Journal, 2023, 46, 70-80.	1.4	8
1529	Cardiovascular reflex tests detect autonomic dysfunction in symptomatic and pre-symptomatic subjects with hereditary transthyretin amyloidosis. Clinical Autonomic Research, 2023, 33, 15-22.	1.4	3
1530	Innate Immunity in Cardiovascular Diseasesâ€"Identification of Novel Molecular Players and Targets. Journal of Clinical Medicine, 2023, 12, 335.	1.0	2
1531	Liver cancer cells as the model for developing liver-targeted RNAi therapeutics. Biochemical and Biophysical Research Communications, 2023, 644, 85-94.	1.0	1
1532	Dissecting Functional Biological Interactions Using Modular RNA Nanoparticles. Molecules, 2023, 28, 228.	1.7	1
1533	The Role of Proteolysis in Amyloidosis. International Journal of Molecular Sciences, 2023, 24, 699.	1.8	5
1534	Microfluidic Post-Insertion Method for the Efficient Preparation of PEGylated Liposomes Using High Functionality and Quality Lipids. International Journal of Nanomedicine, 0, Volume 17, 6675-6686.	3.3	2
1536	Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	6
1537	Amyloidosis and autonomic failure. , 2023, , 575-583.		0

#	Article	IF	Citations
1538	miRNAs: The Road from Bench to Bedside. Genes, 2023, 14, 314.	1.0	13
1539	Inotersen to Treat Polyneuropathy Associated with Hereditary Transthyretin (hATTR) Amyloidosis. Health Psychology Research, 2022, 10, .	0.6	1
1540	Implications of Extra-cardiac Disease in Patient Selection for Heart Transplantation: Considerations in Cardiac Amyloidosis. Cardiac Failure Review, 0, , .	1.2	0
1541	2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the PatientÂWith Cardiac Amyloidosis. Journal of the American College of Cardiology, 2023, 81, 1076-1126.	1.2	89
1542	mRNAâ€"From COVID-19 Treatment to Cancer Immunotherapy. Biomedicines, 2023, 11, 308.	1.4	3
1543	Iterative Design of Ionizable Lipids for Intramuscular mRNA Delivery. Journal of the American Chemical Society, 2023, 145, 2294-2304.	6.6	24
1544	Syncope, Arrhythmia, and Cardiac Devices in Amyloidosis. , 2023, , 49-65.		0
1545	Targeting connexin 43 expression via scaffold mediated delivery of antisense oligodeoxynucleotide preserves neurons, enhances axonal extension, reduces astrocyte and microglial activation after spinal cord injury. Journal of Tissue Engineering, 2023, 14, 204173142211457.	2.3	3
1546	The Transcriptional Response to Lung-Targeting Lipid Nanoparticles in Vivo. Nano Letters, 2023, 23, 993-1002.	4.5	19
1547	Microfluidic synthesis of multilayered lipidâ€"polymer hybrid nanoparticles for the formulation of low solubility drugs. Soft Matter, 2023, 19, 1596-1605.	1.2	1
1548	Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nature Reviews Materials, 2023, 8, 282-300.	23.3	88
1549	Implications of CRISPR-Cas9 Genome Editing Methods in Atherosclerotic Cardiovascular Diseases. Current Problems in Cardiology, 2023, 48, 101603.	1.1	1
1550	Tafamidis concentration required for transthyretin stabilisation in cerebrospinal fluid. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 279-289.	1.4	1
1551	Lipid and Peptide-Oligonucleotide Conjugates for Therapeutic Purposes: From Simple Hybrids to Complex Multifunctional Assemblies. Pharmaceutics, 2023, 15, 320.	2.0	9
1552	Neurological Manifestations in ATTRv Amyloidosis. , 2023, , 5-17.		0
1553	Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications. Pharmaceutics, 2023, 15, 451.	2.0	6
1554	Future directions for medicinal chemistry in the field of oligonucleotide therapeutics. Rna, 2023, 29, 423-433.	1.6	7
1555	Ionizable lipid nanoparticles deliver mRNA to pancreatic Î² cells via macrophage-mediated gene transfer. Science Advances, 2023, 9, .	4.7	35

#	Article	IF	Citations
1556	Microcalcification and 99mTc-Pyrophosphate Uptake without Increased Bone Metabolism in Cardiac Tissue from Patients with Transthyretin Cardiac Amyloidosis. International Journal of Molecular Sciences, 2023, 24, 1921.	1.8	1
1557	Effect of patisiran on stroke volume in hereditary t<scp>ransthyretinâ€mediated</scp> amyloidosis: insights from p<scp>ressureâ€“volume</scp> analysis of the <scp>APOLLO</scp> study. European Journal of Heart Failure, 2023, 25, 727-736.	2.9	3
1558	Regulation of endogenous cardiomyocyte proliferation: The known unknowns. Journal of Molecular and Cellular Cardiology, 2023, 179, 80-89.	0.9	3
1559	Hepatic Manifestations of Systemic Diseases. Medical Clinics of North America, 2023, 107, 465-489.	1.1	1
1560	Solid-phase synthesis and properties of stereocontrolled boranophosphate/phosphate and phosphorothioate/phosphate chimeric oligouridylates. Royal Society Open Science, 2023, 10, .	1.1	1
1561	Vaccine Formulation Strategies and Challenges Involved in RNA Delivery for Modulating Biomarkers of Cardiovascular Diseases: A Race from Laboratory to Market. Vaccines, 2023, 11, 241.	2.1	1
1562	Factors affecting the accuracy of amyloidosis identification and referral to a specialty centre. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 0, , 1-6.	1.4	0
1563	Efficient Delivery of Globotriaosylceramide Synthase siRNA using Polyhistidineâ€Incorporated Lipid Nanoparticles. Macromolecular Bioscience, 2023, 23, .	2.1	4
1564	Composite nerve conduction scores and signs for diagnosis and somatic staging of diabetic polyneuropathy: Mid North American ethnic cohort survey. Muscle and Nerve, 0, , .	1.0	1
1565	Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics. Blood Cancer Journal, 2023, 13, .	2.8	0
1566	Highâ€Precision Synthesis of RNAâ€Loaded Lipid Nanoparticles for Biomedical Applications. Advanced Healthcare Materials, 2023, 12, .	3.9	11
1567	Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2023, 193, 30-43.	0.7	4
1568	Amylose Ã transthyrÃ©tine. , 2022, , 45-52.		0
1569	Treatment of Transthyretin Amyloidosis. , 2023, , 235-276.		1
1570	An old friend with a new face: tRNA-derived small RNAs with big regulatory potential in cancer biology. British Journal of Cancer, 2023, 128, 1625-1635.	2.9	8
1571	Lipid nanoparticle-based ribonucleoprotein delivery for in vivo genome editing. Journal of Controlled Release, 2023, 355, 406-416.	4.8	5
1572	<scp>Ser77Tyr</scp> transthyretin amyloidosis in Israel: Initial manifestations and diagnostic features. Annals of Clinical and Translational Neurology, 2023, 10, 553-567.	1.7	0
1573	Effectiveness of a novel gene nanotherapy based on putrescine for cancer treatment. Biomaterials Science, 2023, 11, 4210-4225.	2.6	2

#	Article	IF	Citations
1574	Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 303-312.	1.4	1
1575	Switchable Lipids: From Conformational Switch to Macroscopic Changes in Lipid Vesicles. Langmuir, 2023, 39, 3072-3082.	1.6	3
1576	RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis. BioDrugs, 2023, 37, 127-142.	2.2	17
1577	Conduction system disease in cardiac amyloidosis. Trends in Cardiovascular Medicine, 2023, , .	2.3	3
1578	Synthesis of folate-labeled siRNAs from a folate derivative phosphoramidite. Organic and Biomolecular Chemistry, 0, , .	1.5	0
1579	Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy. Drug, Healthcare and Patient Safety, 0, Volume 15, 51-62.	1.0	2
1580	Lipid-based colloidal nanoparticles for applications in targeted vaccine delivery. Nanoscale Advances, 2023, 5, 1853-1869.	2.2	8
1581	Research trends and hotspots evolution of cardiac amyloidosis: a bibliometric analysis from 2000 to 2022. European Journal of Medical Research, 2023, 28, .	0.9	1
1583	Delivery challenges for CRISPRâ€"Cas9 genome editing for Duchenne muscular dystrophy. Biophysics Reviews, 2023, 4, .	1.0	2
1584	Gene knockdown in HaCaT cells by small interfering RNAs entrapped in grapefruit-derived extracellular vesicles using a microfluidic device. Scientific Reports, 2023, 13, .	1.6	1
1585	Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia. Leukemia, 2023, 37, 820-834.	3.3	10
1586	Short and Scalable Synthesis of Plantâ€Based Cholesterol in GMP Grade. Advanced Synthesis and Catalysis, 2023, 365, 2406-2409.	2.1	1
1587	Recent advances in using liposomes for delivery of nucleic acid-based therapeutics. OpenNano, 2023, 11, 100132.	1.8	16
1588	Infiltration of Conduction Tissue Is a Major Cause of Electrical Instability in Cardiac Amyloidosis. Journal of Clinical Medicine, 2023, 12, 1798.	1.0	2
1589	A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium. Acta Neurologica Belgica, 2023, 123, 1029-1037.	0.5	1
1590	Single-cell quantification and dose-response of cytosolic siRNA delivery. Nature Communications, 2023, 14, .	5.8	2
1591	Nucleic Acid Pharmaceutical Agents. , 2023, , 231-268.		0
1592	Orphan Drugs in Neurologyâ€"A Narrative Review. Journal of Personalized Medicine, 2023, 13, 420.	1.1	1

#	Article	IF	Citations
1594	Nanoparticle stereochemistry-dependent endocytic processing improves in vivo mRNA delivery. Nature Chemistry, 2023, 15, 508-515.	6.6	16
1596	Follow-up regimens for carriers of hereditary transthyretin variants. Medicina ClÃnica (English) Tj ETQq1 1 0.784314 rgBT /Overlock 1	0.1	0
1597	A Review of Current and Evolving Imaging Techniques in Cardiac Amyloidosis. Current Treatment Options in Cardiovascular Medicine, 2023, 25, 43-63.	0.4	1
1598	Human papillomavirus in the setting of immunodeficiency: Pathogenesis and the emergence of next-generation therapies to reduce the high associated cancer risk. Frontiers in Immunology, 0, 14, .	2.2	12
1599	Chemistry, structureÂand function of approved oligonucleotide therapeutics. Nucleic Acids Research, 2023, 51, 2529-2573.	6.5	110
1600	A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23. Gastroenterology, 2023, 164, 1279-1292.	0.6	8
1601	Nucleotides Entrapped in Liposome Nanovesicles as Tools for Therapeutic and Diagnostic Use in Biomedical Applications. Pharmaceutics, 2023, 15, 873.	2.0	2
1602	Immunomodulationâ€"a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system. Frontiers in Immunology, 0, 14, .	2.2	12
1604	Cardiac Amyloidosis. Annals of Internal Medicine, 2023, 176, ITC33-ITC48.	2.0	8
1605	TTR Amyloidosis. JACC: Case Reports, 2023, 10, 101759.	0.3	0
1606	Machine Learning Approaches in Diagnosis, Prognosis and Treatment Selection of Cardiac Amyloidosis. International Journal of Molecular Sciences, 2023, 24, 5680.	1.8	6
1607	Phenotypes Associated With the Val122Ile, Leu58His, and Late-Onset Val30Met Variants in Patients With Hereditary Transthyretin Amyloidosis. Neurology, 2023, 100, .	1.5	6
1608	Emerging Therapies for Transthyretin Amyloidosis. Current Oncology Reports, 2023, 25, 549-558.	1.8	4
1609	Neuropathy due to bi-allelic SH3TC2 variants: genotype-phenotype correlation and natural history. Brain, 2023, 146, 3826-3835.	3.7	1
1610	Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus. International Journal of Molecular Sciences, 2023, 24, 6012.	1.8	0
1611	The Small RNA Landscape in NSCLC: Current Therapeutic Applications and Progresses. International Journal of Molecular Sciences, 2023, 24, 6121.	1.8	2
1612	<scp>Charcotâ€"Marieâ€"Tooth</scp>neuropathies: Current gene therapy advances and the route toward translation. Journal of the Peripheral Nervous System, 2023, 28, 150-168.	1.4	7
1613	Allogenic microglia replacement: A novel therapeutic strategy for neurological disorders. Fundamental Research, 2023, , .	1.6	3

#	Article	IF	Citations
1614	Aptamer-Based Targeted Delivery of Functional Nucleic Acids. Journal of the American Chemical Society, 2023, 145, 7677-7691.	6.6	21
1615	Crosstalk between SOX Genes and Long Non-Coding RNAs in Glioblastoma. International Journal of Molecular Sciences, 2023, 24, 6392.	1.8	1
1616	State of the Art of Cardiac Amyloidosis. Biomedicines, 2023, 11, 1045.	1.4	2
1617	Challenges with the discovery of RNA-based therapeutics for flaviviruses. Expert Opinion on Drug Discovery, 2023, 18, 371-383.	2.5	0
1618	Lysine-Derived Charge-Altering Releasable Transporters: Targeted Delivery of mRNA and siRNA to the Lungs. Bioconjugate Chemistry, 0, , .	1.8	2
1620	Vial Sharing of High-Cost Drugs to Decrease Leftovers and Costs: A Retrospective Observational Study on Patisiran Administration in Bologna, Italy. Healthcare (Switzerland), 2023, 11, 1013.	1.0	1
1621	Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies. Pharmaceutics, 2023, 15, 1130.	2.0	11
1622	Intracellular trafficking kinetics of nucleic acid escape from lipid nanoparticles via fluorescence imaging. Current Pharmaceutical Biotechnology, 2023, 24, .	0.9	0
1623	Therapeutic gene silencing of CKAP5 leads to lethality in genetically unstable cancer cells. Science Advances, 2023, 9, .	4.7	2
1624	Cell- and subcellular organelle-targeting nanoparticle-mediated breast cancer therapy. Frontiers in Pharmacology, 0, 14, .	1.6	2
1625	Production, Characterization, and Assessment of Permanently Cationic and Ionizable Lipid Nanoparticles for Use in the Delivery of Self-Amplifying RNA Vaccines. Pharmaceutics, 2023, 15, 1173.	2.0	4
1626	RNAi-mediated rheostat for dynamic control of AAV-delivered transgenes. Nature Communications, 2023, 14, .	5.8	2
1627	Treatment Updates for Neuropathy in Hereditary Transthyretin Amyloidosis. Current Treatment Options in Neurology, 0, , .	0.7	0
1629	Brazilian consensus for diagnosis, management and treatment of hereditary transthyretin amyloidosis with peripheral neuropathy: second edition. Arquivos De Neuro-Psiquiatria, 2023, 81, 308-321.	0.3	0
1630	Lysosomal nanotoxicity: Impact of nanomedicines on lysosomal function. Advanced Drug Delivery Reviews, 2023, 197, 114828.	6.6	7
1631	Long-term, in vivo therapeutic effects of a single dose of miR-145 micelles for atherosclerosis. Bioactive Materials, 2023, 27, 327-336.	8.6	3
1632	Impact of stereopure chimeric backbone chemistries on the potency and durability of gene silencing by RNA interference. Nucleic Acids Research, 2023, 51, 4126-4147.	6.5	7
1633	Amyloidoses in Onco-Nephrology Practice: A Multidisciplinary Case-Based Conference Report. Canadian Journal of Kidney Health and Disease, 2023, 10, 205435812311657.	0.6	0

#	Article	IF	Citations
1636	Activatable NIRâ€Ⅱ Photothermal Lipid Nanoparticles for Improved Messenger RNA Delivery. Angewandte Chemie, 0, , .	1.6	0
1637	Activatable NIRâ€Ⅱ Photothermal Lipid Nanoparticles for Improved Messenger RNA Delivery. Angewandte Chemie - International Edition, 2023, 62, .	7.2	6
1638	Treatment of amyloidosis: present and future. European Heart Journal Supplements, 2023, 25, B99-B103.	0.0	5
1639	Microfluidics for nanopharmaceutical and medical applications. , 2023, , 343-408.		0
1640	Engineering Extracellular Vesicles as Delivery Systems in Therapeutic Applications. Advanced Science, 2023, 10, .	5.6	9
1666	ADME considerations for siRNA-based therapeutics. , 2023, , 41-50.		0
1671	Magnetic resonance neurography and diffusion tensor imaging of the sciatic nerve in hereditary transthyretin amyloidosis polyneuropathy. Journal of Neurology, 2023, 270, 4827-4840.	1.8	2
1677	Hexitol Nucleic Acid (HNA): From Chemical Design to Functional Genetic Polymer. , 2023, , 1-34.		0
1702	Editorial: Proceedings and predictions in cardiac amyloidosis: unsolved mysteries and challenges for the future. Frontiers in Medicine, 0, 10, .	1.2	0
1703	The heterocellular heart: identities, interactions, and implications for cardiology. Basic Research in Cardiology, 2023, 118, .	2.5	13
1708	Hexitol Nucleic Acid (HNA): From Chemical Design to Functional Genetic Polymer. , 2023, , 401-434.		0
1709	Nonchromatographic Purification of Synthetic RNA. , 2023, , 2493-2510.		0
1718	New Compound Combining an Integrase-Targeting Aptamer and a Small Interfering RNA Targeting the Trans-Activation Response/Poly A Region of HIV-1 Potently Suppresses HIV-1 Replication. , 0, , .		0
1728	Antimicrobial Potential, Drug Delivery and Therapeutic Applications of Bio-nanoparticles in Medicine. , 2023, , 115-130.		1
1730	Case Report: A rare homozygous patient affected by TTR systemic amyloidosis with a prominent heart involvement. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	0
1734	Drug delivery systems for CRISPR-based genome editors. Nature Reviews Drug Discovery, 2023, 22, 875-894.	21.5	9
1743	Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group. Advances in Therapy, 2023, 40, 4695-4710.	1.3	1
1752	Malaria & mRNA Vaccines: A Possible Salvation from One of the Most Relevant Infectious Diseases of the Global South. Acta Parasitologica, 0, , .	0.4	0

#	Article	IF	Citations
1753	RNA Nanomedicine: Delivery Strategies and Applications. AAPS Journal, 2023, 25, .	2.2	1
1757	Computer-Assisted Design and Characterization of RNA Nanostructures. Methods in Molecular Biology, 2023, , 31-49.	0.4	0
1794	Genetic testing in adults with neurologic disorders: indications, approach, and clinical impacts. Journal of Neurology, 0, , .	1.8	1
1803	Harnessing synthetic biology for advancing RNA therapeutics and vaccine design. Npj Systems Biology and Applications, 2023, 9, .	1.4	0
1807	New Therapeutic Modalities: Transforming Drug Discovery and Development. , 2023, , 1-21.		1
1829	Delivery of nucleic acids using nanomaterials. Molecular Biomedicine, 2023, 4, .	1.7	2
1849	Kardiale Beteiligung bei Amyloidose. Springer Reference Medizin, 2023, , 531-542.	0.0	0
1851	Nichtvirale Vektoren. , 2023, , 87-102.		0
1852	Therapeutic synthetic and natural materials for immunoengineering. Chemical Society Reviews, 2024, 53, 1789-1822.	18.7	0
1854	Breaking the mold with RNAâ€"a â€œRNAissanceâ€•of life science. Npj Genomic Medicine, 2024, 9, .	1.7	0
1856	Controlled Delivery of Target-Specific MicroRNA Analogs as a Key to RNAi Therapeutics in Cancer. , 2024, , .		0
1857	Engineering approaches for RNA-based and cell-based osteoarthritis therapies. Nature Reviews Rheumatology, 2024, 20, 81-100.	3.5	2
1858	Advantages and disadvantages of RNA therapeutics. Progress in Molecular Biology and Translational Science, 2024, , 151-164.	0.9	0
1860	Liposomes and Lipid Nanoparticles as Peritoneal Drug Delivery Systems. , 2023, , 51-77.		0
1871	Advances in RNA therapeutics for modulation of â€˜undruggableâ€™ targets. Progress in Molecular Biology and Translational Science, 2024, , 249-294.	0.9	0
1876	RNA therapeutics history and future perspectives. Progress in Molecular Biology and Translational Science, 2024, , 99-114.	0.9	0
1878	An introduction to RNA therapeutics and their potentials. Progress in Molecular Biology and Translational Science, 2024, , 1-12.	0.9	0
1879	RNA therapeutics for disorders of excretory system. Progress in Molecular Biology and Translational Science, 2024, , 245-256.	0.9	0

#	Article	IF	Citations
1881	Types of RNA therapeutics. Progress in Molecular Biology and Translational Science, 2024, , 41-63.	0.9	0
1886	Recent applications of RNA therapeutic in clinics. Progress in Molecular Biology and Translational Science, 2024, , 115-150.	0.9	0
1900	SPIONs: Superparamagnetic iron oxide-based nanoparticles for the delivery of microRNAi-therapeutics in cancer. Biomedical Microdevices, 2024, 26, .	1.4	0
1906	Huntingtin lowering therapeutics. , 2024, , 523-549.		0